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 ABSTRACT OF DISSERTATION 
DEVELOPMENT OF COCAINE HYDROLASE FOR THERAPEUTIC 
TREATMENT OF COCAINE ABUSE 
Cocaine abuse is a world-wide public health and social problem without a U.S. 
Food and Drug Administration (FDA)-approved medication. An ideal anti-cocaine 
medication would accelerate cocaine metabolism producing biologically inactive 
metabolites by administration of an efficient cocaine-specific exogenous enzyme. 
Recent studies in our lab have led to discovery of the desirable, highly efficient human 
cocaine hydrolases (hCocHs) that can efficiently detoxify and inactivate cocaine 
without affecting normal functions of central nervous system (CNS). Preclinical and 
clinical data have demonstrated that these hCocHs are safe for use in humans and 
effective for accelerating cocaine metabolism. However, the actual therapeutic use of a 
hCocH in cocaine addiction treatment is limited by the short biological half-life (e.g. 8 
hours or shorter in rats) of the hCocH.  
In the investigation described in this thesis, we have demonstrated that mCocH 
and hCocH have improved the catalytic efficiency of mBChE and hBChE against 
cocaine by ~8- and ~2000-fold, respectively, although the catalytic efficiencies of 
mCocH and hCocH against other substrates, including acetylcholine (ACh) and 
butyrylthiocholine (BTC), are close to those of the corresponding wild-type enzymes 
mBChE and hBChE. In addition, we have identified the first 
benzoylecgonine-metabolizing enzymes that can hydrolyze benzoylecgonine and 
accelerate its clearance in rats. The developed LC-MS/MS method has enabled us to 
simultaneously determine cocaine and nine cocaine-related metabolites in whole blood 
samples. 
In development of the long-acting hCocHs, we have designed and discovered a 
novel hCocH form, catalytic antibody analog, which is an Fc-fused hCocH dimer 
(hCocH-Fc). The hCocH-Fc has not only a high catalytic efficiency against cocaine, but 
also a considerably longer biological half-life. A single dose of hCocH-Fc was able to 
accelerate cocaine metabolism in rats even after 20 days and, thus, block 
cocaine-induced hyperactivity for a long period of time. In consideration of the general 
observation that the biological half-life of a protein drug in humans is significantly 
longer than that in rodents, the hCocH-Fc could allow dosing once every 2-4 weeks, or 
longer for cocaine addiction treatment in humans. 
KEYWORDS: Cocaine abuse; benzoylecgonine; enzyme therapy; protein engineering; 
butyrylcholinesterase; LC-MS/MS 
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Chapter 1: Cocaine Abuse and Anti-Cocaine Medication 
 
Cocaine (Figure 1.1) is a powerfully addictive drug which was originally extracted 
from the leaves of the Erythroxylon coca, a plant native to South America. Cocaine has 
been used as a local anesthetic starting from 1884, but currently is mostly used as a 
recreational drug due to its effects on the reward pathway in the brain (1). The use of 
cocaine is associated with the risk of many medical problems, such as drug 
dependence and acute cardiovascular effects in case of cocaine overdose. In the 
United States (US), ~2.3% of population aged 16 to 64 uses cocaine, resulting in over 
500,000 emergency department (ED) visits and many other problems each year (2-5). 
Unfortunately, there is no US Food and Drug Administration (FDA)-approved 
medication specific for cocaine abuse treatment. In this chapter, the molecular 
mechanisms of cocaine addiction and toxicity, and current development of potential 
treatments for cocaine abuse will be discussed.  
 
 
 
Figure 1.1 Molecular structure of (-)-cocaine free base. 
 
1.1 Mechanism of cocaine addiction 
Cocaine is one of the most reinforcing abused drugs, stimulating the reward 
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pathway of the brain and teaching the user to take it again (6-8). While cocaine produces 
its acute rewarding effects by binding mainly to dopamine and serotonin reuptake 
transporters and blocking them, here the focus on just dopamine transporter (DAT) as a 
typical example to describe the mechanism of cocaine addiction. In the brain’s 
communication system which is formed by trillions of neurons, dopamine functions as 
a neurotransmitter. Normally, dopamine is released by a transmitting neuron into the 
synapse, where it can bind to dopamine receptors on the receiving neuron. Then DAT 
terminates dopamine synaptic transmission by recycling dopamine back into the 
transmitting neuron (9). If cocaine is present, it can bind to the DAT and prevent the 
removal of dopamine from synapse through both blocking the initial DAT-dopamine 
binding and reducing the kinetic turnover of transporter after dopamine binds with DAT. 
Although the initial cocaine-binding site in the DAT does not overlap with the 
dopamine-binding site, dopamine cannot reach its binding site if cocaine is bound in the 
DAT as cocaine blocks the dopamine-entry tunnel. Even if dopamine binds with DAT 
before the DAT-cocaine binding (cocaine can always bind with DAT in the 
presence/absence of dopamine), cocaine may inhibit the conformational change of DAT 
which is necessary for the transport of dopamine (10). Blocking the recycling process of 
dopamine back to the transmitting neuron results in the increased level and prolonged 
presence of dopamine in the synapse, which contributes to the continuous response of 
the receiving neuron and therefore pleasurable effects of cocaine. Over time, in 
response to this activity, the receiving neuron begins to reduce the number of dopamine 
receptors on its cell surface. Meanwhile, the transmitting neuron expresses higher level 
of DAT (11, 12).  
Gene expression dysregulationes in the brain’s communication system (e.g. 
dopaminergic pathways) are considered as the main reasons for drug seeking and 
craving. For example, the up-regulation of DAT results in less dopamine available in 
the synapse for neurotransmission, and the down-regulation of the dopamine receptor 
weakens the dopamine signal (13-16). Thus, for cocaine addiction treatment, it is 
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necessary to bring the brain’s communication system back to normal to eliminate the 
drug craving. The problem is that gene expression (e.g. DAT and dopamine receptor) 
can be modulated rapidly in response to stimulant effects of cocaine, but its 
normalization is usually an extremely slow process, resulting in abnormal gene 
expression in the brain’s dopaminergic signaling for at least one month (13, 16, 17). In 
addition, whenever cocaine is used during this long process of gene normalization, it 
can change the brain’s communication system again for an additional month. 
Considering these reasons, successfully treating cocaine addiction requires the cocaine 
abuser to receive a long-term medicine to first effectively antagonize the stimulant 
effects of cocaine, and then bring the function of brain’s communication system back to 
normal.  
1.2 Mechanism of toxic effects of cocaine 
The pharmacology of cocaine toxicity is complex with effects occurring 
simultaneously in several organ systems. However, the initial event of cocaine’s 
toxicity for all of these systems is same: cocaine elicits its effects by binding with a 
variety of proteins, including neurotransmitter transporters, receptors, voltage-gate ion 
channels, and others (18). The effects triggered depend on the cocaine concentration at 
the sites of action. When cocaine is taken at a low dose, it first binds with proteins with 
a high affinity for cocaine. As the serum concentration of cocaine increases, target 
proteins with a high affinity for cocaine begin to be saturated, meanwhile target 
proteins with a low affinity for cocaine start to be occupied with cocaine and trigger 
cocaine’s effect.  
Cocaine elicits its toxic effects primarily by binding to noradrenergic transporters 
(indirect action, modulate calcium metabolism by β-adrenergic stimulation), leading to 
elevated central and peripheral norepinephrine levels, and therefore increased heart rate 
(HR), blood pressure and vasoconstriction seen in cocaine users (19-23). The 
hypertensive and tachycardia effects of cocaine usually cause chest pain, which is the 
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most commonly reported reason for ED cases (24-26). The cardio-toxic effects of cocaine 
are also mediated directly by blocking several voltage-gated ion channels including 
sodium and potassium channels (direct action) (18, 27), which depresses myocardial 
contractility and ejection fraction (28). Of these two primary cardio effects, indirect 
action predominates at low dose of cocaine, whereas the direct action is more 
prominent at high dose of cocaine (29, 30). In addition, cocaine stimulates the release of 
endothelin-1 from endothelial cells. Endothelin-1 acts as a vasoconstrictor by inhibiting 
the production of nitric oxide which is the principal vasodilator (30-32). The use of 
cocaine is also associated with increased thrombosis, severe oxidative stress, reactive 
oxygen species production, and apoptosis in the heart muscle (33-38). Overall, cocaine 
affects the cardiovascular system through the pathways described above and probably 
more pathways remain to be elucidated. Cocaine increases the demand of oxygen by 
increasing heart rate, blood pressure, and myocardial contractility. At the same time, 
cocaine decreases the myocardial oxygen supply by coronary vasoconstriction and 
enhancing thrombosis. Ischemia and infarction may occur when the myocardial oxygen 
demand exceed the myocardial oxygen supply (30). What’s more, cocaine causes 
systolic and diastolic dysfunctions, arrhythmias, atherosclerosis, and decreased 
myocardial contractility and ejection fraction (39). The long-term use of cocaine is 
related to left ventricular hypertrophy (40), prolonged deceleration time (41), and 
coronary endothelial dysfunction (42).  
In addition to cardiovascular effects of cocaine, cocaine abuse is linked to a variety 
of other medical problems including neurological effects, gastrointestinal and 
respiratory complications, AIDS, cancer, and other toxicities (3, 4). Cocaine abuse also 
causes drastic changes in the personality that can lead to aggressive, compulsive, 
criminal and/or erratic behaviors (43). Thus, cocaine abuse is costly to both individuals 
and society. 
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1.3 Treatments for cocaine abuse 
Disastrous medical and social consequences of cocaine make it a high priority to 
develop anti-cocaine medication for treatment-seeking users (44, 45). For emergency 
treatment, diazepam is usually used to decrease the increased blood pressure and heart 
rate, and physical cooling and paracetamol are used to treat hyperthermia; however, 
there is no officially approved drug specific for therapeutic treatment of cocaine 
overdose or addiction. Despite decades of effort, classical pharmacodynamic 
approaches of small molecules to block or counteract the drug’s neuropharmacological 
actions have not proven successful for cocaine abuse, due in part to the extreme 
difficulty in antagonizing cocaine’s physiological effects without affecting normal 
functions of the central nervous system (CNS) (16). In principle, pharmacological 
treatment for a drug of abuse can be pharmacodynamic or pharmacokinetic (46). Most 
current medications for other drugs of abuse employ the classical pharmacodynamic 
approach of small molecules to block or counteract the drug’s neuropharmacological 
actions at one or more neuronal binding sites. The inherent difficulties of antagonizing 
cocaine in the CNS led to the development of protein-based pharmacokinetic 
approaches with biologics like monoclonal antibodies, vaccines that produce antibodies 
in the body, and enzymes (16, 47). Compared to the small molecules used by the 
pharmacodynamics approach, both anti-cocaine antibodies and cocaine-metabolizing 
enzymes are too large to cross the blood brain barrier, thus reducing the off-target 
effects in the CNS (16, 47, 48). 
1.3.1 Pharmacodynamic approach 
According to the mechanisms implicated in cocaine toxicity and addiction, 
decades of effort have been made to yield small molecules to antagonize cocaine’s 
effect at its sites of action. While several therapeutic candidates using small-molecule 
agents have been evaluated clinically (summarized in Table 1.1), none of them has 
been found to be safe and effective for treating cocaine overdose or addiction. The 
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failure in the pharmacodynamic approach may due to several reasons. First, it would be 
extremely difficult to antagonize cocaine’s physiological effects without affecting the 
normal functions of CNS (16). As described above, the cocaine-binding site in DAT is 
close to the dopamine-binding site, so a small-molecule agent that can block the 
cocaine-DAT binding usually affects the dopamine-DAT binding. In this way, DAT 
antagonist actually acts as a cocaine-like drug. Second, cocaine elicits its effects 
through binding with a variety of target proteins in several organs and system. 
Pharmacodynamic treatments that focus on only one or several proteins may not be 
able to completely eliminate the effects of cocaine (49). To make the matters worse, 
patients may just take more cocaine in order to achieve the expected pleasurable effects 
of cocaine, meanwhile increase the toxic effects of cocaine. Finally, the 
pharmacological mechanisms mediating the effects of cocaine have not been fully 
understood. It is difficult to find the key target protein or system for the design and 
discovery of anti-cocaine small-molecule agents. Thus, treatments that do not focus on 
the physiological effects of cocaine may prove more promising as medications. 
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Table 1.1 Pros and cons of various pharmacodynamics approaches for cocaine 
overdose and addiction treatment 
Approaches Purpose Pros Cons 
Dopaminergic agents    
-Bupropion (50) Addiction  Negative effects 
-Buspirone(51) Addiction  Negative effects 
-Modafinil (52-54) Addiction Reduced cocaine use Limited effects 
-Aripiprazole (55-57) Addiction  Limited effects 
GABAergic agents    
-Vigabatrin (58) Addiction  Negative effects 
-Topiramate (59-61) Addiction Safe and well-tolerated Negative or limited 
effects.  
-Benzodiazepines (62) Overdose Decreased 
cardiovascular effects 
of cocaine 
Limited effects 
Adrenergic agents    
-Citicoline (63) Addiction Safe. Reduced cocaine 
use 
Effects diminished over 
time 
-Guanfacine (64) Addiction  Negative effects 
-Doxazosin (65, 66) Addiction Reduced cocaine use Distinct adverse effects 
-Lofexidine (67) Overdose Decrease 
cardiovascular effects 
of cocaine 
Cardiovascular adverse 
effects 
Amphetamine analogs    
-Lisdexamfetamine 
(68) 
Addiction Reduced cocaine use Has abuse potential 
Antipsychotic 
medications (69) 
Addiction  Negative effects 
Opioid antagonist    
-Naltrexone (70) Addiction Reduced cocaine 
craving 
Limited effects 
 
1.3.2 Pharmacokinetic approach 
The pharmacokinetic approach acts on cocaine itself, aiming to lower the 
concentration of free cocaine at sites of action, thereby modulating the physiological 
effects of cocaine. Long-term reduction of (free) cocaine concentration in the brain 
might prevent patients from receiving any reinforcing effects of cocaine, leading to the 
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extinction of cocaine-seeking and cocaine-taking behaviors. In addition, acutely 
reducing the peripheral concentration of free cocaine could minimize the toxic effects 
of cocaine (e.g. the cardiovascular effects) (71). To reduce the concentration of free 
cocaine in both blood and brain, either anti-cocaine antibody or cocaine-metabolizing 
enzyme can be used to sequester cocaine in the blood or hydrolyze it, respectively, 
before cocaine reaches its site of action. Binding or hydrolyzing all cocaine molecules 
is not necessarily required, because for humans, “at least 47% of the transporters had to 
be blocked for subjects to perceive cocaine’s effects” (72); however, the capability of the 
pharmacokinetic approach to keep the cocaine below its minimally effective 
concentration should not be easily overcome by taking more cocaine. Thus, to the 
success of long-term treatment of cocaine addiction, there are three key factors: (1) 
Sufficient pharmacokinetic capability to keep the cocaine concentration in the brain 
lower than the threshold required to produce detectable physiological effects; (2) 
Making it impractical for cocaine abusers to overcome the treatment effect by 
increasing drug intake; (3) Long-term effect to avoid frequent administrations for the 
treatment.  
1.3.2.1 Immunological strategy 
The immunological strategy aims to bind cocaine with an anti-cocaine antibody in 
the periphery, which blocks its access to the CNS to exert physiological effects, 
meanwhile making cocaine not available to activate receptors or ion channels in 
peripheral organs to generate the toxic effects (71). To completely eliminate cocaine’s 
effects, it is necessary for the immunological strategy to generate sufficient 
anti-cocaine antibodies in the body, with not only a high binding affinity but also a 
great specificity for cocaine. The anti-cocaine antibody should not bind with any other 
compounds, such as neurotransmitters and endogenous cocaine-metabolizing enzymes, 
to avoid any interference with normal physiological functions (71).  
The immunological strategy can be administered by either passive monoclonal 
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antibody or active vaccine (73-75). Each approach has its own advantages and 
disadvantages. For the vaccine-approach, it requires weeks to months to generate 
active immunity. However, once the immunity is generated, a certain level of 
anti-cocaine antibody can persist for a long period of time. An anti-cocaine vaccine, 
therefore, might be useful for the long-term treatment of cocaine addiction, but not for 
treating acute cocaine overdose. In contrast, injected anti-cocaine antibody can 
immediately block cocaine’s access to sites of action, thus eliminating the 
physiological effects and acute toxic effects of cocaine (76, 77). One main potential 
disadvantage of the antibody-approach is the need of large doses of the therapeutic 
agent (71). 
The drug-protein conjugate vaccines for cocaine abuse treatment have been 
explored in clinical trials. For example, in a double-blind, placebo-controlled clinical 
trial of a cocaine vaccine which was made by covalently linking succinylnorcocaine to 
cholera B (SNC-rCTB), subjects received five vaccinations of vaccine or placebo. The 
treatment was safe and there were no serious side effects observed (78). Compared to the 
subjects received vaccinations of placebo and subjects with low levels (< 43 μg/ml) of 
serum anti-cocaine antibody, those attained high levels of anti-cocaine antibody (> 43 
μg/ml) had significantly more cocaine-free urines (one of main outcome measures). 
The proportion of subjects having considerably reduced cocaine use was significantly 
greater in the subjects with high IgG anti-cocaine antibody levels than that in subjects 
with low IgG anti-cocaine antibody levels. However, only 38% of patients developed 
relatively high levels of anti-cocaine antibody following multiple vaccinations (78). The 
results of a Phase III clinical trial of this vaccine also demonstrated that those more 
vaccinated than placebo subjects attained abstinence for at least two weeks, and the 
high IgG group had the most cocaine-free urines for the last two weeks of treatment, 
but neither were significant (79). Current effort is focused on new vaccines (e.g. 
produced by linking hapten to a new carrier-agent (80)) that can provide a higher 
concentration of anti-cocaine antibodies (77). Recent work has yield effective 
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monoclonal antibodies with a very high affinity for cocaine. Preclinical studies have 
demonstrated that an anti-cocaine antibody can modify the drug-seeking and taking 
behaviors in animal models; however, a large amount of antibody is required (77, 81, 82). 
However, there is no anti-cocaine monoclonal antibody has been studied in human. 
While immunotherapy provides some promise for treating cocaine abuse and can 
significantly reduce the drug seeking and drug-intake, its chief problem is obvious: one 
binding site of antibody binds stoichiometrically with cocaine (16, 48). There is no 
guarantee that a vaccine or antibody approach can completely eliminate drug reward, 
as the effects of any given level of anti-cocaine antibodies can be overcome with either 
repeated cocaine dosing or increasing the dose. The immunological strategy might 
work when the plasma concentration of cocaine is low (16). However, once the antibody 
is saturated by cocaine, unbound cocaine molecules are still free to either cross the 
blood-brain barrier to elicit their physiological effects, or activate other targeting 
proteins to produce toxic effects (16).  
1.3.2.2 Cocaine-metabolizing enzyme 
Unlike the stoichiometric binding of an antibody with drug, a 
cocaine-metabolizing enzyme can not only bind with cocaine, but also degrade cocaine 
to free itself for further binding and reaction. Each enzyme molecule can degrade 
multiple drug molecules, depending on the turnover number (catalytic rate constant kcat) 
and Michaelis-Menten constant (KM). Administration of an efficient 
cocaine-metabolizing enzyme can dramatically accelerate the elimination of cocaine in 
both brain and blood, effects that are attributable to a rapid hydrolysis of cocaine 
catalyzed by the cocaine-metabolizing enzyme (83, 84), and therefore leading to the 
significantly reduced toxicological and behavioral effects of cocaine (85-87). Two 
cocaine-metabolizing enzymes designed in Dr. Zhan’s lab, including a thermally 
stable mutant of bacterial cocaine esterase (CocE) (88) and a highly efficient mutant of 
human butyrylcholinesterase (BChE) (89), are currently under clinical development for 
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the treatment of cocaine overdose and addiction, respectively. Both enzymes have 
been proven to be safe and effective as anti-cocaine agents (90-92).  
1.4 Bacterial cocaine esterase 
CocE cloned from the Rhodococcus strain of bacteria, which grows in the soil of 
cocaine-producing plants, was recognized as the most efficient natural enzyme for 
hydrolyzing cocaine (93, 94). It catalyzes the hydrolysis of cocaine at the benzoyl ester 
bond to produce biological inactive compounds ecgonine methyl ester (EME) and 
benzoic acid. There is no other natural esterase with a catalytic activity against 
(-)-cocaine (which is the naturally occurring enantiomer of cocaine) comparable to 
that of CocE (95). However, a major obstacle to developing CocE into a therapeutic 
agent for cocaine abuse is the thermoinstability of wild-type CocE with a half-life of 
only ~12 min at physiological temperature (37oC) (88, 96). Based on a rational 
computational approach, CocE mutants were successfully engineered with 
synergistically enhanced thermal stability at 37oC (88, 95, 97). For example, double 
mutations (T172R/G173Q) of CocE significantly increased the half-life at 
physiological temperature by more than 20-fold compared to that of the native CocE, 
making the mutated CocE suitable as a potential medical agent for cocaine abuse (88). 
This double mutated CocE, known as drug RBP-8000, is currently in a randomized, 
double-blind, placebo-controlled trial for treatment of cocaine overdose. In the 
presence of RBP-8000, the plasma concentration of cocaine was reduced by 90% 
within 2 min; cocaine-induced cardiovascular effects were significantly decreased 
compared to placebo (90). Preclinical studies also have been carried out to evaluate the 
effects of CocE mutants in reducing the use of cocaine. Injection of a CocE mutant 
produced rightward shifts in the does-response curves for cocaine self-administration 
and discrimination (85). However, such effects cannot last long due to the short 
biological half-life of the CocE mutant. The improvement of thermal stability actually 
did not significantly prolong the in vivo half-life of CocE, suggesting that factors 
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beyond thermal stability of protein, such as protease degradation and glomerular 
filtration, shorten the biological half-life of CocE (23, 97, 98). Although polyethylene 
glycol conjugation (PEGylation) further improved the in vivo lifetime of CocE, the 
duration of effects of PEGylated CocE mutant (high dosage of CocE) on reducing the 
reinforcing effect and toxic effects of cocaine was still short (85, 95). In addition, no other 
effort has been reported to extend the biological half-life of CocE longer than that of 
PEGylated CocE. 
As a whole, the newly designed CocE mutant can efficiently reduce the toxic 
effects of cocaine by quickly hydrolyzing cocaine into biological inactive compounds. 
It is a promising drug candidate for cocaine overdose treatment, which was strongly 
supported by the results of clinical studies (90). The genes of CocE and thermostable 
CocE mutants have been cloned and proteins can be expressed in Escherichia coli cells 
in large quantities. The rapid elimination of CocE should reduce the likelihood of an 
immune response in humans, and prevent the accumulation of large aggregates, which 
may cause damage to capillary beds or organs (98). Thus, the thermostable CocE mutant 
is a safe and effective therapeutic agent for cocaine overdose treatment, but not a 
suitable medicine for long-term treatment of cocaine addiction.  
1.5 Human butyrylcholinesterase 
BChE, previously known as pseudocholinesterase or serum cholinesterase, can be  
found in plasma and many tissues, such as liver and brain (99, 100). Purified human 
plasma BChE has a long history of clinical application, without any adverse events 
reported (100). Two clinical trials (NCT00333515 and NCT00333528) of hBChE 
derived from plasma were performed by by Baxter Healthcare Corporation, showing 
that human BChE is safe. BChE is the principal metabolic enzyme that catalyzes the 
hydrolysis of cocaine to produce biologically inactive metabolites. Unfortunately, the 
catalytic efficiency (kcat/KM) of wild-type BChE against naturally occurring (-)-cocaine 
is too low (kcat = 4.1 min-1 and KM = 4.5 µM) (101) to be effective for cocaine metabolism. 
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It is highly desired to develop a mutant of human BChE with a considerably improved 
catalytic efficiency against (-)-cocaine.  
1.5.1 Rational protein engineering of BChE 
Extensive studies have been performed to increase the catalytic activity of BChE 
against (-)-cocaine by accelerating the rate-determining step of the entire catalytic 
reaction process without slowing down the other steps. Through structure and 
mechanism based computational design and wet experimental tests, Dr. Zhan’s group 
has successfully designed and discovered a series of human BChE mutants, recognized 
as true cocaine hydrolases (CocHs) in literature (86) when they have at least 1,000-fold 
improved catalytic efficiency against (-)-cocaine compared to wild-type human BChE 
(89, 102-104). The most recently designed BChE mutants, such as CocH3 (the 
A199S/F227A/S287G/A328W/Y332G mutant of BChE) and CocH4 (the 
A199S/F227A/P285A/S287G/A328W/Y332G mutant of BChE), are significantly 
more active against (-)-cocaine than the native CocE which is the fastest natural 
enzyme that can hydrolyze cocaine (102, 104). 
1.5.2 CocHs for cocaine overdose treatment 
As mentioned above, an efficient cocaine-metabolizing enzyme can eliminate 
cocaine’s toxicity quickly, relies on the rapid hydrolysis of cocaine catalyzed by the 
enzyme. The dose of enzyme required to completely remove the toxic effects of cocaine 
is negatively related to the catalytic efficiency of enzyme against cocaine. The higher 
catalytic activity of enzyme, the lower dose of enzyme required for the treatment and, 
thus, the lower the costs of medicine. In the cocaine lethality studies using a 
thermostable CocE, at least 3.2 mg/kg (IV) of CocE was required to protect 100% of the 
animals from a lethal dose of cocaine (180 mg/kg, i.p.). Pretreatment of 1.0 mg/kg (IV) 
of CocE right before the injection of cocaine protected only 40% of the animals from a 
lethal dose of cocaine (105). In comparison with CocE, recently designed CocHs are 
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more effective in protecting animals from cocaine overdose. Approximately 0.3 mg/kg 
of CocH3 or 0.15 mg/kg CocH4 can produce full protection in animals from cocaine 
overdose induced by a lethal dose of cocaine (102, 104). Thus, compared to the CocE, 
highly efficient CocHs might be more promising in treatment of cocaine overdose.  
1.5.3 CocHs for cocaine addiction treatment  
Using a pharmacokinetic agent, the key to successful cocaine addiction treatment 
is that the treatment can continuously keep the cocaine in the body below its minimally 
effective concentration. It requires the enzyme used for cocaine addiction treatment to 
have not only a high catalytic efficiency against cocaine, but also a long in vivo half-life. 
The human serum BChE displays high bioavailability and is long-lasting in human 
circulation (106); however, the recombinant human BChE expressed in mammalian cells, 
goat milk of transgenic goats, insect cells, or tobacco plants displays a short biological 
half-life in the circulation of animals or human being (103, 107-109). The short in vivo 
half-life of the recombinant BChE in animals or humans can be explained by 
incomplete post-translational modification, mainly in glycosylation (100). 
Glycosylation can vary from one expression system to another system; and from lot to 
lot. Although unwanted glycosylation residues can be deleted and necessary residues 
can be coexpressed (109), for now it is impossible to produce recombinant BChE with 
exactly the same post-translational modification as that of plasma-derived BChE, no 
matter what expression system used. The heterogeneity in post-translational 
modification, mainly in glycosylation, makes the recombinant BChE foreign (may not 
be immunogenic) to the test animals or human being, accelerating the clearance of the 
enzyme and shortening its biological half-life (110).  
To prolong the half-life of recombinant BChE, some efforts have been made in 
some research groups. Recombinant human BChE modified chemically with 
polyethyleneglycol (PEG) displayed a residence time which is 2-fold longer than that 
of unmodified recombinant human BChE, suggesting that PEG-modification can 
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extend the biological half-life of recombinant human BChE (111). The first one of 
designed CocHs, known as CocH1 or E14-3 (the A199S/S287G/A328W/Y332G 
mutant of human BChE) (89, 112), truncated after amino acid #529 was fused with human 
serum albumin (HSA) to prolong the biological half-life (86). This HSA-fused BChE 
mutant is also known as Albu-CocH, Albu-CocH1, AlbuBChE, or TV-1380 in 
literature (86, 91, 92, 113), TV-1380 has been proven safe and effective for use in animals 
and humans (91, 92), but its actual therapeutic value for cocaine addiction treatment is still 
limited by the moderate biological half-life which is ~8 hr in rats (86) or 43-77 hr in 
humans (91); in general, the biological half-life of a therapeutic protein in humans is 
significantly longer than that in rats (86). A biological half-life of 43-77 hr in humans 
might be good enough for a twice-weekly therapy, depending on the dose of the enzyme 
used. In addition, more recently designed and discovered CocHs (102-104) are 
significantly more active against (-)-cocaine compared to TV-1380. It is highly desired 
to further engineer a more active CocH with a biological half-life longer than TV-1380.  
1.6 Summary of development of treatment for cocaine abuse and specific aims of 
the investigation described in this dissertation 
In summary, cocaine abuse is a global problem with direct and indirect adverse 
impact on human health and social welfare. Unfortunately, there is no FDA-approved 
effective treatment specific for cocaine abuse. Despite decades of efforts, none of the 
pharmacodynamic agents tested so far has been proven effective for treatment of 
cocaine addiction or overdose. The inherent difficulties of antagonizing cocaine in the 
central nervous system have led to exploring protein-based pharmacokinetic 
approaches with biologics like monoclonal antibodies, vaccines that produce antibodies 
in the body, and enzymes (16, 47). The pharmacokinetic approach using an efficient 
metabolic enzyme is recognized as a truly promising treatment strategy for cocaine 
overdose and addiction (16, 86, 91, 92). Clinical studies show that the CocE mutant is safe 
and efficacious for accelerating the cocaine conversion to EME and benzoic acid in 
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humans (90), but is not able to hydrolyze benzoylecgonine (a major, biologically active 
metabolite of cocaine, will be discussed in more detail below) at all. TV-1380 has been 
proven safe and effective for use in animals and humans (91, 92), but its actual therapeutic 
value for cocaine addiction treatment is still limited by the moderate biological half-life 
(86, 91). The investigation described in this dissertation is mainly focused on addressing 
some possible concerns in the further development of promising CocHs for cocaine 
abuse treatment. We have carried out kinetic characterization of an hCocH and a 
mCocH for their catalytic activities against (-)-cocaine and other substrates, identified 
enzymes that can hydrolyze not only cocaine, but also its major biologically active 
metabolite benzoylecgonine developed a LC-MS/MS method for determining 
pharmacokinetic profiles of cocaine and metabolites, and developed a long-acting form 
of hCocH.  
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Chapter 2: Kinetic Characterization of a Cocaine Hydrolase Engineered from 
Mouse Butyrylcholinesterase 
 
Summary: In the investigation described in this chapter, mouse BChE (mBChE) 
and an mBChE-based cocaine hydrolase (mCocH, i.e. the 
A199S/S227A/S287G/A328W/Y332G mutant) have been characterized for their 
catalytic activities against cocaine, i.e. naturally occurring (-)-cocaine, in comparison 
with the corresponding human BChE (hBChE) and an hBChE-based cocaine 
hydrolase (hCocH, i.e. the A199S/F227A/S287G/A328W/Y332G mutant). It has been 
demonstrated that mCocH and hCocH have improved the catalytic efficiency of 
mBChE and hBChE against (-)-cocaine by ~8- and ~2000-fold, respectively, although 
the catalytic efficiencies of mCocH and hCocH against other substrates, including 
acetylcholine (ACh) and butyrylthiocholine (BTC), are close to those of the 
corresponding wild-type enzymes mBChE and hBChE. According to the kinetic data, 
the catalytic efficiency of mBChE against (-)-cocaine is comparable to that of hBChE, 
but the catalytic efficiency of mCocH against (-)-cocaine is remarkably lower than 
that of hCocH by ~250-fold. The remarkable difference in the catalytic activity 
between mCocH and hCocH is consistent with the difference between the 
enzyme-(-)-cocaine binding modes obtained from molecular modeling. Further, both 
mBChE and hBChE demonstrated substrate activation for all of the examined 
substrates ((-)-cocaine, ACh, and BTC) at high concentrations, whereas both mCocH 
and hCocH showed substrate inhibition for all three substrates at high concentrations. 
The amino-acid mutations have remarkably converted substrate activation of the 
enzymes into substrate inhibition, implying that the rate-determining step of the 
reaction in mCocH and hCocH might be different from that in mBChE and hBChE. 
The main results described in this chapter have been published (114).  
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2.1 Why a cocaine hydrolase engineered from mouse butyrylcholinesterase is 
interesting 
Previous efforts of Dr. Zhan’s group were focused on improving the catalytic 
activity of hBChE against (-)-cocaine, leading to discovery of various hBChE mutants 
(89, 101-104, 115-117) with a considerably improved catalytic efficiency towards that drug. 
The highly efficient hBChE mutants, such as A199S/S287G/A328W/Y332G (kcat = 
3060 min-1 and KM = 3.1 M) (89, 112) or A199S/F227A/S287G/A328W/Y332G (kcat = 
5700 min-1 and KM = 3.1 M) (102), can be described as CocH. Initial experiments in 
rats and mice showed that CocH is likely to be effective as an enzyme therapy or gene 
therapy for treating cocaine abuse by greatly reducing the reward value of a given 
drug dosage (83, 86, 102, 103, 118-125). In addition, we have not seen any acute toxicity of 
hCocH in mice or rats nor have other investigators found that wild-type hBChE 
elicited adverse effects in experimental animals (126-128). Two clinical trials 
(NCT00333515 and NCT00333528) of hBChE have been performed by Baxter 
Healthcare Corporation, although the clinical data have not been made available.  
Not surprisingly, some mice and rats eventually develop antibodies against 
hBChE and hCocH, accelerating the clearance of these enzymes and lowering their 
plasma levels (122), although no immune response is noted when mouse BChE 
(mBChE) is injected into mice (129). This outcome was expected because hBChE 
shares only ~80% sequence identity with its rodent counterparts (130). We deemed it 
unlikely that human beings would generate antibodies to hCocH as the mutated 
residues are not exposed on the surface but occupy a deep and narrow catalytic gorge. 
Nonetheless, the mouse response called for further experiments to test the hypothesis 
that mutations in the catalytic site are not antigenic. Therefore we developed a 
conspecific cocaine hydrolase with equivalent mutations in mBChE: 
A199S/S227A/S287G/A328W/Y332G, designated mouse CocH or “mCocH”. The 
catalytic properties of mCocH were compared with those of mBChE, hBChE, and 
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hCocH, and it was incorporated into viral gene transfer vector for in vivo studies with 
the aim of avoiding complications from an immune response in the animals.   
In fact, initial gene transfer experiments with mCocH showed that very high 
levels of enzyme protein could be generated, on the order of 1000-fold above the 
native mBChE background level (122). However, the levels of cocaine hydrolysis did 
not increase to the extent achieved with hCocH. This outcome suggested that although 
mCocH and hCocH contain similar mutations, their catalytic efficiencies with 
(-)-cocaine are different, and results from the gene transfer study were consistent with 
this interpretation (122). To explore the reason, in the study described in this chapter, 
mBChE and mCocH proteins were compared with hBChE and hCocH in regard to 
catalytic properties against (-)-cocaine and various other substrates. In addition, 
homology modeling and molecular dynamics (MD) simulations (carried out by Dr. 
Xiaoqin Huang) were used to compare structural features of the two mutated enzymes. 
As will be shown in this chapter, the catalytic efficiency of mCocH against 
(-)-cocaine is indeed lower than that of hCocH, and computational modeling of the 
detailed three-dimensional (3D) structures provides some insight into the reasons for 
this conclusion, which in turn may facilitate future attempts at re-engineering 
enzymes for therapeutic purposes. 
2.2 Materials and methods 
2.2.1 Materials 
The cDNA for mBChE containing N-terminal signal was kindly provided by Dr. 
Palmer Taylor (Skaggs School of Pharmacy and Pharmaceutical Sciences, University 
of California, San Diego, CA). Cloned pfu DNA polymerase and Dpn I endonuclease 
were obtained from Stratagene (La Jolla, CA). Restriction enzyme, alkaline 
phosphatase (CIP), and T4 DNA ligase were purchased from New England Biolabs 
(Ipswich, MA). All oligonucleotides were synthesized by Eurofins MWG Operon 
(Huntsville, AL). Vector pCMV-MCS was obtained from Agilent Technologies 
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(Santa Clara, CA). The QIAprep Spin Plasmid Miniprep Kit and QIAquick Gel 
Extraction Kit were obtained from QIAGEN (Valencia, CA). Chinese hamster 
ovary (CHO)-S cells and FreeStyle™ CHO Expression Medium were ordered from 
Invitrogen (Grand Island, NY). [3H](-)-Cocaine (50 Ci/mmol) and [3H]acetylcholine 
(ACh) were purchased from PerkinElmer Life and Analytical Sciences (Waltham, 
MA). Butyrylthiocholine (BTC) was obtained from Sigma-Aldrich (St Louis, MO).  
2.2.2 Construction of eukaryotic expression plasmids 
Site-directed mutagenesis for obtaining the mCocH cDNA was carried out using 
the QuikChange method (131). The cDNA for full-length mBChE or mCocH was 
constructed in a pCMV-MCS expression plasmid by using restriction enzyme EcoR I 
to digest the original vector and cDNA. Before the ligation, alkaline phosphatase (CIP) 
was used to dephosphorylate the 5' end of vector. Gel-purified cDNA was ligated with 
pCMV-MCS vector using T4 DNA ligase. Plasmids encoding hBChE and hCocH 
were obtained as previously described (102).  
2.2.3 Protein expression and purification 
All proteins (m/hBChE and m/hCocH) were expressed in CHO-S cells separately. 
Cells were incubated at 37°C in a humidified atmosphere containing 8% CO2, and 
transfected with plasmids encoding various proteins using TransIT-PRO® 
transfection kit once cells had grown to a density of ~1.0 × 106 cells/ml. The culture 
medium (Gibco® FreeStyle™ CHO expression medium with 8 mM glutamine) was 
harvested 7 days after transfection. Secreted enzyme in the culture medium was 
purified by a two-step approach described previously (83), including ion exchange 
chromatography using QFF anion exchanger and affinity chromatography using 
procainamide-sepharose. Pre-equilibrated procainamide-sepharose was added into 
protein sample purified by ion exchange chromatography, and incubated for 3 h with 
occasional stirring. After washing the column with 20 mM potassium phosphate, 1 
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mM EDTA, pH 7.0 until OD280 < 0.02, enzyme was eluted by buffer containing 0.3 
M NaCl and 0.1 M procainamide-HCl. The eluate was dialyzed in phosphate buffer, 
pH 7.4 by Millipore centrifugal filter device. The entire purification process was 
carried out in a cold-room at 4°C. Concentration of the active enzyme was determined 
through active site titration with diisopropylfluorophosphate (DFP) as described 
previously (122). Purified enzymes were stored at 4°C before enzyme activity assays.  
2.2.4 Enzyme activity assays 
The catalytic activities of enzymes against (-)-cocaine were determined with a 
radiometric assay based on toluene extraction of [3H](-)-cocaine labeled on its 
benzene ring. 150 μl enzyme solution (100 mM phosphate buffer, pH 7.4) was added 
to 50 μl [3H](-)-cocaine solution with varying concentration. The reactions were 
stopped by adding 200 μl of 0.1 M HCl which neutralized the liberated benzoic acid 
while ensuring a positive charge on the residual (-)-cocaine. [3H]Benzoic acid was 
extracted by 1 ml of toluene and measured by scintillation counting. The assays to 
determine catalytic activity with [3H]ACh differed only in that the reaction was 
stopped with 200 µl of 0.2 M HCl containing 2 M NaCl. To determine catalytic 
activities of enzymes against BTC, UV-Vis spectrophotometric assays were carried 
out in a GENios Pro Microplate Reader (TECAN, Research Triangle Park, NC) with 
XFluor software. 100 µl enzyme solution was mixed with 50 µl of 25 mM 
dithiobisnitrobenzoic acid and 50 µl of BTC in varying concentrations. Reaction rates 
were measured by recording the time-dependent absorption at 450 nm. All 
measurements were performed at 25oC. Kinetic data were analyzed by performing 
non-linear, least-squares fitting to Eq.(2.1) (which accounts for the potential 
secondary binding site of the enzyme, i.e. a peripheral anionic binding site around 
D70) (132, 133).  
)/1)(/1(
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In Eq.(2.1), S represents the concentration of the substrate, Vmax = kcat[E] in which [E] 
is the enzyme concentration, Kss is a binding constant for substrate at the secondary 
binding site, and b is a factor reflecting whether or not there is a substrate 
activation/inhibition. When b = 1, there is no substrate activation or inhibition, and the 
enzymatic reaction follows Michaelis-Menten kinetics. There is substrate activation 
when b > 1, and substrate inhibition when b < 1. Kinetic data were analyzed with 
Microsoft Excel, coding Eq.(2.1) for non-linear fitting .  
2.2.5 Homology modeling  
The 3D structure of mCocH was modeled based on our previously refined 3D 
structure (102, 134) of hCocH as a template. The hCocH structure was refined through 
MD simulations and hybrid quantum mechanics/molecualr mechanics (QM/MM) 
calculations (102, 134) starting from the X-ray crystal structure (PDB entry code: 1P0P) 
(135) available for hBChE. With the refined hCocH structure as a template, a 3D 
structure of mCocH was constructed and refined using the Protein Modeling module 
of Discovery Studio (Version 2.5.5, Accelrys, San diego, CA). The amino-acid 
sequence of mBChE was directly extracted from the PubMed website (NCBI access 
No. AAH99977), with the sequence changes necessary to generate the sequence of 
mCocH. The sequence alignment was generated by using ClusterW with the Blosum 
scoring function (136, 137). The best alignment was selected according to both the 
alignment score and the reciprocal positions of the conserved residues between human 
and mouse proteins, particularly the residues forming the catalytic triad 
(S198-H438-E325) and the oxyonion hole (G116-G117-A/S199). The sequence 
identity between mCocH and hCocH reached 80%. The coordinates of the conserved 
regions were directly transformed from the template structure, whereas the 
non-equivalent residues were mutated from the template to the corresponding ones of 
mCocH. The side chains of those non-conserved residues were relaxed during the 
process of homology modeling in order to remove the possible steric overlap or 
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hindrance with the neighboring conserved residues. The initial structure of mCocH 
was subject to energy minization by using the Sander module of the Amber program 
(138) with a conjugate gradient energy-minimization method and a non-bonded cutoff 
of 10 Å. First, the structure of mCocH was solvated in an orthorhombic box of TIP3P 
water molecules (139) with a minimum solute-wall distance of 10 Å. Standard 
protonation states at physiological environment (pH ~7.4) were used for all ionizable 
residues of the proteins, and the proton positions were set properly on the N1 atom 
of histidine residues. Additional Cl- ions were added to the solvent as counter ions to 
neutralize the system. The final system size was about 94 Å  91 Å × 87 Å, composed 
of 62,489 atoms, including 18,555 water molecules. The first 2,000 steps of the 
energy minimization were carried out for the backbone while the side chains were 
fixed, and then the next 60,000 steps for the side chains and water molecules. Finally, 
the system (mCocH) was energy-minimized for 6,000 steps for all atoms, and a 
convergence criterion of 0.001 kcal mol-1 Å-1 was achieved. 
2.2.6 Molecular dynamics (MD) simulation 
Using the homology model of mCocH, we further examined how mCocH binds 
with (-)-cocaine. First, (-)-cocaine was docked into the binding site, giving a binding 
mode similar to that for the corresponding hCocH binding with (-)-cocaine through 
the superposition. The atomic charges for (-)-cocaine were the restrained electrostatic 
potential (RESP) charges determined and used in our previous studies on hBChE and 
hCocH interacting with (-)-cocaine (89, 102). MD simulations were carried out on the 
mCocH-(-)-cocaine binding complex by using the Sander module of the Amber 
program. Each system was slowly heated to 300 K by the weak-coupling method (140) 
and then equilibrated for 50 ps. During the MD simulations, a 10 Å non-bonded 
interaction cutoff was used and the non-bonded list was updated every 1,000 steps. 
The particle-mesh Ewald (PME) method (141) was applied to treat long-range 
electrostatic interactions. The lengths of covalent bonds involving hydrogen atoms 
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were fixed with the SHAKE algorithm (142), enabling the use of a 2-fs time step to 
numerically integrate the equations of motion. Finally, the production MD was kept 
running for 4.0 ns with a periodic boundary condition in the NTP (constant 
temperature and pressure) ensemble at T = 300 K with Berendsen temperature 
coupling and at P = 1 atm with anisotropic molecule-based scaling (143).  
2.3 Catalytic parameters kcat and KM  
The kinetic data are depicted in Figures 2.1 to 2.3, and the obtained kinetic 
parameters are summarized in Table 2.1. As seen in Table 2.1, compared to hBChE, 
mBChE has a smaller kcat value (1.4 min-1 vs 4.1 min-1) and a smaller KM value (1.6 µM 
vs 4.5 µM) against (-)-cocaine. Overall, the catalytic efficiency of mBChE against 
(-)-cocaine (kcat/KM = 8.8 × 105 min-1 M-1) is comparable to that of hBChE (kcat/KM = 9.1 
× 105 min-1 M-1). Concerning the effects of the mutations, hCocH has a ~2000-fold 
improved catalytic efficiency against (-)-cocaine compared to hBChE. From that 
standpoint, one might expect that mCocH would also have considerably greater 
catalytic efficiency against (-)-cocaine than mBChE. In fact, as seen in Table 2.1, the 
kcat of mCocH against (-)-cocaine is ~180-fold larger than that of mBChE against 
(-)-cocaine, but the KM of mCocH against (-)-cocaine is also larger than that of mBChE 
against (-)-cocaine (~22-fold). So, the improvement in kcat is compromised by the 
significant increase of KM, resulting in only ~8-fold improved catalytic efficiency over 
mBChE (kcat/KM = 7.1 × 106 min-1 M-1). As a result, compared to hCocH, mCocH has 
~250-fold lower catalytic efficiency against (-)-cocaine.  
According to the kinetic parameters in Table 2.1, against substrate ACh, mBChE 
has a slightly smaller kcat value (38400 min-1 vs 61200 min-1) and a slightly larger KM 
value (400 µM vs 148 µM) compared to hBChE. Therefore, the catalytic efficiency of 
mBChE against ACh is ~4-fold lower than that of hBChE. Concerning the mutational 
effects on hydrolysis of ACh, both mCocH and hCocH exhibit catalytic efficiencies 
 25 
 
only slightly lower than those of the wild-type enzymes (mBChE and hBChE).  In 
other words, the mutations caused no substantial effect.  
Against substrate BTC, mBChE has a slightly larger kcat value than hBChE (35600 
min-1 vs 29500 min-1) but a significantly larger KM value (72 µM vs 17 µM). Overall, 
the catalytic efficiency of mBChE against BTC is ~3-fold lower than that of hBChE. 
Concerning the mutational effects on enzyme activity against BTC, the catalytic 
efficiency of mCocH is only slightly lower than that of mBChE, whereas the catalytic 
efficiency of hCocH is only slightly higher than that of hBChE. Overall changes in the 
catalytic efficiency against BTC are probably not physiologically significant in either 
mutated enzyme. 
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Table 2.1 Kinetic parameters determined for (-)-cocaine, ACh, and BTC hydrolyses 
catalyzed by mBChE, mCocH, hBChE, and hCocH. This table came from ref. (114).  
aRCE refers to the relative catalytic efficiency (kcat/KM), i.e. the ratio of the kcat/KM 
value of a mutant (mCocH or hCocH) to that of the corresponding wild-type enzyme 
(mBChE or hBChE) against the same substrate.   
bThe kcat and KM for hBChE against (-)-cocaine were reported in ref.(101). 
cThe kcat and KM for hCocH against (-)-cocaine were reported in ref.(102). 
dThe kcat and KM for hBChE against ACh were reported in ref.(86). 
eThe kcat and KM for hCocH against ACh and BTC were reported in ref.(144). 
fThe kcat and KM for hBChE against BTC were reported in ref.(118). 
 
 
 
 
 
 
 
 
Enzyme Substrate 
kcat  
(min-1)
KM  
(μM)
kcat/KM   
(min-1 M-1) 
RCEa 
Kss 
(μM) 
b 
mBChE (-)-cocaine 1.4 1.6 8.8 × 105 1 1300 3.13 
mCocH (-)-cocaine 250 35 7.1 × 106 8.2 1500 0.88 
hBChEb (-)-cocaine 4.1 4.5 9.1 × 105 1 216 1.80 
hCocHc (-)-cocaine 5700 3.1 1.8 × 109 2020 137 0.40 
mBChE ACh 38400 400 9.6× 107 1 15200 1.79 
mCocH ACh 19000 210 9.0 × 107 0.94 25800 0.30 
hBChEd ACh 61200 148 4.1 × 108 1 31600 2.58 
hCocHe ACh 11900 37 3.2 × 108 0.78 30000 0.68 
mBChE BTC 35600 72 4.9 × 108 1 5000 2.77 
mCocH BTC 28200 99 2.8 × 108 0.58 254 0.19 
hBChEf BTC 29500 17 1.7 × 109 1 3010 3.36 
hCocHe BTC 28000 13 2.2 × 109 1.24 243 0.49 
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Figure 2.1 Kinetic data obtained in vitro for (-)-cocaine hydrolysis catalyzed by 
mCocH, mBChE, hCocH, and hBChE. The reaction rate is represented in M min-1 
per nM enzyme. This figure came from ref.(114). 
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Figure 2.2 Kinetic data obtained in vitro for ACh hydrolysis catalyzed by mCocH, 
mBChE, hCocH, and hBChE. The reaction rate is represented in M min-1 per nM 
enzyme. This figure came from ref.(114). 
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Figure 2.3 Kinetic data obtained in vitro for BTC hydrolysis catalyzed by mCocH, 
mBChE, hCocH, and hBChE. The reaction rate is represented in M min-1 per nM 
enzyme. This figure came from ref.(114). 
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2.4 Insights from molecular modeling  
To understand why mCocH has much lower catalytic efficiency against 
(-)-cocaine compared to hCocH, we modeled the 3D structure of mCocH binding with 
(-)-cocaine for comparison with the corresponding hCocH-(-)-cocaine binding. 
Depicted in Figure 2.4 are the aligned sequences of mCocH and hCocH, showing that 
the overall sequence identity between these two enzymes is as high as 80%. As shown 
in Figure 2.4, mCocH and hCocH share the same residues for the catalytic triad that 
reacts with (-)-cocaine (S198, H438, and E325), and the same oxyanion hole residues 
(G116, G117, and S199) that form hydrogen bonds with the carbonyl oxygen atom on 
the benzoyl group of (-)-cocaine. Another common feature of cocaine binding with 
hCocH and mCocH is that the cationic head of (-)-cocaine has a similar cation-π 
interaction with the side chain of W82.    
The main difference between hCocH and mCocH is that the cationic head of 
(-)-cocaine interacts more favorably with the protein environment including side 
chains of F73 and W328 in hCocH, compared to the corresponding interactions in 
mCocH. This appears to be due to a difference in the detailed shape of the binding 
pockets in the two enzymes. For example, residue #72 is an alanine in mCocH and 
serine in hCocH. In hCocH, the hydroxyl group of S72 side chain forms a strong 
hydrogen bond with an oxygen atom in the carboxylate moiety of the D70 side chain 
(Figure 2.5C and D). This hydrogen bond apparently influences the orientation of the 
aromatic ring in F73 such that the cationic head of (-)-cocaine aligns nearly parallel to 
the vector normal to the plane of the aromatic ring of F73 side chain. As a result, the 
MD-simulated average distance between the positively charged N atom of (-)-cocaine 
and the center of the hCocH F73 side chain aromatic ring was 7.06 Å, and the 
MD-simulated average distance between the positively charged N atom of (-)-cocaine 
and the center of aromatic ring of W328 side chain was 5.99 Å.  
In mCocH, with no hydrogen bond between the side chains of A72 and D70, the 
side chain of altered residue #72 is farther away from D70 than it is in hCocH. This 
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causes the orientation of the aromatic ring of the F73 side chain in mCocH to differ 
substantially from that in hCocH. Due to this alteration, the hydrogen atoms on the 
aromatic ring of F73 side chain in the initial model of mCocH-(-)-cocaine binding 
structure seemed too close to the (-)-cocaine atoms. After further simulation, the F73 
side chain pushed away from the (-)-cocaine atoms and the MD-simulated average 
distance between the positively charged N atom of (-)-cocaine and the center of 
aromatic ring of F73 side chain grew to 8.58 Å (1.52 Å longer than that in hCocH). The 
difference in residue #72 also indirectly affected the interaction of (-)-cocaine with 
W328. The MD-simulated average distance between the positively charged N atom of 
(-)-cocaine and the center of the W328 side-chain aromatic ring was 6.90 Å in mCocH 
(0.91 Å longer than that in hCocH). Due to the less favorable interactions of the cationic 
head of (-)-cocaine with F73 and W328 side chains in mCocH, the overall binding of 
(-)-cocaine with mCocH can be expected to be weaker, which is consistent with the 
experimental observation that, compared to hCocH, mCocH has a significantly larger 
KM value and a significantly smaller kcat value against (-)-cocaine.  
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Figure 2.4 Sequence alignment between mCocH and hCocH. Stars refer to identical 
residues, whereas filled period and double filled period refer to the conservative 
substitutions. This figure came from ref.(114). 
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Figure 2.5 The MD-simulated structures of mCocH and hCocH binding with 
(-)-cocaine. (A) mCocH-(-)-cocaine binding structure; (B) and (C) plots of key 
distances in the mCocH-(-)-cocaine complex versus the simulation time; (D) plot of 
root-mean-squares deviation (RMSD) of the atomic positions of (-)-cocaine in the 
mCocH-(-)-cocaine complex versus the simulation time; (E) hCocH-(-)-cocaine 
binding structure; (F) to (H) plots of key distances in the hCocH-(-)-cocaine complex 
versus the simulation time; (I) plot of the RMSD of the atomic positions of (-)-cocaine 
in the hCocH-(-)-cocaine complex versus the simulation time. COC refers to 
(-)-cocaine. COC(O33)---G117(H) represents the distance between the carbonyl 
oxygen on the benzoyl group of (-)-cocaine and the backbone hydrogen atom of G117; 
COC(O33)---S199(HG) the distance between the carbonyl oxygen on the benzoyl 
group of (-)-cocaine and the hydroxyl hydrogen of S199 side chain; 
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COC(N+)---W328(side chain) the distance between the positively charged nitrogen of 
(-)-cocaine and the center of aromatic side chain of W328; S198(HG)---H438(NE2) 
the distance between the hydroxyl hydrogen of S199 side chain and the nitrogen atom 
(NE2) of H438 side chain; H438(HD1)---E325(OE1/OE2) the distance between the 
hydrogen atom (HD1) on the nitrogen atom of H438 side chain; 
COC(C32)---S198(OG) the distance between the carbonyl carbon on the benzoyl 
group of (-)-cocaine and the hydroxyl oxygen of S198 side chain; 
D70(OD1/OD2)---S72(HG) the shortest distance between the oxygen atoms of D70 
side chain and the hydroxyl hydrogen of S72 side chain; and F73(side 
chain)---W328(side chain) the distance between the positively charged N atom of 
(-)-cocaine and the center of aromatic ring of W328 side chain. All distances and 
RMSD are given in Å. This figure came from ref.(114). 
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2.5 Main insights obtained in from this investigation 
Kinetic analysis reveals that the catalytic efficiencies (kcat/KM) of mBChE against 
ACh, BTC, and (-)-cocaine resemble those of hBChE. After comparable substitutions 
at five homologous sites in the catalytic gorge, the corresponding mutant forms 
mCocH and hCocH both retain similar activities against ACh and BTC and both show 
enhanced hydrolysis of (-)-cocaine. However, the magnitude of enhancement differs 
radically between the two enzymes: ~8-fold with mCocH and ~2000-fold with hCocH, 
leaving the mouse protein ~250-fold less efficient with (-)-cocaine than its human 
counterpart. A second surprise was that ACh, BTC, and (-)-cocaine all showed 
substrate activation in wild-type mouse and human BChE, but uniformly caused 
substrate inhibition in both of the mutated enzymes. That result implies that the 
rate-determining step of the reactions in mCocH and hCocH may differ from that in 
mBChE and hBChE. These unexpected outcomes posed an interesting challenge to 
rational, structure and mechanism based enzyme mutation. However, homology 
modeling and molecular dynamics simulations shed light on the underlying causes. In 
other words, the observed behavior was consistent with the enzyme-(-)-cocaine 
binding structures obtained from molecular modeling.  
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Chapter 3: Metabolic Enzymes of Cocaine Biomarker Benzoylecgonine 
 
Summary: Enzyme therapy using an efficient cocaine-metabolizing enzyme is 
recognized as the most promising approach to cocaine overdose treatment. The actual 
enzyme, known as RBP-8000, under current clinical development for cocaine overdose 
treatment is previously designed T172R/G173Q mutant of bacterial cocaine esterase 
(CocE). The T172R/G173Q mutant is effective in hydrolyzing cocaine, but inactive 
against benzoylecgonine (a major, biologically active metabolite of cocaine) at all. 
Unlike cocaine itself, benzoylecgonine has an unusually stable zwitterion structure 
resistant to further hydrolysis in the body and environment. In fact, benzoylecgonine 
can last in the body for a very long time (a few days) and, thus, is responsible for the 
long-term toxicity of cocaine and a commonly used biomarker for drug abuse diagnosis 
in pre-employment drug tests (145, 146). Because CocE and its mutants are all active 
against cocaine and inactive against benzoylecgonine, one might simply assume that 
other enzymes that are active against cocaine are also inactive against benzoylecgonine. 
In the study described in this chapter, through combined computational modeling and 
experimental studies, we demonstrate for the first time that human BChE is actually 
active against benzoylecgonine, and that a rationally designed BChE mutant can not 
only more efficiently accelerate cocaine hydrolysis, but also significantly hydrolyze 
benzoylecgonine in vitro and in vivo. This sets the stage for advanced studies to design 
more efficient mutant enzymes valuable for development of an ideal cocaine overdose 
enzyme therapy and for benzoylecgonine detoxification in environment. The main 
results discussed in the chapter have been published (147).  
3.1 Cocaine overdose and benzoylecgonine 
Efficient and thermally stable cocaine-metabolizing enzymes have been designed 
and developed recently as potential therapeutic candidates for treatment of cocaine 
overdose and addiction (88, 89, 102-104, 148). These computationally designed enzymes, that 
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are mutants of human BChE or bacterial CocE, can rapidly convert cocaine to 
physiologically inactive EME and benzoic acid. In particular, a thermally stable CocE 
mutant (T172R/G173Q) (88), known as RBP-8000 (90), is currently in clinical 
development for cocaine overdose treatment; the human clinical trial Phase IIa has 
been completed, showing that the CocE mutant is safe and efficacious for accelerating 
the cocaine conversion to EME and benzoic acid in humans (90).  
A potential concern for practical clinical use of the enzyme therapy for cocaine 
overdose is that cocaine is also converted to benzoylecgonine (BE) by endogenous liver 
carboxylesterase-1 (hCE-1) in the body (see Figure 3.1). BE is actually a more potent 
vasoconstrictor than cocaine, norepinephrine, and norcocaine (145), and cerebral artery 
segments are significantly more sensitive to BE than to cocaine and the other cocaine 
metabolites (146). More importantly, compared to cocaine itself, BE can exist in the body 
for a considerably longer period of time. For this reason, BE is a commonly used 
cocaine biomarker for cocaine abuse diagnosis in human drug tests. For cocaine 
overdose treatment in an ED, a patient intakes cocaine before going to the ED and, thus, 
a lot of cocaine molecules have already been converted to BE in the body prior to 
administration of an exogenous enzyme (145). Hence, an ideal enzyme therapy for 
cocaine overdose should detoxify not only cocaine itself (which is mainly responsible 
for the acute toxicity and lethality), but also its long-lasting metabolite BE (which is 
mainly responsible for the long-term toxicity of cocaine). However, unlike cocaine, BE 
is a zwitterion extremely difficult to hydrolyze in not only human body, but also 
environment (149). It has been extremely challenging to efficiently hydrolyze BE for 
both cocaine overdose treatment and BE detoxification in environment. In fact, CocE 
and its T172R/G173Q mutant (RBP-8000) (88) are highly efficient against cocaine and 
norcocaine, but inactive against BE (4). To the best of our knowledge, no metabolic 
enzyme of BE has ever been reported in literature. Here we report the first observation 
of metabolic enzymes of BE, providing a promising starting point for future 
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development of an ideal enzyme therapy for cocaine overdose and for BE 
detoxification in environment. 
 
 
Figure 3.1 Metabolic pathways of cocaine in humans and animals with metabolic 
enzymes including BChE, hCE-1, and oxidation by cytochrome P450 (CYP) 3A4. This 
figure came from ref.(147). 
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3.2 Materials and methods 
3.2.1 Molecular modeling 
BE binding with human BChE and mutants was modeled by using our previously 
modeled structures of the same enzymes (89, 102, 103, 116, 125, 150-152). Our previous 
molecular dynamics (MD) simulations (103) on the structures of enzyme-cocaine 
complexes (125) started from the X-ray crystal structure deposited in the Protein Data 
Bank (pdb code: 1P0P). For each enzyme (human BChE or mutant), BE was docked 
into the active site of the enzyme by using the AutoDock 4.2 program (153), as we 
previously did for the enzyme binding with (-)-cocaine, norcocaine, and cocaethylene 
(125). During the docking process, the Solis and Wets local search method (154) was used 
for the conformational search and the Lamarkian genetic algorithm (LGA) (153) was 
employed to deal with the enzyme-ligand interactions. The grid size was set to be 120  
120  120. The finally obtained enzyme-BE binding structures were the ones with the 
lowest binding free energies.   
3.2.2 In vitro enzyme activity assays 
All enzymes (wild-type human BChE, E14-3, and E12-7) were expressed and 
purified as described previously (155), and the catalytic activities of the purified enzymes 
against BE (and (-)-cocaine for comparison) were determined by performing a UV-Vis 
spectrophotometric assay. Using the UV-Vis spectrophotometric assay, the catalytic 
activity of the enzymes against BE and (-)-cocaine were determined at the same time 
under the same experimental conditions except the concentration of the enzymes and 
substrates, to make sure that the known enzyme activity against (-)-cocaine can be 
reproduced. The enzymatic reaction was initiated by adding 180 l of a substrate (BE 
or (-)-cocaine) solution to 20 l of an enzyme solution. The final reaction systems of 
BE have the initial BE concentrations of 500, 300, 200, 100, 50, 20, and 10 µM, 
whereas the final reaction systems of (-)-cocaine have initial (-)-cocaine concentrations 
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of 50, 30, 20, 10, 5, 2, and 1 M. The reaction temperature was 25°C, and the buffer 
used was 0.1 M potassium phosphate (pH 7.4). The initial rates of the enzymatic 
hydrolysis of BE/(-)-cocaine in various initial substrate concentrations were estimated 
by following the change in the intrinsic absorbance peak of BE/(-)-cocaine at 230 nm 
with time using a GENios Pro Microplate Reader (TECAN, Research Triangle Park, 
NC) with the XFluor software. The initial reaction rates were calculated from the linear 
portions of the progress curves. All assays were carried out in triplicate. The 
Michaelis-Menten kinetic analysis was performed by using Prism 5 (GraphPad 
Software Inc., San Diego, CA) to determine the Vmax and KM values. 
3.2.3 Kinetic modeling 
Kinetic modeling of (-)-cocaine in humans was performed by use of a MatLab 
program (developed in house) (125, 156, 157) in a way similar to that of our recently 
developed pharmacokinetic modeling of (-)-cocaine in the presence of a 
cocaine-metabolizing enzyme (125, 158). The previously used kinetic model (155) did not 
involve BE. By using a one-compartment model, the present kinetic modeling also 
accounted for the transformation of (-)-cocaine to BE and the subsequent BE hydrolysis 
in the presence of wide-type BChE or a highly efficient cocaine-metabolizing enzyme 
E12-7.  
3.2.4 Subjects for in vivo studies 
Male Sprague-Darley rats (200-250 g) were ordered from Harlan (Harlan, 
Indianapolis, IN) and were housed initially in 2 to 4 rats per cage. All rats were allowed 
ad libitum access to food and water and were maintained on a 12-hour light and dark 
cycle with lights on at 8 AM in a room kept at a temperature of 21 to 22°C. Experiments 
were performed in a same colony room in accordance with the Guide for the Care and 
Use of Laboratory Animals as adopted and promulgated by the National Institutes of 
Health. The animal protocol was approved by the Institutional Animal Care and Use 
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Committee (IACUC) at the University of Kentucky. 
3.2.5 In vivo tests of BE, ecgonine, and E12-7 in rats 
BE and ecgonine were provided by the National Institute on Drug Abuse (NIDA) 
Drug Supply Program (Bethesda, MD). General anesthetic isoflurane was utilized with 
nose cone during the administration of BE and E12-7 (or saline). Rats were injected 
with saline, 0.15 or 5 mg/kg of E12-7 through tail vein 1 min before IV injection of 2 
mg/kg BE (~6.9 μmole/kg). Four rats were used for each set of experiments (n=4), 
About 50 to 75 μl of blood was collected from saphenous veins into capillary tubes and 
immediately diluted in 100 μl of 250 μM paraoxon at 2, 5, 10, 30, 60, 90, 120, 150, and 
180 min after the IV injection of BE or ecgonine. Paraoxon is an irreversible BChE 
inhibitor that can stop the enzymatic hydrolysis of BE between blood sampling and 
analysis. The diluted blood samples were stored at -70°C and assayed by using a high 
performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method 
(details described in chapter four). For determination of the active E12-7 concentration, 
the collected blood samples were not diluted with paraoxon, but centrifuged to obtain 
the plasma for the enzyme activity assays. 
3.3 Identification of enzymes hydrolyzing BE 
Our search for a metabolic enzyme of BE started from molecular docking (using a 
protocol described previously (155)) which enabled us to predict whether BE may bind 
with various serine esterases, including AChE, BChE and various mutants available in 
our lab, in a way suitable for the enzymatic hydrolysis of cocaine benzoyl ester group. 
Potential BE-hydrolyzing enzymes predicted by molecular docking were assayed in 
vitro for their catalytic activity against BE (see Methods section). Because it has been 
known that CocE and the T172R/G173Q mutant are active against cocaine and inactive 
against BE, one might simply assume that BChE and its mutants that are active against 
cocaine are also inactive against BE. Surprisingly, unlike CocE and its mutants, both 
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molecular docking and in vitro activity assays consistently revealed that BChE and our 
rationally designed mutant enzymes, i.e. the A199S/S287G/A328W/Y332G mutant 
(E14-3) (89) and A199S/F227A/S287G/A328W/Y332G mutant (E12-7)(102) of human 
BChE, are all active against BE. E12-7 is also known as CocH3, and E14-3 is also 
known as CocH1, in literature (48, 125).  
According to the enzyme-substrate binding structures obtained from molecular 
docking, BChE and the two mutants all can bind with BE in a similar way as their 
binding with (-)-cocaine, suitable for the desired enzymatic hydrolysis of (-)-cocaine 
benzoyl ester group. Depicted in Figure 3.2A and B are the obtained structures of 
wild-type BChE binding with (-)-cocaine and BE, showing that the backbone NH 
groups of G117 and A199 residues (within the oxyanion hole) are all close to the 
common carbonyl oxygen of the substrates such that they may form two favorable 
hydrogen bonds with the carbonyl oxygen of the substrate in the anticipated transition 
state (89) during the enzymatic reaction process for both (-)-cocaine and BE. Further, 
according to the E12-7-BE binding structure depicted in Figure 3.2C, the carbonyl 
oxygen of BE is also close to the hydroxyl group of S199 side chain; similar structure 
(not shown) was also obtained for the E14-3-BE binding. Thus, the carbonyl oxygen of 
BE may form three hydrogen bonds with G117 and S199 residues of the enzyme (E12-7 
or E14-3) within the oxyanion hole in the anticipated transition state during the 
enzymatic reaction process, suggesting that E12-7 (and E14-3) may have significantly 
improved catalytic activity against BE compared to wild-type BChE. Based on the 
modeling insights, we decided to carry out in vitro enzyme activity assays on human 
BChE, E14-3, and E12-7 against BE. Depicted in Figure 3.2D to F are data obtained 
from in vitro kinetic analysis on human BChE, E14-3, and E12-7 against BE. 
According to the kinetic data in Figure 3.2D to F, wild-type human BChE has a kcat of 
3.6 min-1 against BE comparable to its kcat against (-)-cocaine (kcat = 4.1 min-1). The 
main difference is that it has a relatively larger Michalis-Menten constant value (KM = 
83 M) against BE compared to its KM against (-)-cocaine (KM = 4.5 M). Notably, 
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despite of the relatively lower catalytic efficiency against BE compared to its own 
efficiency against (-)-cocaine, the catalytic efficiency of human BChE against BE is 
actually higher than that of the known most active anti-cocaine catalytic antibody 
15A10 (kcat = 2.3 min-1 and KM = 220 µM) against (-)-cocaine (159, 160).  
Interestingly, compared to wild-type human BChE, both enzymes E14-3 and E12-7 
that have considerably improved catalytic activities against (-)-cocaine and norcocaine 
also have significantly improved catalytic activity against BE. As seen in Figure 3.2, 
kcat = 23 min-1 for E14-3, kcat = 65 min-1 for E12-7, and kcat = 3.6 min-1 for the wild-type 
BChE against BE. So, E14-3 and E12-7 have improved the kcat of the wild-type BChE 
against BE by ~6-fold and ~18-fold, respectively. Meanwhile, E14-3 and E12-7 have 
slightly larger KM values (133 M for E14-3 and 207 M for E12-7). The improvement 
in kcat against BE is significant, although not as much as that (>1000-fold improvement) 
against (-)-cocaine (155).  
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Figure 3.2 Data obtained from molecular docking and in vitro kinetic analysis. (A) 
Wild-type BChE binding with (-)-cocaine; (B) Wild-type BChE binding with BE; (C) 
E12-7 binding with BE; (D) Kinetic data for wild-type BChE against BE; (E) Kinetic 
data for E14-3 against BE; (F) Kinetic data for E12-7 against BE. Indicated in the 
docked binding structures are the key internuclear distances in Å. For the kinetic data, 
the reaction rate (represented in nM min-1 per nM enzyme) was determined by 
measuring the rate of the change of the absorbance at 230 nm. This figure came from 
ref.(147). 
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Figure 3.3 Reaction scheme and kinetic equations used in the kinetic modeling. This 
figure came from ref.(147). 
 
3.4 Effects of E12-7 on the pharmacokinetics of (-)-cocaine and BE 
Following the identification of endogenous metabolic enzyme of BE (i.e. BChE) 
and its improved mutants (E14-3 and E12-7), we wanted to know whether E12-7 may 
significantly accelerate BE metabolism in the body. For this purpose, we first carried 
out kinetic modeling of cocaine and its metabolites (including norcocaine and BE). The 
kinetic model was based on our previous kinetic modeling (155) without accounting for 
BE formation and metabolism. Using the catalytic parameters for wild-type BChE- and 
E12-7-catalyzed hydrolysis of BE determined in the present study, we were able to 
expand the previous kinetic model (155) so that we may model the possible effects of 
E12-7 on the kinetic profile of BE when the plasma concentration of E12-7 is the same 
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as that of endogenous BChE in human plasma ([E] = 0.07 M) (155) or higher. Briefly, 
kinetic modeling of (-)-cocaine metabolism was carried out by using the kinetic 
equations shown in Figure 3.3 in the presence of three enzymes: BChE or CocH (which 
refers to either wild-type human BChE or E12-7) in human plasma; liver 
carboxylesterase; and CYP 3A4. Concerning CocH, a typical adult has a blood volume 
of ~5 L (158). Previously reported concentrations of endogenous BChE protein in human 
plasma ranged from 4 to 7 mg/L (161-163), giving an average value of ~6 mg/L or ~0.07 
M in terms of the total BChE protein concentration (denoted as [E]), assuming that a 
tetramer of human BChE has four active sites (164, 165). According to the known kinetic 
data reported previously (155) and obtained in the present study, we should have Vmax = 
0.29 M min-1 and KM = 4.5 M for the wild-type BChE against (-)-cocaine, Vmax = 
0.20 M min-1 and KM = 15 M for the wild-type BChE against norcocaine, and V'''max 
= 0.25 M min-1 and K'''M = 83 M for the wild-type BChE against BE when [E] = 0.07 
M. These kinetic parameters were used in our modeling with the wild-type BChE. 
Similarly, for E12-7, according to the kinetic data reported previously (155) and obtained 
in the present study, we should have Vmax = 400 M min-1 and KM = 3.1 M against 
(-)-cocaine, Vmax = 180 M min-1 and KM = 13 M against norcocaine, and V'''max = 
4.55 M min-1 and K'''M = 207 M against BE when [E] = 0.07 M. It was reported that 
non-specific carboxylesterase in humans and rodents is responsible for catalyzing the 
hydrolysis of the methyl ester group of (-)-cocaine to BE, and the reaction follows the 
simple Michaelis-Menten kinetics with KM = 116 µM (166). The human carboxylesterase 
mainly exists in liver, as well as other tissues. It is known that (-)-cocaine can diffuse in 
the body very rapidly to reach the equilibrium (158). Thus, it is reasonable to assume that 
(-)-cocaine, BE, and norcocaine distributions in the blood and other tissues can rapidly 
reach the equilibrium during the metabolic reactions. It was roughly estimated that F3 = 
4.5 M min-1 and k3 = 116 µM for (-)-cocaine hydrolysis to BE, according to the 
available experimental data including the enzyme activity (167) and the enzyme 
distribution in the body (168). In our previous study, it has been estimated that F2 = 14.4 
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M min-1 and k2 = 2.7 mM for the enzymatic oxidation of (-)-cocaine to norcocaine (125). 
These roughly estimated kinetic parameters were used in our kinetic modeling with 
various initial concentrations; our additional modeling tests revealed that kinetic 
modeling using different values of the catalytic parameters would lead to the same 
qualitative conclusions mentioned below.  
For possible cocaine overdose treatment using an exogenous cocaine-metabolizing 
enzyme, the cocaine abusers have already taken (-)-cocaine, and converted some 
(-)-cocaine to BE and norcocaine before the enzyme administration. In order to know 
whether E12-7 is also efficacious in hydrolysis of BE, in addition to (-)-cocaine and 
norcocaine, for the cocaine overdose treatment, we performed an additional, simplified 
kinetic modeling by assuming that 45% (-)-cocaine has been converted to BE, 5% 
(-)-cocaine has been converted to norcocaine, and only 50% (-)-cocaine remains as 
(-)-cocaine when t = 0. Depicted in Figure 3.4 are data obtained from the simplified 
kinetic modeling when A(0) (the initial concentration of (-)-cocaine) = 50 μM, B(0) (the 
initial concentration of BE) = 45 μM, and F(0) (the initial concentration of norcocaine) 
= 5 μM. As seen in Figure 3.4A to C, in the absence of E12-7, (-)-cocaine has a half-life 
(t1/2) of 98 min (t1/2 = 98 min), and t1/2 = 65 min for norcocaine and t1/2 = 318 min for BE. 
As seen in Figure 3.4D to F, in the presence of 0.07 μM E12-7, both (-)-cocaine and 
norcocaine are eliminated completely in less than 1 min. However, there was still a 
significant amount of BE left (AUC of BE = 2270 μM·min), but the half-life of BE is 
reduced significantly from 318 min to 36 min. These data qualitatively suggest that 
E12-7 can be effective for cocaine overdose treatment as it can completely break down 
(-)-cocaine and norcocaine, prevent (-)-cocaine from converting to BE, and 
significantly decrease the half-life and AUC of BE. So, E12-7 can lower the BE 
concentration in plasma through accelerating not only (-)-cocaine benzoyl ester 
hydrolysis, but also BE hydrolysis.  
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Figure 3.4 The modeled concentrations of (-)-cocaine, BE, and norcocaine in human 
blood when the initial concentrations of (-)-cocaine, BE, and norcocaine are 50, 45, and 
5 M, respectively. (A) to (C) refer to the time-dependent concentrations in the 
presence of wild-type human BChE (without E12-7), whereas (D) to (F) refer to the 
time-dependent concentrations in the presence of 0.07 μM E12-7. This figure came 
from ref.(147). 
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Figure 3.5 LC-MS/MS calibration curves for BE and ecgonine. Calibration curves 
were established by calculating the ratios of the peak area for analyte to that for the 
internal standard and plotting the ratio as a function of the ratio of the analyte 
concentration to the internal standard. X-axis (Analyte Conc. / IS Conc.) refers to the 
ratio of the analyte concentration to the corresponding internal standard concentration 
(IS Conc. = 0.1 µM for each internal standard compound). Y-axis (Analyte Area / IS 
Area) represents the ratio of the measured area for the analyte to that for the 
corresponding internal standard. For each compound (BE or ecgonine), data were 
fitted to a linear curve using the least-squares analysis with 1/x weighting. This figure 
came from ref.(147). 
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Figure 3.6 Metabolic profiles of BE in the presence and absence of an exogenous 
enzyme E12-7 (0.15 or 5 mg/kg) in rats (n=4 for each group). (A) Time course of BE 
concentration in rat blood. (B) Time course of ecgonine concentration formed from BE 
in rat blood. (C) Time course of ecgonine in rat blood after IV injection of 2 mg/kg 
ecgonine. (D) Time course of plasma E12-7 concentration in rat plasma after IV 
injection of 5 mg/kg E12-7. p < 0.001 represents that there were statistical differences 
in blood concentrations of BE and ecgonine between different experimental groups 
(treated with saline or 0.15 mg/kg E12-7 or 5 mg/kg E12-7) as determined by the 
two-way analysis of variance (ANOVA) tests using the SigmaPlot software (Systat 
Software, San Jose, CA). This figure came from ref.(147). 
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To validate the effectiveness of E12-7 in accelerating BE hydrolysis in vivo, four 
groups of rats (n=4 for each group) were used in this study. The obtained calibration 
curves for detecting BE and its hydrolysis product ecgonine are depicted in Figure 3.5, 
and the obtained in vivo data are shown in Figure 3.6. The first three groups of rats were 
injected intravenously (IV) with 0.15 mg/kg E12-7 or 5 mg/kg E12-7 or saline, 
followed by IV injection of 2 mg/kg BE one minute after the enzyme/saline injection. 
The dose of 0.15 mg/kg E12-7 led to an E12-7 concentration of ~3 mg/L (which is 
about a half of the average concentration of the endogenous BChE in human (155)) in 
plasma at ~2 min after IV injection of E12-7 according to our previous study (83). The 
dose of 5 mg/kg resulted in a plasma E12-7 concentration between 0.45 M at 5 min 
and ~0.1 M at 180 min (Figure 3.6D). The final group of rats were injected with 2 
mg/kg ecgonine (metabolite of BE), instead of 2 mg/kg BE, in order to know the 
elimination profile of ecgonine. For each rat, blood samples were collected at 2, 5, 10, 
30, 60, 90, 120, 150, and 180 min after the BE or ecgonine injection. The collected 
blood samples were analyzed by using a sensitive LC-MS/MS method to determine 
the blood concentrations of BE and ecgonine. In addition, blood samples collected 
from the rats injected with E12-7 were also analyzed for the E12-7 concentrations.  
Statistical analysis using the two-way analysis of variance (ANOVA) method 
implemented in the SigmaPlot software (Systat Software, San Jose, CA) revealed that p 
< 0.001, i.e. significant differences exist in the blood concentrations of BE and 
ecgonine between different experimental groups (treated with saline or 0.15 mg/kg 
E12-7 or 5 mg/kg E12-7). Further, according to the two-way ANOVA with post hoc 
Dunnett’s testing, the differences in the mean BE concentrations between the high-dose 
group (treated with 5 mg/kg E12-7) and the control group (treated with saline) were 
significant (p < 0.001), although the differences between the low-dose group (0.15 
mg/kg E12-7) and the control group were insignificant (p = 0.117). So, according to the 
in vivo data depicted in Figure 3.6, E12-7 dose-dependently accelerated BE hydrolysis 
to ecgonine. The enzyme-accelerated BE clearance (Figure 3.6A) is consistent with the 
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increased production of BE metabolite ecgonine (Figure 3.6B). In comparison with the 
ecgonine elimination profile shown in Figure 3.6C, the data depicted in Figure 3.6B 
revealed that ecgonine was formed continuously until BE was consumed. 
3.5 Perspectives in further enzyme development for cocaine overdose treatment 
This is the first identification of metabolic enzymes of BE, demonstrating that 
plasma enzyme BChE is the endogenous metabolic enzyme of BE and the BChE 
mutant E12-7 with significantly improved catalytic efficiency against BE compared to 
wild-type BChE may be used as an exogenous enzyme to effectively accelerate BE 
hydrolysis in the body for cocaine overdose treatment. Compared to RBP-8000 (the 
T172R/G173Q mutant of CocE) (88, 90) under current clinical development for cocaine 
overdose treatment, E12-7 is not only more efficient against cocaine (102), but also 
effective in hydrolyzing BE. Hence, E12-7 should be a more promising therapeutic 
candidate for cocaine overdose treatment in comparison with the T172R/G173Q 
mutant of CocE, although one would like to further improve the catalytic efficiency 
against BE for cocaine overdose treatment.  
In addition, our most recently reported study (169) demonstrated a novel protein 
form of E12-7 (or CocH3) (see Chapter 5), denoted as CocH3-Fc or catalytic antibody 
analog, which is an Fc-fused CocH3 dimer (CocH3-Fc) constructed by using CocH3 to 
replace the Fab region of human immunoglobulin G1. A single dose of CocH3-Fc was 
able to accelerate cocaine metabolism in rats even after 20 days and, thus, block 
cocaine-induced hyperactivity and toxicity for a long period of time (48). Thus, taking all 
of these together, E12-7 (or CocH3) in its Fc-fusion protein form may be used as a truly 
promising therapeutic candidate for treatment of both cocaine addiction and overdose.  
Further, the findings in this study provide an exciting starting point for future 
efforts to rationally design and discover new BChE mutants with further improved 
catalytic efficiency against BE, in addition to cocaine itself and other toxic metabolites 
(124, 155). A highly efficient enzyme which can efficiently convert BE to biologically 
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inactive metabolites is valuable for not only cocaine overdose treatment, but also BE 
detoxification in environment because BE widely exists in environment worldwide (149) 
including drinking water due to cocaine abuse. 
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Chapter 4: A Quantitative LC-MS/MS Method for Simultaneous Determination 
of Cocaine and Its Metabolites in Whole Blood 
 
Summary: As new metabolic pathways of cocaine were recently identified, a 
LC-MS/MS method was developed to simultaneously determine cocaine and nine 
cocaine-related metabolites in whole blood samples. One-step solid phase extraction 
was used to extract all of the ten compounds and corresponding internal standards 
from blood samples. All compounds and internal standards extracted were separated 
on an Atlantis T3 (100Å, 3 µm, 2.1 mm X 150 mm I.D) column and detected in 
positive ion and high sensitivity mode with multiple reaction monitoring. This method 
was validated for its sensitivity, linearity, specificity, accuracy, precision, recovery, 
and stability. All of the ten compounds were quantifiable ranging from the lower limit 
of quantification (LLOQs) of ~10 nM (1.9-3.2 ng/ml) to ~1000 nM (190-320 ng/ml) 
without any interfering substance. Accuracy and precision were determined; and both 
of them were within the acceptance criteria of the US FDA and European Medicines 
Agency (EMA) guidelines. The recovery was above 66.7% for all compounds. Stability 
tests demonstrated the stability of compounds under different storage conditions in 
whole blood samples. The method was successfully applied to a pharmacokinetic study 
with co-administration of cocaine and alcohol to rats.  
4.1 The need for development of a LC-MS/MS method 
Cocaine is one of the most reinforcing and hepatotoxic drugs, accounting for 
majority of illicit drug-related ED visits in the United State (170). In humans, 
approximately 40% of cocaine is hydrolyzed to biologically inactive metabolite EME 
by plasma enzyme BChE and liver CE-2, but more cocaine is biotransformed to BE 
via hydrolysis catalyzed by CE-1, and to norcocaine via oxidization catalyzed by liver 
microsomal cytochrome P450 (CYP) 3A4 (46, 171, 172). This metabolic profile of 
cocaine is highly affected by alcohol co-consumption which commonly happens 
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among cocaine users (173).  Especially, alcohol decreases the hydrolysis of cocaine to 
BE by inhibiting the catalytic activity of CE-1 (26, 174, 175). Meanwhile, ethanol reacts 
with cocaine via catalysis by CE-1 to produce cocaethylene, which is further oxidized 
to norcocaethylene by CYP 3A4 (26, 46, 171, 172). With alcohol co-administration, ~34% 
(oral), ~24% (IV), or ~18% (smoked) of cocaine is converted to cocaethylene through 
transesterification (173).  
Among the cocaine metabolites described above, BE, norcocaine, cocaethylene, 
and norcocaethylene are all physiologically/biologically active. These active 
metabolites have strong physiological effects such as vasoconstrictive effects, causing 
the hemodynamic changes, and producing lethality (171, 176-180). Recently, the metabolic 
pathways of those toxic compounds were identified during the process of developing 
therapeutic treatment for cocaine abuse. Briefly, BChE can catalyze the hydrolysis of 
BE to ecgonine (ECG), norcocaine to norecgonine methyl ester (NEME), 
cocaethylene to ecgonine ethyl ester (EEE), and norcocaethylene to norecgonine ethyl 
ester (NEEE) (124, 125, 147, 181).  
Disastrous medical and social consequences of cocaine make it a high priority to 
develop an anti-cocaine medication for treatment-seeking users (44, 45). There have 
been extensive efforts in development of therapeutic agents for cocaine abuse (16, 47, 48, 
77, 83, 91, 92, 102, 104, 172, 182-186). Although target-based, traditional pharmacodynamics 
approaches using a small-molecule compound to treat cocaine have not yielded a truly 
effective drug (77), alternative approaches using biologics (vaccines, monoclonal 
antibodies, and cocaine-metabolizing enzymes) have been shown some promise. 
Preclinical and clinical studies indicate that biologic approaches are effective in both 
blocking cocaine toxicity and reducing drug craving (48, 83, 102, 104, 172, 182, 183) (91, 92). 
Biologics block cocaine’s access to the central nervous system (CNS) or other acting 
sites by either binding with cocaine or hydrolyzing it (16, 47, 48), possibly resulting in a 
significant change of cocaine’s metabolic profile. There are extensive ongoing studies 
in developing highly effective medicines and, meanwhile, investigating their effects 
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on the altering metabolic profiles of cocaine in the presence/absence of other 
substances (e.g. alcohol) co-administrated. Therefore, it is highly desirable to develop 
a thoroughly validated bio-analytical method to simultaneously determine the blood 
concentrations of cocaine and related compounds.  
A HPLC method with a UV detector was established in our previous studies to 
characterize pharmacokinetic profiles of cocaine and cocaine-related compounds in 
rats (83, 124, 125). However, the UV method cannot be used to determine EME, ECG, 
NEME, EEE, and NEEE due to the lack of a conjugated system in these compounds. 
Several GC-MS and LC-MS/MS methods have been reported for simultaneous 
determination of cocaine and its metabolites including BE, norcocaine, cocaethylene, 
EME and ECG (187-192). These methods provided great separation, sensitivity and 
selectivity. However, none of them was developed to determine NEME, EEE, or 
NEEE in whole blood. We hereby present a LC-MS/MS method combined with 
one-step solid phase extraction, allowing simultaneous determination of cocaine and 
all of the nine cocaine-related compounds. The method was applied to the analysis of 
whole blood samples for pharmacokinetic study in rats with co-administration of 
cocaine and alcohol.  
4.2 Materials and methods 
4.2.1 Materials 
Cocaine, EME, BE, ECG, norcocaine, cocaethylene, EEE, and norcocaethylene 
were provided by the National Institute of Drug Abuse (NIDA) Drug Supply Program 
(Bethesda, MD). NEME and NEEE were synthesized in this study with the purity 
of >99%. The isotopic corresponding internal standards (IS) including cocaine-D3, 
EME-D3, BE-D3, ECG-D3, and cocaethylene-D3 were ordered from Cerilliant (Round 
Rock, TX). Ethanol, paraoxon, heparin, HPLC-grade methanol, and acetonitrile were 
purchased from Thermo Fisher Scientific (Waltham, MA). Formic acid was from 
Sigma-Aldrich (St. Louis, MO). Drug-free blank rat whole blood was sampled from 
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male Sprague–Darley rats that were ordered from Harlan (Indianapolis, IN). Mixed 
cation exchange model solid phase extraction cartridges (Oasis MCX 1 cc Vac 
Cartridge, 10 mg) were obtained from Waters (Milford, MA).  
4.2.2 Liquid chromatographic and mass spectrometric conditions 
A Shimadzu HPLC system (Shimadzu, Kyoto, Japan), consisting of a 
DGU-20A/3R degasser, LC-20AD binary pumps, CBM-20A controller, and 
SIL-20A/HT auto sampler, was used in this study. The chromatographic analysis was 
carried out on an Atlantis T3 (100Å, 3 µm, 2.1 mm X 150 mm I.D) column (Waters, 
Milford, MA). The mobile phase A consisted of 0.1% formic acid and mobile phase B 
consisted of mobile phase A: acetonitrile (10:90, v/v). The flow rate was set at 0.2 
ml/min. A 5 μl injection of each sample was loaded on to the column, separated and 
eluted using the following gradient: 0% B at 0 min, hold 0% B for 5 min, then B 
increased to 20% at 6 min, 40% B at 16 min, and 90% B at 18 min, hold 90% B for 4 
min, 0% B at 23 min, and re-equilibrate at 0% B for 5 min. The total run time was 28 
min. The column temperature was maintained at room temperature (~21oC). The auto 
sampler temperature was maintained at 15oC, and the auto sampler injection needle was 
washed with 200 μl mobile phase A: methanol (50:50, v/v) after each sample injection 
to reduce the carryover.  
The mass spectrometer, AB SCIEX tripleTOFTM 5600 (AB SCIEX, Redwood City, 
CA), was run in positive ion and high sensitivity mode under the following conditions 
and settings: positive ions were generated in the source using nitrogen as the source 
gases. Ion source gas 1 (GS1) and 2 (GS2) were set at 25 and 35 respectively, and 
curtain gas (CUR) was set at 40. Source gas temperature was set at 500oC. Ion spray 
voltage floating (ISVF) was 3000 V. Compound-specific ionization parameters, ion 
transition, declustering potential (DP), collision energy (CE), collision energy spread 
(CES), ion release delay (IRD), and ion release width (IRW) were optimized and 
summarized in Table 4.1. Analyst® TF 1.7 software (AB SCIEX, Redwood City, CA) 
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was used for instrument control and data acquisition. MultiQuant™ 3.0 software (AB 
SCIEX, Redwood City, CA) was used for quantitative analysis.  
 
Table 4.1 Optimized compound-specific source parameters for electrospray ionization 
Drugs Ion transition DP (V) CE (eV) CES (V) IRD IRW
Cocaine 304.1⟶182.1 100 30 3.0 45 17 
EME 200.1⟶182.1 80 31 3.0 45 17 
BE 290.1⟶168.1 60 28 3.0 45 17 
ECG 186.1⟶168.1 40 27 3.0 45 17 
Norcocaine 290.1⟶168.1 50 25 3.0 45 17 
NEME 186.1⟶136.1 90 36 3.0 45 17 
Cocaethylene 318.2⟶196.1 50 29 3.0 45 17 
EEE 214.1⟶196.1 40 28 3.0 45 17 
Norcocaethylene 304.2⟶182.1 80 24 3.0 45 17 
NEEE 200.1⟶182.1 60 22 3.0 45 17 
Cocaine-D3 307.2⟶185.1 50 30 3.0 45 17 
EME-D3 203.1⟶185.1 60 30 3.0 45 17 
BE-D3 293.2⟶171.1 60 30 3.0 45 17 
ECG-D3 189.1⟶171.1 30 25 3.0 45 17 
Cocaethylene-D3 321.2⟶199.2 50 28 3.0 45 17 
 
4.2.3 Treatment of blood samples for mass spectrometry 
The sample extraction method used in this study was established in our previously 
studied (147, 169, 181). Briefly, internal standard (IS) solution (0.1 μM for each IS) with a 
volume equal to that of the whole blood was added to each blood sample. The mixture 
was vortexed and then centrifuged for 15 min at 13,000 rpm; and the supernatant was 
collected and mixed with 500 μl 4% formic acid. Before being loaded onto solid-phase 
extraction column, Oasis MCX 1 cc Vac Cartridge, conditioned by 1 ml methanol 
followed by 1 ml water, the sample was centrifuged at 13,000 rpm for 15 min. Loaded 
cartridge was washed twice with 1 ml methanol, and the contents were eluted twice 
with 500 μl methanol/water solution (95:5, v/v, with 7.5% ammonium hydroxide). 
Eluate was evaporated to dryness at 25oC using a vacuum concentrator, reconstituted in 
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74 μl 0.1% formic acid, and centrifuged at 13,000 rpm for 15 min. Supernatant was 
transferred to a vial and stored refrigerated until analysis by LC-MS/MS. 
4.2.4 Preparation of stock, calibration standards and quality control samples 
Combined stock solution was prepared by mixing solutions of cocaine and its 
metabolites with those of the corresponding deuterium-labeled IS. The final 
concentration is 10 μM for each analyte, and 0.1 μM for each IS. Combined standard 
solutions, prepared by diluting the combined stock solution using the IS solution (0.1 
μM for each IS), with the various concentrations for each analyte and 0.1 μM for each 
corresponding IS. Calibration standards were prepared by adding 74 μl different 
concentrations of combined standard solutions into 174 μl blood mixture (74 μl whole 
blood + 100 μl paraoxon solution) from untreated Sprague-Dawley rats. Quality control 
samples were prepared in the same manner. The same method as described above was 
used to extract cocaine, nine cocaine-related compounds, and all ISs.  
4.2.5 Method validation 
Linearity and sensitivity. The validation was performed according to the United 
States (US) Food and Drug Administration (FDA) and European Medicines Agency 
(EMA) guidelines (193, 194). A calibration curve was established by calculating the ratio 
of the peak area for analyte to that for the internal standard and plotting the ratio as a 
function of the ratio of the analyte concentration to the internal standard. The limit of 
detection (LOD) was considered the lowest concentration of analyte where the 
signal-noise ratio was greater than 3. The lower limit of quantification (LLQC) was 
defined as the lowest concentration of analyte with accuracy < 20% of the coefficient of 
variation (CV) and a precision within 20% of the nominal concentration.  
Selectivity and carryover. Six sources of blank rat blood were individually 
analyzed and evaluated to determine if any interfering components were more than 20% 
of the LLQC for the analytes and 5% for the internal standards. Carryover was assessed 
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by injection of a drug-free blank sample after a high concentration sample. Carryover in 
the blank sample should be less than 20% of the LLQC for the analytes and 5% for the 
internal standards.  
Extraction recovery and matrix effect. Matrix effect and extraction recovery 
were determined in six replicates, at LLOQ, medium, and high concentration for all 
analytes. Samples were prepared in three ways as described by Liu et al. [2]: (a) 
prepared in the absence of blank matrix, (b) prepared by adding analyte to blank matrix 
extract, and (c), prepared by adding analyte to blank matrix prior to solid phase 
extraction. The matrix effect was calculated by dividing peak area of sample b by 
sample a; and the extraction recovery was calculated by dividing peak area of sample c 
by sample b. 
Precision and accuracy. Accuracy was expressed as the percentage of the 
determined concentration to the nominal concentration of the analyte; and precision 
was expressed as % CV. Intra-day accuracy and precision of this method were assessed 
by analyzing in a single run of six QC samples at three levels including LLOQ, medium 
QC, and high QC. For inter-day accuracy and precision, LLOQ, medium QC, and high 
QC from three runs on three different days were evaluated.  
Stability. The stabilities of cocaine and cocaine-related compounds in whole blood 
were evaluated using low, medium, and high QC samples (n = 6 for each level). The 
analyte was considered to be stable if the mean concentration at each level was within 
±15% of the nominal concentration except for the LLOQ which should be within ±20% 
of the nominal value. The freeze and thaw stability samples were analyzed following 
four freeze-thaw cycles. The short-term stability samples were stored at room 
temperature for 4 hours, and the long-term stability samples were stored at -70oC for 4 
months.  
4.2.6 Animal tests and sample collection 
Male Sprague–Darley rats (wt) were ordered from Harlan (Indianapolis, IN), and 
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housed initially as one or two rats per cage. All rats were allowed ad libitum access to 
food and water and maintained on a 12 h light/12 h dark cycle, with the lights on at 8:00 
a.m. at a room temperature of 21–22oC. Experiments were performed in the same 
colony room in accordance with the Guide for the Care and Use of Laboratory Animals 
as adopted and promulgated by the National Institutes of Health. The animal protocol 
was approved by the IACUC (Institutional Animal Care and Use Committee) at the 
University of Kentucky. Rats (n=10) received IP injection of 1 g/kg alcohol followed by 
cocaine administration (60 mg/kg, IP) 30 min after the injection of alcohol. Blood 
samples (5075 μl) were collected into a heparin-treated capillary tube at 5, 10, 15,20, 
30, 45, 60, 90, 120, 180, 240, 300, 360, 420, 480, and 600 min after the cocaine 
administration, and mixed with 100 µl paraoxon solution (250 μM paraoxon, 10 U/ml 
heparin) immediately. Blood samples were stored at −80oC until sample extraction. 
4.3 Method development 
The optimization of sample preparation was performed with rat whole blood. Both 
perchloric acid and formic acid were tested for the sample acidification. With the 
treatment of perchloric acid, majority of protein in blood samples was precipitated, but 
the extraction recovery rates of analytes were significantly lower than those with the 
treatment of formic acid. Thus, the formic acid was chosen to acidify the sample. 
Various concentrations of formic acid with different volumes were also tested to clean 
up the blood samples before being loaded on the SPE column. Eventually, 4% formic 
acid with a volume 500 μl was selected.  
A great challenge of this LC-MS/MS method is to separate three pairs of 
compounds: cocaine and norcocaethylene, norcocaine and BE, and ECG and NEME. 
Both compounds within each pair have exactly the same m/z, and very similar 
physicochemical properties and ion transition. Unqualified separation within the pair 
makes it extremely difficult to avoid the interference from each other. To solve this 
problem, the liquid chromatography method was modified according to the 
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well-established method by Dr. Imbert (195). The aqueous phase (phase A) of 2 mM 
ammonium formate, pH 3.0, was replaced by 0.1% formic acid. The gradient program 
was also adjusted with 0% B for the first 5 min separation, and longer holding of the 
initial condition before the next injection.  
Although the liquid chromatography method was optimized to get the good 
separation, the retention time of ECG (3.27 min) is still close to that of NEME (3.04 
min). In order to further avoid the interference between ECG and NEME, 
compound-specific source parameters for electrospray ionization were optimized to 
generate fragment ion of ECG mainly at m/z 168.1 and fragment ion of NEME mainly 
at m/z 136.1.  
4.4 Method validation 
Selectivity and carryover. Six blank matrix samples from different sources were 
analyzed to access the selectivity. There was no endogenous interference observed. The 
auto sampler injection needle was washed with 200 μl mobile phase A: methanol 
(50:50, v/v) after each sample injection to reduce carryover. Only slight carryover 
effects (less than 20% of the LLQCs for the analytes and 5% for the internal standards) 
in the blank samples were observed. To further avoid the carryover, a 0.1% formic acid 
sample was always injected following the samples.  
Linearity and sensitivity. LODs, LLOQs, and regression diagnostics of all 
analytes were reported in Table 4.2. The LODs and LLOQs for this method ranged 
from 0.2 to 0.9 ng/ml and 1.9 to 3.2 ng/ml, respectively, for all the substrates in whole 
blood samples. The calibration curve was linear over the concentration range of LLOQ 
to 200/300 ng/ml, with the correlation coefficients (r) > 0.99.  
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Table 4.2 Linearity, regression diagnostics, LODs, and LLOQs 
Compound Internal standard Slope Intercept r LOD 
(ng/ml) 
LLOQ 
(ng/ml)
Cocaine Cocaine-D3 0.7279 0.0319 0.9973 0.9 3.0 
EME EME-D3 0.8994 0.0352 0.9984 0.6 2.0 
BE BE-D3 0.6905 0.0562 0.9969 0.9 2.9 
ECG ECG-D3 0.6526 0.0263 0.9965 0.6 1.9 
Norcocaine Coc-D3 0.3274 0.0054 0.9974 0.3 2.9 
NEME Coc-D3 0.0816 0.0044 0.9942 0.2 1.9 
Cocaethylene Cocaethylene-D3 0.8920 0.0178 0.9986 0.3 3.2 
EEE Coc-D3 0.5001 0.0030 0.9972 0.2 2.1 
Norcocaethylene Coc-D3 0.4590 0.0061 0.9974 0.3 3.0 
NEEE Coc-D3 0.1131 0.0026 0.9966 0.2 2.0 
 
Extraction recovery and matrix effect. Extraction recovery and matrix effect 
values at low, medium, and high concentrations are reported in Table 4.3. Significant 
ion suppression was observed for EME at low, medium, and high concentrations, with 
matrix effects of 23.2%, 31.2%, and 34.6% respectively. Although the similar ion 
suppression for ECG in the blood matrix was reported (192), there was no such strong ion 
suppression for ECG observed in this study, with the matrix effects of ECG 67.6%, 
70.2 %, and 71.8% at low, medium, and high concentrations, respectively. The matrix 
effects of other eight substrates ranged from 52.1% to 104.1% at low concentration, 
from 57.7% to 88.3% at medium concentration, and from 59% to 84.7% at high 
concentration. The one-step solid phase extraction yielded good recoveries for all of the 
ten analytes, with the extraction recovery rates ranging from 66.7% to 96.2 at low 
concentration, from 82.9% to 113.9% at medium concentration, and from 76.8% to 
96.7 at high concentration.  
Precision and accuracy. Intra- and inter-day precision and accuracy were 
evaluated by analyzing QC samples (n = 6) at the low, medium, and high concentrations. 
The accuracy and precision data are summarized in Table 4.4. The intra-day precision 
(%CV) was 12.5% or less, and the inter-day precision was 13.6% or less. The intra-day 
accuracy was within ±13.6, and the inter-day accuracy was within ±15.0. According to 
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the US FDA and EMA guidelines (193, 194), the bias values for intra- and inter-accuracy 
should be within 15% of the nominal values for QC samples, except for the LLOQ 
which should be within 20% of nominal concentrations, and the CV values for intra- 
and inter-precision should not be larger than 15% for QC samples, except for the LLOQ 
which should not exceed 20%. Therefore, the accuracy and precision values for the 
intra- and inter-studies of all cocaine and the nine related compounds are acceptable.  
Stability. The stability testing is very important to evaluate the stability of all 
substrates during the sample collection and handling. The stability of analytes was 
evaluated at three concentrations after long-term and short-term storage, and after four 
freeze-thaw cycles. Results of stability testing are shown in Table 4.5. The mean 
concentration of each compound (cocaine or metabolite) at each level was always 
within 15% of the nominal concentration for all stability tests. These results indicate 
that all compounds were stable at room temperature for at least four hours and at -80oC 
for at least four months; and the QC samples of all compounds were not affected by the 
four freeze-thaw cycles.  
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Table 4.3 Matrix effect (ME) and extraction recovery at low, medium, and high concentrations in rat whole blood 
Compound Low concentration Medium concentration High concentration IS 
 ME (%) ER (%) ME (%) ER (%) ME (%) ER (%) ME (%) ER (%) 
Cocaine 62.3 ± 8.3 78.8 ± 19.2 82.2 ± 3.8 97.1 ± 7.4 81.8 ± 3.2 77.8 ± 8.2 84.2 ± 4.9 73.9 ± 3.0 
EME 23.2 ± 3.4 87 ± 8.6 31.2 ± 1.8 82.9 ± 5.6 34.6 ± 2.3 87.9 ± 3.4 23.6 ± 1.4 79.4 ± 5.6 
BE 104.1 ± 7.4 96.2 ± 6.8 82.8 ± 4.5 112.5 ± 9.3 65.5 ± 2.8 87.9 ± 3.4 87.8 ± 4.8 81.4 ± 5.2 
ECG 67.6 ± 6.5 95.1 ± 18.9 70.2 ± 4.7 113.9 ± 3.8 71.8 ± 3.7 90.8 ± 3.5 91.2 ± 5.6 84.2 ± 7.5 
Norcocaine 82.1 ± 6.1 73.1 ± 3.1 88.3 ± 4.8 92.2 ± 8.3 83.8 ± 4.4 83.9 ± 8.9 84.2 ± 4.9 73.9 ± 3.0 
NEME 52.1 ± 5.2 66.7 ± 11.3 57.7 ± 5.2 98 ± 6.9 59 ± 4.3 91.5 ± 5.0 84.2 ± 4.9 73.9 ± 3.0 
Cocaethylene 58.5 ± 4.8 73.9 ± 4.9 72.3 ± 2.6 90.3 ± 2.9 75.3 ± 4.1 76.8 ± 6.3 59.7 ± 4.8 72.9 ± 4.3 
EEE 75.6 ± 7.7 81.3 ± 10.2 82.6 ± 6.7 103.7 ± 8.2 84.7 ± 4.2 86.4 ± 4.5 84.2 ± 4.9 73.9 ± 3.0 
Norcocaethylene 79.9 ± 10.6 69.1 ± 4.7 77.7 ± 5.7 92.8 ± 2.8 75.9 ± 4.3 76.8 ± 8.4 84.2 ± 4.9 73.9 ± 3.0 
NEEE 84.3 ± 13.2 86.5 ± 11.5 81.6 ± 10.1 100.3 ± 13.8 81.8 ± 10.9 96.7 ± 9.1 84.2 ± 4.9 73.9 ± 3.0 
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Table 4.4 The intra- and inter-day precision and accuracy of the LC-MS/MS method used to quantify cocaine and its related compound in 
whole blood samples 
Drug Intra-day  Inter-day 
 L M H  L M H 
 CV 
(%) 
Bias 
(%) 
CV 
(%) 
Bias 
(%) 
CV 
(%) 
Bias 
(%) 
 CV 
(%) 
Bias 
(%) 
CV 
(%) 
Bias 
(%) 
CV 
(%) 
Bias 
(%) 
Cocaine 10.3 -11.1 7.1 4.5 4.0 0.3  10.8 -13.3 2.0 2.2 0.6 0.9 
EME 8.0 -2.9 4.0 -0.4 3.5 -3.2  7.8 -8.8 3.2 3.3 2.7 -0.2 
BE 11.1 -13.6 5.9 -0.7 7.1 -4.4  0.7 -14.8 1.1 0.6 1.9 -3.2 
ECG 12.5 9.7 10.9 -3.7 5.2 1.2  6.9 3.5 2.9 -0.5 4.3 1.7 
Norcocaine 2.5 11.8 2.9 2.3 7.9 9.9  0.9 12.8 1.1 3.4 1.6 11.5 
NEME 9.8 11.9 4.2 -6.4 5.9 10.2  13.6 8.5 7.0 -11.1 2.3 12.6 
Cocaethylene 4.1 -11.6 2.0 1.7 5.8 -1.1  1.9 -10.4 0.5 1.2 1.1 -2.3 
EEE 8.2 5.7 3.2 1.1 3.4 5.6  7.7 -1.1 6.4 -5.9 4.3 10.1 
Norcocaethylene 2.2 13.5 4.7 3.3 7.4 1.2  1.2 15.0 1.2 1.8 1.4 2.9 
NEEE 5.9 12.5 3.5 -4.1 6.0 7.2  11.9 11.4 1.6 -5.8 0.6 7.8 
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Table 4.5 Stability of analytes in whole blood samples 
Drug Stability Low concentration Medium concentration High concentration 
  CV (%) Bias (%) CV (%) Bias (%) CV (%) Bias (%) 
Cocaine Freeze-thaw (4 cycles) 15.0 2.8 9.8 -0.7 4.5 -4.7 
Bench top (4 hours) 12.4 2.3 6.7 0.3 4.8 -6.7 
Long-term (-70oC, 4 months) 17.7 -0.4 9.9 3.1 5.7 -3.1 
EME Freeze-thaw (4 cycles) 19.8 2.1 9.8 4.2 5.9 4.0 
Bench top (4 hours) 15.4 -9.6 4.7 5.9 6.9 0.3 
Long-term (-70oC, 4 months) 6.9 -3.1 8.6 6.3 4.6 3.5 
BE Freeze-thaw (4 cycles) 10.7 -0.9 7.2 5.5 7.9 3.4 
Bench top (4 hours) 13.6 -0.5 8.6 0.7 6.1 1.7 
Long-term (-70oC, 4 months) 9.3 -1.4 5.1 2.2 6.3 3.8 
ECG Freeze-thaw (4 cycles) 14.9 3.5 9.4 10.2 6.9 2.6 
Bench top (4 hours) 9.5 -1.5 4.8 7.6 10.4 3.6 
Long-term (-70oC, 4 months) 12.7 -4.9 9.7 10.7 6.5 3.8 
Norcocaine Freeze-thaw (4 cycles) 8.2 -1.0 11.7 -0.2 3.2 -1.2 
Bench top (4 hours) 8.4 -1.1 4.6 3.5 7.2 0.6 
Long-term (-70oC, 4 months) 3.3 -2.9 6.4 2.2 4.2 -1.4 
NEME Freeze-thaw (4 cycles) 12.4 -12.8 6.6 -5.4 9.4 0.1 
Bench top (4 hours) 11.3 -14.3 5.7 -1.5 10.6 -2.2 
Long-term (-70oC, 4 months) 10.0 -13.0 4.0 -1.7 10.8 -8.7 
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Table 4.5 (continued) Stability of analytes in whole blood samples 
Drug Stability Low concentration Medium concentration High concentration 
  CV (%) Bias (%) CV (%) Bias (%) CV (%) Bias (%) 
Cocaethylene Freeze-thaw (4 cycles) 4.7 0.7 4.8 -3.7 3.2 -4.1 
Bench top (4 hours) 4.2 1.7 4.5 -2.1 7.6 0.2 
Long-term (-70oC, 4 months) 5.4 3.7 3.9 -1.8 1.4 -0.6 
EEE Freeze-thaw (4 cycles) 7.0 -3.2 9.4 -9.3 7.7 9.4 
Bench top (4 hours) 8.5 1.2 4.4 -4.4 8.3 6.8 
Long-term (-70oC, 4 months) 6.2 -2.2 8.8 -5.2 13.5 -5.2 
Norcocaethylene Freeze-thaw (4 cycles) 5.9 0.1 7.2 -4.4 5.4 -6.4 
Bench top (4 hours) 3.2 -0.2 7.2 -0.9 4.1 -2.2 
Long-term (-70oC, 4 months) 5.1 -1.0 7.7 -1.3 3.6 2.8 
NEEE Freeze-thaw (4 cycles) 4.9 1.2 13.3 3.3 4.7 6.5 
Bench top (4 hours) 8.6 1.4 5.1 2.4 12.1 3.7 
Long-term (-70oC, 4 months) 10.1 -1.3 8.1 -0.2 9.0 -11.9 
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4.5 Application of the method 
The validated method was used to quantify the concentrations of cocaine and the 
nine related compounds in blood samples collected in a pharmacokinetic study with 
co-administration of cocaine and alcohol to rats. The mean blood concentration 
time-course profiles for cocaine and its metabolites after the IP injection of 60 mg/kg 
cocaine (30 min after the injection of 1 g/kg alcohol) to rats are depicted in Figure 4.1. 
Cocaine reached its highest concentration of 2400 ng/ml 20 min after the injection of 
cocaine, and then slowly fell over the 600-min period. Although part of cocaine was 
hydrolyzed to biological inactive product EME, majority of cocaine was converted to 
physiologically/biologically active metabolites, including BE, norcocaine, 
cocaethylene, and norcocaethylene. These active metabolites were further metabolized 
to compounds with no or little physiological effects (125, 147, 196) such as ECG and EEE 
by the endogenous enzymes, but their concentrations fell very slowly.  
 
 
Figure 4.1 Metabolic profiles of cocaine in the presence of alcohol in rats. Rats (n=10) 
were injected (IP) with 1 g/kg alcohol 30 min before the IP injection of 60 mg/kg 
cocaine. 
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4.6 Potential applications of the developed method to future studies 
We have successfully developed a simple and rapid LC-MS/MS method combined 
with one-step solid phase extraction to simultaneously determine the concentrations of 
cocaine, EME, BE, ECG, norcocaine, NEME, cocaethylene, EEE, norcocaethylene, 
and NEEE in the rat blood samples. Great specificity, sensitivity, linearity, recovery, 
accuracy, precision, and stability of the method have been well demonstrated. With a 
successful application to a pharmacokinetic study in rats with co-administration of 
cocaine and alcohol, this method will be valuable for further studies that aim to 
characterize anti-cocaine therapeutic agents and their effects on metabolic profiles of 
cocaine in the presence/absence of alcohol.   
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Chapter 5：Long-acting Cocaine Hydrolase for Addiction Therapy 
 
Summary: In the investigation described in this chapter, we demonstrate a novel 
CocH form, catalytic antibody analog, which is an Fc-fused CocH dimer (CocH-Fc) 
constructed by using CocH to replace the Fab region of human immunoglobulin G1. 
The CocH-Fc has not only a high catalytic efficiency against cocaine, but also a 
considerably longer biological half-life (e.g. ~107 hours in rats) like an antibody. A 
single dose of CocH-Fc was able to accelerate cocaine metabolism in rats even after 20 
days and, thus, block cocaine-induced hyperactivity and toxicity for a long period of 
time. In consideration of the general observation that the biological half-life of a protein 
drug in humans is significantly longer than that in rodents, the CocH-Fc reported in this 
study could allow dosing once every 2-4 weeks, or longer for cocaine addiction 
treatment in humans. The main results described in this chapter have been published 
(48).  
5.1 Cocaine hydrolase for cocaine addiction and its biological half-life 
Preclinical and clinical data have demonstrated that these CocHs are safe for use in 
humans and effective for accelerating cocaine metabolism. However, the actual 
therapeutic use of a CocH in cocaine addiction treatment is limited by the short 
biological half-life (e.g. 8 hours or shorter in rats) of the CocH. While TV-1380 (Figure 
5.1 B) has been proven safe and effective for use in animals and humans (91, 92), its 
actual therapeutic value for cocaine addiction treatment is still limited by the 
moderate biological half-life which is ~8 hr in rats (86) or 43-77 hr in humans (91). In 
addition, our more recently designed and discovered CocHs (102-104) are significantly 
more active against (-)-cocaine compared to TV-1380. It is highly desired to further 
engineer a more active CocH with a biological half-life longer than TV-1380. 
Our current enzyme engineering design strategy is based on the observation that an 
antibody (Ab), like human immunoglobulin G (IgG), has a very long biological 
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half-life, because the Fc region of IgG can bind with neonatal Fc receptor (FcRn) in the 
acidic environment of the endosome, and is later transported to the cell surface where 
upon exposure to a neutral pH IgG is released back to the main bloodstream (197). In 
comparison, a recombinant enzyme such as BChE usually has a very short biological 
half-life, and an antibody usually has no catalytic activity. Using a stable analog of 
transition state for cocaine hydrolysis, Landry et al. (198) successfully generated the first 
anti-cocaine catalytic antibody (CAb). Further effort generated the most active 
anti-cocaine CAb (Figure 5.1C), known as 15A10 (kcat = 2.3 min-1 and KM = 220 µM) 
(159, 160), whose catalytic activity is still significantly lower than that of wild-type BChE 
against (-)-cocaine. It has been difficult to further improve the CAb activity because a 
CAb, unlike an enzyme, can only help to stabilize the transition state for the 
non-enzymatic cocaine hydrolysis; there is no covalent bond formation or breaking 
between the substrate and CAb during the reaction process in light of a mechanistic 
study (150).  
We aimed to design a long-acting CocH form which has both the long biological 
half-life of an antibody and the high catalytic activity of a CocH against (-)-cocaine. For 
this purpose, starting from human IgG1 (dimer) which has both the Fc region (constant) 
and Fab region (variable) as seen in Figure 5.1C, we may replace the Fab region by a 
CocH for each subunit of the dimeric IgG1 to construct a catalytic antibody analog. 
Technically, the C-terminus of CocH3 (the A199S/F227A/S287G/A328W/Y332G 
mutant (102) of human BChE, full-length (FL) or truncated after amino acid #529 to 
delete the tetramerization domain) was fused with the N-terminus of the hinge region 
linked with Fc. CocH3 has a significantly higher catalytic efficiency (102) than CocH1 or 
TV-1380 against (-)-cocaine. The obtained dimeric CocH3-Fc fusion enzyme depicted 
in Figure 5.1D is highly efficient for cocaine hydrolysis. Obviously, the CocH3-Fc is 
not, but structurally similar to, antibody IgG1, containing Fc which can bind with FcRn 
in the acidic environment to prolong the biological half-life. Further, possible mutations 
on the Fc region of CocH3-Fc were also examined in order for the CocH3-Fc to have 
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the longest possible biological half-life. Various CocH3-Fc forms including Fc mutants 
were proposed, prepared, and tested for their actual in vitro and in vivo profiles. In 
addition, Albu-CocH1 or TV-1380 was also prepared and tested for comparison. As 
shown below, the CocH3-Fc optimized, indeed, has not only a significantly higher 
catalytic activity against cocaine, but also a much longer biological half-life compared 
to TV-1380. 
 
 
Figure 5.1 Protein structures and their catalytic parameters for cocaine hydrolysis. (A) 
Human BChE; (B) Albu-CocH1 (or TV-1380); (C) CAb 15A10; and (D) CocH3-Fc. 
This figure came from ref.(48). 
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5.2 Materials and methods  
5.2.1 Materials 
The cDNAs for CocH1 (the A199S/S287G/A328W/Y332G mutant of human 
BChE) and CocH3 (the A199S/F227A/S287G/A328W/Y332G mutant of human BChE) 
containing N-terminal signal were generated in our previous studies (89, 102). 
pFUSE-hIgG1-Fc2 plasmid was purchased from InvivoGen (San Diego, CA). The 
cDNA (Clone ID: HsCD00005810) for human serum albumin (HSA) was obtained 
from DF/HCC DNA Resource Core (Boston, MA). Protein expression vector 
pCMV-MCS was ordered from Agilent (Santa Clara, CA), and pCSC-SP-PW lentiviral 
vector (plasmid 12335), pMDLg/pRRE (plasmid 12251), pRSV-Rev (plasmid 12253), 
and pCMV-VSV-G (plasmids 8454) were obtained from Addgene (Cambridge, MA). 
Phusion DNA polymerase, restriction endonucleases, T4 DNA ligase were ordered 
from New England Biolabs (Ipswich, MA). DpnI endonuclease was obtained from 
Thermo Fisher Scientific (Waltham, MA). All oligonucleotides were synthesized by 
Eurofins MWG Operon (Huntsville, AL). Chinese Hamster Ovary-suspension (CHO-S) 
cells, Human Embryonic Kidney (HEK)-293FT, FreeStyleTM CHO Expression 
Medium, HT Supplement, L-glutamine, Dulbecco’s Modified Eagle’s Medium 
(DMEM), Fetal Bovine Serum (FBS), 4-12% Tris-Glycine Mini Protein Gel, and 
SimpleBlue SafeStain were from Invitrogen (Grand Island, NY). TransIT-PRO® 
Transfection Kit was obtained from Mirus (Madison, WI). The rmp Protein A 
Sepharose Fast Flow was purchased from GE Healthcare Life Sciences (Pittsburgh, 
PA). Centrifugal Filter Units were from Millpore (Billerica, MA). (−)-Cocaine was 
provided by the National Institute on Drug Abuse (NIDA) Drug Supply Program 
(Bethesda, MD); and [3H](−)-Cocaine (50 Ci/mmol) was ordered from PerkinElmer 
(Waltham, Massachusetts).  
Sprague-Darley rats (200–250 g) and CD-1 mice (25–30 g) were ordered from 
Harlan (Harlan, Indianapolis, IN). All other chemicals were purchased from Thermo 
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Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO). 
5.2.2 Expression plasmids construction 
With specific base-pair alterations, site-directed mutagenesis was performed to 
obtain the cDNAs for Fc(WT) (i.e. wild-type Fc), Fc(M1) (i.e. the 
A1Q/C6S/C12S/C15S/P24S mutant Fc), Fc(M2) (i.e. the 
A1V/E58Q/E69Q/E80Q/D98N/N101D/D142E/L144M mutant Fc), and Fc(M3) of 
human IgG1 using pFUSE-hIgG1-Fc2 plasmid as the template (199). Five expression 
plasmids, pCMV-CocH3-Fc(WT), pCMV-CocH3-Fc(M1), pCMV-CocH3-Fc(M2), 
pCMV-CocH3-Fc(M3), and pCMV-CocH3(FL)-Fc(M3), were constructed. Each 
plasmid contains a sequence encoding native BChE signal peptide followed by CocH3 
(truncated or full length) linked to the N-terminal of Fc (WT or mutant). To fuse CocH3 
to Fc, overlap extension polymerase chain reaction (PCR) with Phusion DNA 
polymerase was used. Primers (4 primers for each construction) used for plasmid 
construction were listed in Table 5.1. Primers 1 and 2 were used to amplify CocH3 with 
N-terminal signal peptide using pRc/CMV-CocH3 as template; primers 3 and 4 were 
used to amplify Fc using corresponding Fc cDNA as template. Once two DNA 
fragments were obtained, they were fused together by using another PCR reaction with 
primers for the far ends (primers 1 and 4). Then the PCR product was digested with 
restrict endonucleases, Hind III and Bgl II, and was ligated to pCMV-MCS expression 
vector using T4 DNA ligase. The same method was used to construct plasmids 
pCSC-CocH3-Fc(M3) and pCSC-Albu-CocH1 for large-scale protein production as 
well.   
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Table 5.1 Primers for plasmids construction. This table came from ref. (48). 
Construction Primer 
name 
Primer sequence 
pCMV-CocH3(FL)-Fc(
M3) 
Primer 1 CCCAAGCTTGGGAAGCCACCATGGATAGC
AAAGTCACAAT 
Primer 2 GCAGGACTTAGGCTCCACGAGACCCACAC
AACTTTCTTTCTTGCTAG 
Primer 3 TCTCGTGGAGCCTAAGTCCTGCGACAAAA
CTCACACATGCCCACCGTGCC 
Primer 4 GGAAGATCTTCATTTACCCGGAGACAGGG
AGAG 
pCMV-CocH3-Fc(WT) 
pCMV-CocH3-Fc(M1) 
pCMV-CocH3-Fc(M2) 
pCMV-CocH3-Fc(M3) 
Primer 1 CCCAAGCTTGGGAAGCCACCATGGATAGC
AAAGTCACAAT 
Primer 2 GCAGGACTTAGGCTCCACGACTTTTGGAA
AAAATGATGTCCAGAAT 
Primer 3 AGTCGTGGAGCCTAAGTCCTGCGACAAA
ACTCACACATGCCCACCGTGCC 
Primer 4 GGAAGATCTTCATTTACCCGGAGACAGGG
AGAG 
pCSC-CocH3-Fc(M3) Primer 1 CCCGGATCCGGGAAGCCACCATGGATAGC
AAAGTCACAAT 
Primer 2 ACTCTTGTGTGCATCGACTTTTGGAAAAA
ATGATGTCCAGAA 
Primer 3 CATTTTTTCCAAAAGTCGATGCACACAAG
AGTGAGGTTGCTC 
Primer 4 GGAGGGCCCTCATTTACCCGGAGACAGGG
AGAG 
pCSC-Albu-CocH1 Primer 1 CCCGGATCCGGGAAGCCACCATGGATAGC
AAAGTCACAAT 
Primer 2 ACTCTTGTGTGCATCGACTTTTGGAAAAA
ATGATGTCCAGAA 
Primer 3 CATTTTTTCCAAAAGTCGATGCACACAAG
AGTGAGGTTGCTC 
Primer 4 GGACTCGAGTTATAAGCCTAAGGCAGCTT
GACTTG 
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5.2.3 Protein expression and purification in small-scale 
CHO-S cells, incubated at 37°C in a humidified atmosphere containing 8% CO2, 
were transfected with plasmids encoding the proteins using TransIT-PRO® 
Transfection Kit once cells had grown to a density of 1.0 × 106 cells/ml. The culture 
medium (FreeStyle™ CHO Expression Medium with 8 mM L-glutamine) was 
harvested 7 days after transfection. Secreted enzyme in the culture medium was 
purified by using protein A affinity chromatography. Pre-equilibrated rmp Protein A 
Sepharose Fast Flow was added into cell-free medium, and incubated overnight with 
occasional stirring; then packed the suspension in a column. After washing the column 
with 20 mM Tris-HCl, pH 7.4 until OD280 < 0.02, protein was eluted by pH and salt 
concentration adjustment. The eluate was dialyzed in storage buffer (50 mM HPEPS, 
20% Sorbitol, 1 M Glycine, pH 7.4) by Millipore Centrifugal Filter Units. This whole 
purification process was carried out in cold room at 6°C. The purified protein was 
stored at −80°C before enzyme activity tests and in vivo studies.  
5.2.4 Protein expression and purification in large-scale 
A lentivirus-based method described in our previous report (83) was performed to 
generate a high-efficient stable cell line expressing CocH3-Fc(M3). Briefly, to package 
the lentivirus particles carrying the gene of CocH3-Fc(M3), lentivirus was produced by 
co-transfecting pCSC-CocH3-Fc(M3) plasmid with the packaging vectors 
(pMDLg/pRRE and pRSV-Rev) and envelope plasmid (pCMV-VSV-G) into 
HEK-293FT cells by lipofection. The packaged lentivirus particles were transfected to 
CHO-S cells. After lentiviral transductions, infected cells were allowed to recover from 
the infection for 2 or more days, and transferred to a shake flask for further culture. The 
obtained stable CHO-S cell pool was kept frozen before being used for large-scale 
protein production. 
The large-scale protein production was performed in an agitated bioreactor 
BioFlo/CelliGen 115 (Eppendorf, Hauppauge, NY). Before being transferred into the 
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bioreactor, cells grew at 37oC in shake flasks till to designated volume and density. On 
the day of transferring, cells in shake flasks were centrifuged at 1500 rpm for 5 minutes 
at room temperature, resuspended in fresh culture medium, and transferred into the 
bioreactor. CO2/air gas overlay was set such that the pH of cell culture medium was 
maintained at 7.0-8.0. The bioreactor was run in a batch model with a temperature of 
32oC. After 9 days, the culture medium was harvested and the protein was purified. 
CocH3-Fc(M3) was purified by using the aforementioned protein A affinity 
chromatography which was performed on ÄKTA avant 150 system (GE Healthcare 
Life Sciences, Pittsburgh, PA). The purified protein was dialyzed in storage buffer, and 
stored at −80°C.  
5.2.5 Electrophoresis 
Purified CocH3-Fc(M3) was analyzed by SDS-PAGE electrophoresis. Two protein 
samples, protein in its native state and protein in a denatured state, were loaded in a 
4-12% Tris-Glycine Mini Protein Gel. In order to break up quaternary protein structure, 
protein sample was mixed with SDS-loading buffer, heated at 95oC for 10 minutes in 
the presence of a reducing agent, dithiothreitol (DTT). Electrophoresis was run at 100 
volt for 2 hours. The protein gel was stained with SimpleBlue SafeStain.  
5.2.6 In vitro activity test against (−)-cocaine 
A radiometric assay which was used in our previous studies (102, 104) was used to test 
catalytic activities of enzymes against (−)-cocaine. Briefly, 150 μl enzyme solution 
(100 mM phosphate buffer, pH 7.4) was added to 50 μl varying concentrations of 
[3H]-labeled (−)-cocaine, denoted as [3H](−)-cocaine (with 3H labeled on the benzene 
ring). The reaction was stopped by adding 200 μl 0.1 M HCl, which neutralized the 
liberated benzoic acid while ensuring a positive charge on the residual (−)-cocaine. 
[3H]Benzoic acid was extracted by 1 ml of toluene and measured by scintillation 
counting. All measurements were performed at 25oC. Substrate 
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concentration-dependent data were analyzed using standard Michaelis-Menten kinetics 
so that the catalytic parameters (kcat and KM) were determined.  
5.2.7 Determination of biological half-lives in rats 
Rats were used with the Guide for the Care and Use of Laboratory Animals as 
adopted and promulgated by the National Institutes of Health. The experimental 
protocols were approved by the IACUC (Institutional Animal Care and Use Committee) 
at University of Kentucky. Rats were injected with purified protein via tail vein (0.06, 
0.2 or 0.6 mg/kg for CocH3-Fc(M3); 0.06 or 5 mg/kg for Albu-CocH1; and 0.06 mg/kg 
for all other CocH3-Fc protein forms). Blood samples were taken from saphenous vein 
puncture using a needle. Approximately 50-100 µl blood was collected into a 
heparin-treated capillary tube at various time points after enzyme administration. 
Collected blood samples were centrifuged for 15 min at a speed of 5000 g to separate 
the plasma, which was kept at 4oC before analysis. Radiometric assay using 100 μM 
(−)-cocaine was used to measure the enzyme concentration in plasma. The 
time-dependent enzyme concentrations ([E]t) were fitted to a well-known 
double-exponential equation (200) by GraphPad Prism 5: ( tktkt BeAeE 21][
  ) which 
accounts for both the enzyme distribution process (the fast phase, associated with k1) 
and elimination process (the slow phase, associated with k2). The half-life (t1/2) 
associated with the enzyme elimination rate constant k2 is known as the elimination 
half-life or biological half-life.  
5.2.8 Characterization of cocaine clearance accelerated by CocH3-Fc(M3) 
Four rats received saline (IV) before injection of (−)-cocaine (5 mg/kg, IV), and 
other four rats received enzyme CocH3-Fc(M3) (0.2 mg/kg, IV) on Day 0, followed by 
(−)-cocaine administration (5 mg/kg, IV) on Days 8, 11, 14, and 20 after the 
CocH3-Fc(M3) injection. Blood samples (50-100 μl) were collected from saphenous 
vein into a heparin-treated capillary tube at 2, 5, 10, 15, 30, and 60 minutes after the 
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(−)-cocaine administration, and mixed with 100 µl of 25 µM paraoxon (which 
inactivates the enzymes) immediately. Blood samples were stored at −80oC until 
analysis by using an HPLC. To assay the (−)-cocaine and benzoic acid (the product of 
cocaine hydrolysis by the enzyme) concentrations in the blood samples, frozen blood 
samples were thawed on ice for more than 3 hours. Then 150 µl mobile phase (76% 0.1% 
trifluoroacetic acid and 24% acetonitrile) and 50 µl 7% HClO4 were added to each 
sample. The extraction mixture was vortex mixed for 1 minute, then centrifuged at 4oC 
for 15 minutes at 13,200 rpm. The supernatant was decanted into a 1.5 mL tube, labeled 
and stored at –80°C until analysis by HPLC. The chromatographic analysis was carried 
out on a Gemini® 5 µm C18 column (Phenomenex, Torrance, CA), using a mobile 
phase at a flow rate of 1 ml/min. (−)-cocaine fluorescence was monitored at 315 nm 
while exciting at 230 nm (83, 201), and benzoic acid absorbance was monitored at 230 nm. 
Chromatographic system used is composed a Waters 1525 binary HPLC pump, a 717 
plus antosampler, a 2487 dual λ absorbance detector, and a 2475 multi λ fluorescence 
detector (Waters, Milford, MA). 
5.2.9 Locomotor activity assay 
The effects of CocH3-Fc(M3) on cocaine-induced hyperactivity was evaluated by 
using a video-tracking system at the University of Kentucky’s Rodent Behavior Core. 
Mice received a single dose of CocH3-Fc(M3) (0.2 or 2 mg/kg, IV) or saline, followed 
by multiple doses of cocaine (15 mg/kg, IV) or saline after 1 hour, 1, 3, 5, 7, 9, 11, 13 
and 15 days. Before cocaine or saline administration, mice were allowed to acclimate to 
the test chambers for 1 h. The total distance traveled during the last half hour, which 
was collected in 5-min bins, was used as the basal level. After cocaine or saline 
administration, mice were immediately returned to the test chamber for the remaining 1 
hour of the session for activity monitoring. The locomotor tests were performed in high 
density, non-porous plastic chambers measuring 50 cm (L) × 50 cm (W) × 38 cm (H) in 
a light- and sound-attenuating behavioral test enclosure (San Diego Instruments, San 
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Diego, CA). Cumulative distance traveled was recorded by EthoVision XT video 
tracking system (Noldus Information Technology, Wageningen, Netherlands) to 
represent the locomotor activity. 
5.2.10 Protection study in mice 
Cocaine-induced acute toxicity was characterized in this study by the occurrence of 
convulsions. Cocaine-induced convulsion was defined as loss of righting posture for at 
least 5 seconds with the simultaneous presence of clonic limb movements (202). Mice 
received a single dose of CocH3-Fc(M3) (2 mg/kg, IV) or saline (IV) on Day 0, 
followed by daily dosing of cocaine (100 mg/kg, IP) starting on Day 4 until the 
occurrence of convulsion for a given mouse. Following cocaine administration, mice 
were immediately placed in containers for observation. The presence or absence of a 
convulsion was recorded for 60 min following cocaine administration (102).  
5.3 Optimization of the CocH3-Fc entity 
Key in vivo data obtained are depicted in Figures 5.2, 5.4, 5.7, 5.8, 5.9, 5.10, and 
5.11. All pharmacokinetic (PK) data depicted in Figures 5.2, 5.4, 5.7, and 5.8 were 
based on intravenous (IV) injection of the enzymes in rats. The PK data reveal that a 
CocH3-Fc form with the truncated CocH3 (without the tetramerization domain) has a 
much longer biological half-life (with t1/2 up to ~107 hours) compared to that (t1/2 = ~18 
hours) of the corresponding CocH3-Fc containing the full-length CocH3, denoted as 
CocH3(FL) in Figure 5.2, with a given Fc region. Notably, the only difference between 
CocH3(FL) and CocH3 is that CocH3(FL) has the extra 45 amino-acid residues (#530 
to #574, an -helix) (203) on the C-terminus. Compared to the CocH3-Fc structure, 
CocH3(FL)-Fc has an extra 45 amino-acid residues between CocH3 and Fc. These 45 
residues increase the length of the linker between CocH3 and Fc. Due to the existence 
of the longer linker, the CocH3 region is far away from the Fc region in CocH3(FL)-Fc 
as shown in Figure 5.3. The longer linker may be proteolyzed more easily because it is 
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flexible and, thus, CocH3(FL)-Fc has a shorter biological half-life than CocH3-Fc. The 
CocH3-Fc forms to be discussed below will be only those with the same CocH3 region, 
i.e. the truncated CocH3.  
To optimize the Fc region of the CocH3-Fc, we tested the use of wild-type Fc, 
denoted as Fc(WT), and a triple mutant (i.e. A1V/D142E/L144M) denoted as Fc(M3). 
In addition, we also tested the use of known Fc mutants, denoted as Fc(M1) (204) and 
Fc(M2) (205) here for convenience (see Methods section for the detail), that have been 
used to significantly prolong the half-lives of other types of therapeutic proteins 
(abatacept (204) and alefacept (205)). As seen in Figure 5.4, CocH3-Fc(M3) showed the 
longest biological half-life (t1/2 = ~107 hours) in rats within the CocH3-Fc forms 
examined. The A1V/D142E/L144M mutations on the Fc region prolonged the 
biological half-life of the CocH3-Fc by ~21 hours. The other two CocH3-Fc forms, i.e. 
CocH3-Fc(M1) and CocH3-Fc(M2), as the Fc region actually shortened the biological 
half-life of CocH3-Fc compared to Fc(WT), although Fc(M1) and Fc(M2) successfully 
prolonged the biological half-lives of other fusion proteins (204, 205) compared to 
Fc(WT).  
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Figure 5.2 Time-dependent normalized CocH activity of various CocH3-Fc forms. For 
convenience, CocH3(FL) represents the full-length (FL) CocH3, whereas CocH3 
(without indicating “FL”) refers to the truncated CocH3 (amino-acid residues 1-529). 
Rats (n=3 for each dose condition) were injected (IV) with the enzyme 
(CocH3(FL)-Fc(M3) or CocH3-Fc(M3)) at a dose of 0.06 mg/kg body weight. Blood 
samples were collected at various time points, and the separated plasma samples were 
analyzed by using a sensitive radiometric assay using [3H](-)-cocaine. This figure came 
from ref.(48). 
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Figure 5.3 Molecular structure of CocH3(FL)-Fc. Compared to the CocH3-Fc structure 
depicted in Figure 5.1D, the only difference is that CocH3(FL)-Fc shown in this figure 
has extra 45 amino-acid residues (forming an -helix) existing between the CocH3 and 
Fc regions. Here, CocH3 refers to the truncated CocH3 consisting of the first 529 
amino-acid residues the enzyme, whereas CocH3(FL) represents the full-length 
enzyme consisting of 574 amino-acid residues. This figure came from ref.(48). 
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Figure 5.4 Time-dependent normalized CocH activity of various CocH3-Fc forms. Rats 
(n=3 for each dose condition) were injected (IV) with the enzyme at a dose of 0.06 
mg/kg body weight. Blood samples were collected at various time points, and the 
separated plasma samples were analyzed by using a sensitive radiometric assay using 
[3H](-)-cocaine. This figure came from ref.(48). 
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5.4 Dose dependence of the enzyme activity in comparison with TV-1380 
To further characterize the most promising CocH3-Fc form, CocH3-Fc(M3), we 
developed a stable cell line using a lentiviral vector (83) to produce CocH3-Fc(M3) in 
large-scale. The purified CocH3-Fc(M3) is indeed a dimer as expected (see Figure 5.5). 
The in vitro kinetic parameters of the fused CocHs are essentially the same as the 
corresponding unfused CocHs (see Figure 5.1B and D and Figure 5.6 for the 
determined kcat and KM values).   
As seen in Figure 5.7, the biological half-life of CocH3-Fc(M3) (injected IV) in rats 
is independent of the dose and, therefore, the CocH3-Fc(M3) concentration at a given 
time point is linearly proportional to the dose. Depicted in Figure 5.9 are the 
time-dependent maximum CocH activity against cocaine: Vmax  kcat[E] where [E] 
represents the concentration of the enzyme (CocH3-Fc(M3) or Albu-CocH1) in rat 
plasma. Vmax = 1 U/L means that the enzyme is capable of hydrolyzing up to 1 µmole 
cocaine in 1 liter of plasma per minute (i.e. 1 µM min-1). The data in Figure 5.8 indicate 
that CocH3-Fc(M3) is far superior to Albu-CocH1 (TV-1380). In particular, after 
injection of 5 mg/kg Albu-CocH1 (TV-1380), the rat plasma had Vmax ≥ 50 U/L within 
~48 hours. In comparison, Vmax ≥ 50 U/L within ~100 hours after 0.2 mg/kg 
CocH3-Fc(M3) injection and ~275 hours after 0.6 mg/kg CocH3-Fc(M3) injection. 
Even a tiny dose (0.06 mg/kg) of CocH3-Fc(M3) produced a larger Vmax value in the 
plasma compared to that produced by 5 mg/kg Albu-CocH1 (TV-1380) starting at ~80 
hours after the CocH (CocH3-Fc(M3) or Albu-CocH1) injection; 0.2 mg/kg 
CocH3-Fc(M3) generated a larger Vmax value in the plasma compared to that generated 
by 5 mg/kg Albu-CocH1 (TV-1380) starting at ~38 hours after the CocH injection; and 
0.6 mg/kg CocH3-Fc(M3) led to a larger Vmax value in the plasma compared to that 
generated by 5 mg/kg Albu-CocH1 (TV-1380) starting at ~18 hours after the CocH 
injection.   
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Figure 5.5 Coomassie-Blue stained SDS electrophoresis gel of the purified 
CocH3-Fc(M3) (Marker – protein ladder; Native – native state; Reduced: under 
reducing conditions), supporting that the native structure of the purified CocH3-Fc(M3) 
was a dimer. This figure came from ref.(48). 
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Figure 5.6 Kinetic data obtained in vitro for (-)-cocaine hydrolysis catalyzed by 
CocH3-Fc(M3) and Albu-CocH1 (TV-1380). All measurements were in triplicate 
(n=3). The reaction rate is represented in M min-1 per nM enzyme. Based on the 
Michaelis-Menten analysis, kcat = 5,700 min-1 and KM = 2.8 µM for CocH3-Fc(M3) 
against (-)-cocaine, and kcat = 3,080 min-1 and KM = 3.0 µM for Albu-CocH1 against 
(-)-cocaine. This figure came from ref.(48). 
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Figure 5.7 Time-dependent normalized CocH activity of CocH3-Fc(M3). Rats (n=3 for 
each dose condition) were injected (IV) with the enzyme at a dose of 0.06, 0.2, and 0.6 
mg/kg body weight. Blood samples were collected at various time points, and the 
separated plasma samples were analyzed by using a sensitive radiometric assay using 
[3H](-)-cocaine. This figure came from ref.(48). 
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Figure 5.8 Time-dependent normalized CocH activity or Vmax (U/L) of CocH3-Fc(M3) 
and Albu-CocH1 (or TV-1380). Rats (n=3 for each dose condition) were injected (IV) 
with the enzyme (CocH3-Fc(M3) or Albu-CocH1) at a dose of 0.06 mg/kg body weight 
unless indicated explicitly otherwise. Blood samples were collected at various time 
points, and the separated plasma samples were analyzed by using a sensitive 
radiometric assay using [3H](-)-cocaine. This figure came from ref.(48). 
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5.5 Cocaine clearance accelerated by CocH3-Fc(M3) 
In a further in vivo test, rats were injected with a single dose of CocH3-Fc(M3) (0.2 
mg/kg, IV on Day 0), followed by IV injection of cocaine (5 mg/kg) on Days 8, 11, 14, 
and 20. After each cocaine injection, blood samples were collected at 2, 5, 10, 15, 30, 
and 60 min and analyzed for the concentrations of cocaine and benzoic acid (cocaine 
metabolite). The control curves in Figure 5.9 reflect the overall effects of all possible 
cocaine elimination pathways (83, 124, 206). In the control rats, the average concentration 
of cocaine at the first time point (2 min) was ~7.4 μM, while the average concentration 
of benzoic acid was ~0.2 μM. In the presence of CocH3-Fc(M3) on Day 8 after 
CocH3-Fc(M3) injection, the average concentration of cocaine at ~2 min in the blood 
sample was below 1 μM (~0.9 μM, see Figure 5.9A), while the average concentration 
of benzoic acid at the first time point (2 min) was ~11 μM (Figure 5.9B). So, 
CocH3-Fc(M3) hydrolyzed nearly all of the cocaine molecules within ~2 min after the 
cocaine injection on Day 8. According to the data in Figure 5.9B, the overall enzyme 
activity in rats gradually decreased from Day 8 to Days 11, 14, and 20 as expected. But 
the CocH3-Fc(M3) activity in rats at even such a low dose (0.2 mg/kg) was still 
significant after 20 days.  
It should be pointed out that CocH3-Fc(M3) is constructed from human protein 
sequences with mutations on only a few residues. As the human protein sequences 
associated with CocH3-Fc(M3) are different from the corresponding rodent protein 
sequences, we did not try to examine the potential antigenicity/immunogenicity of 
CocH3-Fc(M3) in animals in this study. However, according to clinical data reported 
for TV-1380 (91), one can reasonably assume that CocH3-Fc(M3) would induce none, a 
weak, or merely a transient immune response in humans. The fact that the 
CocH3-Fc(M3) was effective in these animals for 20 days suggests that this assumption 
might be true. 
 
 92 
 
5.6 Effectiveness of CocH3-Fc(M3) in blocking the physiological effects of cocaine 
In animal behavior studies, mice were injected (IV) with a single dose (2 or 0.2 or 0 
mg/kg) of CocH3-Fc(M3) on Day 0, followed by multiple sessions of intraperitoneal 
(IP) injection of cocaine (15 mg/kg) and hyperactivity (measured by increased 
horizontal distance traveled) recording after 1 hour and 24 hours (Day 1) and then every 
other day (Days 3, 5, 7, 9, 11, 13, and 15). For each session, the hyperactivity recording 
started 30 min prior to cocaine injection. Data recorded for these sessions are depicted 
in Figure 5.10A to H. The data show that CocH3-Fc(M3) completely blocked 
cocaine-induced hyperactivity one day (24 hours) after the 0.2 mg/kg CocH3-Fc(M3) 
injection, and still significantly attenuated cocaine-induced hyperactivity even after 11 
days. At a dose of 2 mg/kg, CocH3-Fc(M3) completely blocked cocaine-induced 
hyperactivity within 9 days, and still significantly attenuated cocaine-induced 
hyperactivity even after 15 days. 
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Figure 5.9 Cocaine clearance accelerated by CocH3-Fc(M3). Saline or 0.2 mg/kg 
CocH3-Fc(M3) was injected IV in rats (n=4), followed by IV injection of 5 mg/kg 
cocaine after 8, 11, 14, and 20 days. After each IV injection of 5 mg/kg cocaine, blood 
samples were collected at 2, 5, 10, 15, 30, and 60 min, and analyzed for the 
concentrations of (A) cocaine and (B) benzoic acid (a metabolite of cocaine). This 
figure came from ref.(48). 
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Figure 5.10 Effects of CocH3-Fc(M3) on cocaine-induced hyperactivity in mice. 
Hyperactivity test (n=8 for each dose condition): Saline or CocH3-Fc(M3) (enzyme) 
was injected IV, followed by multiple sessions of locomotor activity tests with IP 
injection of 15 mg/kg cocaine or saline after 1 hour and 24 hours (one day) and then 
every other day. Panels (A) to (H) respectively refer to the locomotor activity sessions 
on Days 1, 3, 5, 7, 9, 11, 13, and 15 after the CocH3-Fc(M3) injection. For each 
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locomotor activity session, the locomotor activity recording started at 30 min prior to 
the cocaine injection. This figure came from ref.(48). 
5.7 Effectiveness of CocH3-Fc(M3) in blocking the lethal effects of cocaine 
It is well-known that cocaine is lethal when the dose is high, with LD50 (the lethal 
dose which causes the death of 50% of a group of test animals) = 14 mg/kg (IV) (207) or 
95.1 mg/kg (IP) (208) for mouse. To examine how long CocH3-Fc(M3) can protect mice 
from the acute toxicity of a lethal dose of cocaine, mice were injected with a single dose 
of CocH3-Fc(M3) (2 mg/kg, IV) on Day 0, followed by a lethal dose of cocaine (100 
mg/kg, IP) every day (starting on Day 4) until convulsion occurred (end point of the 
toxicity test) for a given mouse. For the control group (without CocH3-Fc(M3) 
injection), all mice had convulsions within minutes after the first cocaine challenge, 
and 60% of the mice died soon after convulsion. For the test group receiving 2 mg/kg 
CocH3-Fc(M3), convulsions occurred only during the final cocaine challenge after 
10.2 days in average; convulsions did not occur during the daily cocaine challenge 
within 9.2 days in average. The average protection time <tp> provided by 2 mg/kg 
CocH3-Fc(M3) is 9.7 ± 1.7 days. Thus, injection of 2 mg/kg CocH3-Fc(M3) can 
effectively protect mice from the acute toxicity of the lethal dose of cocaine (100 mg/kg, 
IP) for nearly 10 days.  
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Figure 5.11 Effects of CocH3-Fc(M3) on cocaine-induced toxicity in mice. Toxicity 
test (n=5): A single dose of CocH3-Fc(M3) (2 mg/kg, IV) was followed by a daily 
dosing of cocaine (100 mg/kg, IP) starting on Day 4 until convulsions occurred (end 
point of the toxicity test) for a given mouse. For a given mouse, if convulsions occurred 
during the final cocaine challenge on Day m, but did not occur during the cocaine 
challenge on and before Day m-1, then the protection time (tp) for this mouse was 
considered as between m-1 and m days: m-1 < tp > m or tp = m-1/2 days. <tp> represents 
the average tp value for all mice in the group. This figure came from ref.(48). 
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5.8 Perspectives in clinical development of cocaine hydrolase for cocaine addiction 
treatment 
We have successfully designed a novel long-acting cocaine-metabolizing enzyme 
form, CocH3-Fc. The optimized CocH3-Fc entity, CocH3-Fc(M3), indeed has a long 
biological half-life like an antibody, but with an unprecedentedly high catalytic 
efficiency compared to all catalytic antibodies known to date. Compared to the most 
active anti-cocaine catalytic antibody 15A10 (kcat = 2.3 min-1, KM = 220 µM, and t1/2 < 
24 hours in rats) (209), the CocH3-Fc(M3) has an even significantly longer biological 
half-life (kcat = 5,700 min-1, KM = 2.8 µM, and t1/2 = ~107 hours in rats) and 
~200,000-fold improved catalytic efficiency against cocaine. The long-acting 
CocH3-Fc(M3) is highly efficient in blocking the physiological and toxic effects of 
cocaine for a long period of time. Further, it is well known that a protein drug generally 
has a significantly longer biological half-life in humans compared to that in rats, e.g. t1/2 
= 3-6 days in rats and 12-23 days in humans for abatacept, Fc(M1)-fused human 
cytotoxic lymphocyte associated antigen (204). Thus, one may reasonably expect that an 
appropriately chosen dose of CocH3-Fc(M3) may effectively prevent both relapse and 
overdose for 2-4 weeks or longer during cocaine addiction treatment for humans.  
The general strategy of developing a long-acting drug-metabolizing enzyme for the 
treatment of cocaine abuse may also be useful in the development of long-acting forms 
of other therapeutic enzymes. To develop a truly long-acting enzyme form fused with 
Fc, one must structurally optimize both the enzyme and Fc portions of the Fc-fused 
enzyme. Further, even if the protein fusion with Fc can really prolong the biological 
half-life of a therapeutic protein, the data obtained in this investigation demonstrate that 
certain amino-acid mutations on the Fc portion that can prolong biological half-life of 
an Fc-fused therapeutic protein may not necessarily prolong the biological half-life of 
another Fc-fused therapeutic protein.  
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Chapter 6: Concluding Remarks and Future Plan 
 
Enzyme therapy using an efficient cocaine-metabolizing enzyme is recognized as 
the most promising treatment strategy for cocaine overdose and addiction (16, 86, 91, 92). 
While the thermal instability and low catalytic activity against cocaine limit the clinical 
use of wild-type bacterial CocE and human BChE, site-directed mutagenesis based on 
molecular modeling have solved these problems and created efficient and thermally 
stable cocaine-metabolizing enzymes, that are mutants of CocE and BChE, as  
promising anti-cocaine medications (88, 89, 102-104, 148). A thermally stable CocE mutant 
(T172R/G173Q) (88), known as RBP-8000 (90), is currently in clinical development for 
cocaine overdose treatment; the human clinical trial Phase IIa has been completed, 
showing that the CocE mutant is safe and effective in hydrolyzing cocaine (90), but 
inactive against BE (a major, biologically active metabolite of cocaine) (4). 
Theoretically speaking, CocHs should be more promising candidates for the treatment 
of not only cocaine overdose, but also cocaine addiction, due to a relatively higher 
catalytic activity against cocaine, and longer biological half-life. However, whether 
CocHs can degrade BE into biological inactive metabolites remain to be one of the 
main concerns for cocaine overdose treatment as no metabolic enzyme of BE has ever 
been reported in literature. In addition, while TV1380, an HSA-fused CocH, showed 
some promise for cocaine addiction treatment, its actual therapeutic value for cocaine 
addiction treatment is still limited by the moderate biological half-life which is ~8 hr 
in rats (86) or 43-77 hr in humans (91). Thus, to address these two problems and some 
other concerns in further development of CocHs for the treatment of cocaine overdose 
and addiction, in the investigation described in this thesis, we have carried out kinetic 
characterization of an hCocH and a mCocH for their catalytic activities against cocaine 
and other substrates, identified enzymes that can hydrolyze not only cocaine, but also 
its long-lasting metabolite benzoylecgonine, developed a LC-MS/MS method for 
determining pharmacokinetic profiles of cocaine and metabolites, and developed a 
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long-acting form of hCocH.  
6.1 Summary of the major conclusions obtained from this investigation 
1) Enzymes mCocH and hCocH have improved the catalytic efficiency of mBChE 
and hBChE against (-)-cocaine by ~8- and ~2000-fold, respectively, although the 
catalytic efficiencies of mCocH and hCocH against other substrates, including ACh and 
BTC, are close to those of the corresponding wild-type enzymes mBChE and hBChE. 
According to the kinetic data, the catalytic efficiency of mBChE against (-)-cocaine is 
comparable to that of hBChE, but the catalytic efficiency of mCocH against (-)-cocaine 
is remarkably lower than that of hCocH by ~250-fold. The remarkable difference in the 
catalytic activity between mCocH and hCocH is consistent with the difference between 
the enzyme-(-)-cocaine binding modes obtained from molecular modeling.  
2) We have demonstrated for the first time that plasma enzyme BChE is the 
endogenous metabolic enzyme of BE and the BChE mutant E12-7 with significantly 
improved catalytic efficiency against BE compared to wild-type BChE may be used as 
an exogenous enzyme to effectively accelerate BE hydrolysis in the body for cocaine 
overdose treatment. Compared to RBP-8000 (the T172R/G173Q mutant of CocE) (88, 90) 
under current clinical development for cocaine overdose treatment, E12-7 is not only 
more efficient against cocaine (102), but also effective in hydrolyzing BE. Hence, E12-7 
should be a more promising therapeutic candidate for cocaine overdose treatment in 
comparison with the T172R/G173Q mutant of CocE, although one would like to 
further improve the catalytic efficiency against BE for cocaine overdose treatment.  
3) We have successfully developed a simple and rapid LC-MS/MS method 
combined with one-step solid phase extraction to simultaneously determine the 
concentrations of cocaine, EME, BE, ECG, norcocaine, NEME, cocaethylene, EEE, 
norcocaethylene, and NEEE in the rat blood samples. Great specificity, sensitivity, 
linearity, recovery, accuracy, precision, and stability of the method have been well 
demonstrated. With a successful application to a pharmacokinetic study in rats with 
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co-administration of cocaine and alcohol, this method will be valuable for further 
studies that aim to characterize anti-cocaine therapeutic agents and their effects on 
metabolic profiles of cocaine in the presence/absence of alcohol.   
4) We have developed a novel CocH form, catalytic antibody analog, which is an 
Fc-fused CocH dimer (CocH-Fc) constructed by using CocH to replace the Fab region 
of human immunoglobulin G1. The CocH-Fc has not only a high catalytic efficiency 
against cocaine, but also a considerably longer biological half-life (e.g. ~107 hours in 
rats) like an antibody. A single dose of CocH-Fc was able to accelerate cocaine 
metabolism in rats even after 20 days and, thus, block cocaine-induced hyperactivity 
and toxicity for a long period of time. In consideration of the general observation that 
the biological half-life of a protein drug in humans is significantly longer than that in 
rodents, the CocH-Fc reported in this study could allow dosing once every 2-4 weeks, 
or longer for cocaine addiction treatment in humans. The long-acting enzyme approach 
may provide a novel, truly promising therapy capable of effectively blocking the 
physiological and toxic effects of cocaine without affecting normal functions of the 
brain and other critical organs and prevent relapse during abstinence. 
6.2 Future plan concerning rational design of CocHs for cocaine abuse 
1) To further improve the catalytic efficiency of CocH against BE for cocaine 
overdose treatment;  
2) To further characterize the detailed toxicological and pharmacological profiles 
of CocH-Fc, such as the effectiveness, selectivity, and duration of CocH-Fc’s actions in 
cocaine self-administration and discrimination;  
3) To optimize a promising CocH form which has not only a higher catalytic 
activity against cocaine, but also a longer in vivo half-life compared to CocH-Fc;  
4) The most promising CocH form optimized in the further investigation will 
possiblely be ready for cGMP (current Good Manufacturing Practices) protein 
manufacturing and subsequent clinical trials.   
 101 
 
References 
1. Chiu, Y. C., Brecht, K., DasGupta, D., and Mhoon, E. (1986) Myocardial 
infarction with topical cocaine anesthesia for nasal surgery, Archives of 
Otolaryngology—Head & Neck Surgery 112, 988. 
2. UNODC (2014) World Drug Report 2014, New York, United Nations 
Publications. 
3. Schrank, K. S. (1993) Cocaine-related emergency department presentations, 
NIDA Research Monograph 123, 110-110. 
4. Brim, R. L., Noon, K. R., Collins, G. T., Nichols, J., Narasimhan, D., Sunahara, 
R. K., and Woods, J. H. (2011) The ability of bacterial cocaine esterase to 
hydrolyze cocaine metabolites and their simultaneous quantification using 
high-performance liquid chromatography-tandem mass spectrometry, 
Molecular Pharmacology 80, 1119-1127. 
5. Abuse, S., and Administration, M. H. S. (2012) The DAWN Report: Highlights 
of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related 
Emergency Department Visits, SAMHSA Rockville, MD. 
6. Landry, D. W., Zhao, K., Yang, G., Glickman, M., and Georgiadis, T. M. (1993) 
Antibody-catalyzed degradation of cocaine, Science 259, 1899-1901. 
7. Milton, A. L., and Everitt, B. J. (2012) Wiping drug memories, science 336, 
167-168. 
8. Ersche, K. D., Jones, P. S., Williams, G. B., Turton, A. J., Robbins, T. W., and 
Bullmore, E. T. (2012) Abnormal brain structure implicated in stimulant drug 
addiction, Science 335, 601-604. 
9. Kalivas, P. W. (2007) Neurobiology of cocaine addiction: implications for new 
pharmacotherapy, American Journal on Addictions 16, 71-78. 
10. Huang, X., Gu, H. H., and Zhan, C.-G. (2009) Mechanism for cocaine blocking 
the transport of dopamine: insights from molecular modeling and dynamics 
simulations, The Journal of Physical Chemistry B 113, 15057-15066. 
 102 
 
11. Bradberry, C. W. (2000) Acute and chronic dopamine dynamics in a nonhuman 
primate model of recreational cocaine use, The Journal of Neuroscience 20, 
7109-7115. 
12. Volkow, N. D. (2010) Cocaine: Abuse and addiction, NIH Publication, 
10-4166. 
13. Schmitt, K. C., and Reith, M. E. (2010) Regulation of the dopamine transporter, 
Annals of the New York Academy of Sciences 1187, 316-340. 
14. Fang, Y., and Rønnekleiv, O. K. (1999) Cocaine upregulates the dopamine 
transporter in fetal rhesus monkey brain, The Journal of Neuroscience 19, 
8966-8978. 
15. Di Chiara, G., Bassareo, V., Fenu, S., De Luca, M. A., Spina, L., Cadoni, C., 
Acquas, E., Carboni, E., Valentini, V., and Lecca, D. (2004) Dopamine and drug 
addiction: the nucleus accumbens shell connection, Neuropharmacology 47, 
227-241. 
16. Zheng, F., and Zhan, C.-G. (2012) Are pharmacokinetic approaches feasible for 
treatment of cocaine addiction and overdose?, Future Medicinal Chemistry 4, 
125-128. 
17. Beveridge, T. J., Smith, H. R., Nader, M. A., and Porrino, L. J. (2009) 
Abstinence from chronic cocaine self-administration alters striatal dopamine 
systems in rhesus monkeys, Neuropsychopharmacology 34, 1162-1171. 
18. Heard, K., Palmer, R., and Zahniser, N. R. (2008) Mechanisms of acute cocaine 
toxicity, The Open Pharmacology Journal 2, 70-78. 
19. Benowitz, N. L. (1993) Clinical pharmacology and toxicology of cocaine, 
Pharmacology & toxicology 72, 3-12. 
20. Johanson, C.-E., and Fischman, M. W. (1989) The pharmacology of cocaine 
related to its abuse, Pharmacological Reviews 41, 3-52. 
21. Uhl, G., Hall, F., and Sora, I. (2001) Cocaine, reward, movement and 
monoamine transporters, Molecular Psychiatry 7, 21-26. 
 103 
 
22. Crumb Jr, W. J., Kadowitz, P. J., Xu, Y.-Q., and Clarkson, C. W. (1990) 
Electrocardiographic evidence for cocaine cardiotoxicity in cat, Canadian 
Journal of Physiology and Pharmacology 68, 622-625. 
23. Narasimhan, D., Woods, J. H., and Sunahara, R. K. (2012) Bacterial cocaine 
esterase: a protein-based therapy for cocaine overdose and addiction, Future 
Medicinal Chemistry 4, 137-150. 
24. Brody, S. L., Slovis, C. M., and Wrenn, K. D. (1990) Cocaine-related medical 
problems: consecutive series of 233 patients, The American Journal of 
Medicine 88, 325-331. 
25. Mittleman, M. A., Mintzer, D., Maclure, M., Tofler, G. H., Sherwood, J. B., and 
Muller, J. E. (1999) Triggering of myocardial infarction by cocaine, Circulation 
99, 2737-2741. 
26. Collins, G. T., Zaks, M. E., Cunningham, A. R., Clair, C. S., Nichols, J., 
Narasimhan, D., Ko, M.-C., Sunahara, R. K., and Woods, J. H. (2011) Effects of 
a long-acting mutant bacterial cocaine esterase on acute cocaine toxicity in rats, 
Drug and Alcohol Dependence 118, 158-165. 
27. O'Leary, M. E., and Hancox, J. C. (2010) Role of voltage‐gated sodium, 
potassium and calcium channels in the development of cocaine‐associated 
cardiac arrhythmias, British Journal of Clinical Pharmacology 69, 427-442. 
28. Hollander, J. E., Shih, R. D., Hoffman, R. S., Harchelroad, F. P., Phillips, S., 
Brent, J., Kulig, K., and Thode Jr, H. C. (1997) Predictors of coronary artery 
disease in patients with cocaine-associated myocardial infarction. 
Cocaine-Associated Myocardial Infarction (CAMI) Study Group, The 
American Journal of Medicine 102, 158-163. 
29. Egashira, K., Morgan, K. G., and Morgan, J. P. (1991) Effects of cocaine on 
excitation-contraction coupling of aortic smooth muscle from the ferret, 
Journal of Clinical Investigation 87, 1322-1328. 
30. Schwartz, B. G., Rezkalla, S., and Kloner, R. A. (2010) Cardiovascular effects 
 104 
 
of cocaine, Circulation 122, 2558-2569. 
31. Wilbert-Lampen, U., Seliger, C., Zilker, T., and Arendt, R. M. (1998) Cocaine 
Increases the Endothelial Release of Immunoreactive Endothelin and Its 
Concentrations in Human Plasma and Urine Reversal by Coincubation With 
σ-Receptor Antagonists, Circulation 98, 385-390. 
32. Mo, W., Singh, A. K., Arruda, J. A., and Dunea, G. (1998) Role of nitric oxide 
in cocaine-induced acute hypertension, American Journal of Hypertension 11, 
708-714. 
33. Turillazzi, E., Bello, S., Neri, M., Pomara, C., Riezzo, I., and Fineschi, V. (2012) 
Cardiovascular effects of cocaine: cellular, ionic and molecular mechanisms, 
Current Medicinal Chemistry 19, 5664-5676. 
34. Devi, B., and Chan, A. (1999) Effect of cocaine on cardiac biochemical 
functions, Journal of Cardiovascular Pharmacology 33, 1-6. 
35. Moritz, F., Monteil, C., Mulder, P., Derumeaux, G., Bizet, C., Renet, S., 
Lallemand, F., Richard, V., and Thuillez, C. (2003) Prolonged cardiac 
dysfunction after withdrawal of chronic cocaine exposure in rats, Journal of 
Cardiovascular Pharmacology 42, 642-647. 
36. Pacifici, R., Fiaschi, A. I., Micheli, L., Centini, F., Giorgi, G., Zuccaro, P., 
Pichini, S., Di Carlo, S., Bacosi, A., and Cerretani, D. (2003) 
Immunosuppression and oxidative stress induced by acute and chronic 
exposure to cocaine in rat, International Immunopharmacology 3, 581-592. 
37. Ren, S., Tong, W., Lai, H., Osman, N. F., Pannu, H., and Lai, S. (2006) Effect of 
long-term cocaine use on regional left ventricular function as determined by 
magnetic resonance imaging, The American Journal of Cardiology 97, 
1085-1088. 
38. Isabelle, M., Vergeade, A., Moritz, F., Dautréaux, B., Henry, J.-P., Lallemand, F., 
Richard, V., Mulder, P., Thuillez, C., and Monteil, C. (2007) NADPH oxidase 
inhibition prevents cocaine-induced up-regulation of xanthine oxidoreductase 
 105 
 
and cardiac dysfunction, Journal of Molecular and Cellular Cardiology 42, 
326-332. 
39. Hale, S. L., Alker, K. J., Rezkalla, S. H., Eisenhauer, A. C., and Kloner, R. A. 
(1991) Nifedipine protects the heart from the acute deleterious effects of 
cocaine if administered before but not after cocaine, Circulation 83, 1437-1443. 
40. Brickner, M. E., Willard, J. E., Eichhorn, E. J., Black, J., and Grayburn, P. A. 
(1991) Left ventricular hypertrophy associated with chronic cocaine abuse, 
Circulation 84, 1130-1135. 
41. Tong, W., Lima, J. A., Meng, Q., Flynn, E., and Lai, S. (2004) Long-term 
cocaine use is related to cardiac diastolic dysfunction in an African–American 
population in Baltimore, Maryland, International Journal of Cardiology 97, 
25-28. 
42. Havranek, E. P., Nademanee, K., Grayburn, P. A., and Eichhorn, E. J. (1996) 
Endothelium-dependent vasorelaxation is impaired in cocaine arteriopathy, 
Journal of the American College of Cardiology 28, 1168-1174. 
43. Reviews, C. T. (2013) e-Study Guide for Ethical Reasoning for Mental Health 
Professionals, textbook by Gary G. Ford: Psychology, Psychology, Cram101. 
44. Karila, L., Gorelick, D., Weinstein, A., Noble, F., Benyamina, A., Coscas, S., 
Blecha, L., Lowenstein, W., Martinot, J. L., and Reynaud, M. (2008) New 
treatments for cocaine dependence: a focused review, The International Journal 
of Neuropsychopharmacology 11, 425-438. 
45. Xi, Z.-X., and Gardner, E. L. (2008) Hypothesis-driven medication discovery 
for the treatment of psychostimulant addiction, Current Drug Abuse Reviews 1, 
303-327. 
46. Gorelick, D. A. (2008) Pharmacokinetic approaches to treatment of drug 
addiction, Expert Review of Clinical Pharmacology 1, 277-290. 
47. Skolnick, P., White, D., and B Acri, J. (2015) Editorial (Thematic Issue: 
Emerging Targets for Stimulant Use Disorders: Where To Invest In An Era Of 
 106 
 
Constrained Resources?), CNS & Neurological Disorders-Drug Targets 
(Formerly Current Drug Targets-CNS & Neurological Disorders) 14, 691-691. 
48. Chen, X., Xue, L., Hou, S., Jin, Z., Zhang, T., Zheng, F., and Zhan, C.-G. (2016) 
Long-acting cocaine hydrolase for addiction therapy, Proceedings of the 
National Academy of Sciences 113, 422-427. 
49. Schindler, C. W., and Goldberg, S. R. (2012) Accelerating cocaine metabolism 
as an approach to the treatment of cocaine abuse and toxicity, Future Medicinal 
Chemistry 4, 163-175. 
50. Mooney, M. E., Poling, J., Gonzalez, G., Gonsai, K., Kosten, T., and Sofuoglu, 
M. (2008) Preliminary study of buprenorphine and bupropion for 
opioid-dependent smokers, American Journal on Addictions 17, 287-292. 
51. Winhusen, T., Lewis, D., Sharma, G., and Sparenborg, S. (2015) A multi-site, 
double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of 
buspirone as a relapse-prevention treatment for cocaine dependence, Drug & 
Alcohol Dependence 146, e24-e25. 
52. Kampman, K. M., Lynch, K. G., Pettinati, H. M., Spratt, K., Wierzbicki, M. R., 
Dackis, C., and O’Brien, C. P. (2015) A double blind, placebo controlled trial of 
modafinil for the treatment of cocaine dependence without co-morbid alcohol 
dependence, Drug and Alcohol Dependence 155, 105-110. 
53. Anderson, A. L., Reid, M. S., Li, S.-H., Holmes, T., Shemanski, L., Slee, A., 
Smith, E. V., Kahn, R., Chiang, N., and Vocci, F. (2009) Modafinil for the 
treatment of cocaine dependence, Drug and Alcohol Dependence 104, 133-139. 
54. Dackis, C. A., Kampman, K. M., Lynch, K. G., Plebani, J. G., Pettinati, H. M., 
Sparkman, T., and O'Brien, C. P. (2012) A double-blind, placebo-controlled trial 
of modafinil for cocaine dependence, Journal of Substance Abuse Treatment 43, 
303-312. 
55. Lofwall, M. R., Nuzzo, P. A., Campbell, C., and Walsh, S. L. (2014) 
Aripiprazole effects on self-administration and pharmacodynamics of 
 107 
 
intravenous cocaine and cigarette smoking in humans, Experimental and 
Clinical Psychopharmacology 22, 238-247. 
56. Meini, M., Moncini, M., Cecconi, D., Cellesi, V., Biasci, L., Simoni, G., 
Ameglio, M., Pellegrini, M., N Forgione, R., and Rucci, P. (2011) Aripiprazole 
and ropinirole treatment for cocaine dependence: evidence from a pilot study, 
Current Pharmaceutical Design 17, 1376-1383. 
57. Haney, M., Rubin, E., and Foltin, R. W. (2011) Aripiprazole maintenance 
increases smoked cocaine self-administration in humans, Psychopharmacology 
216, 379-387. 
58. Somoza, E. C., Winship, D., Gorodetzky, C. W., Lewis, D., Ciraulo, D. A., 
Galloway, G. P., Segal, S. D., Sheehan, M., Roache, J. D., and Bickel, W. K. 
(2013) A multisite, double-blind, placebo-controlled clinical trial to evaluate 
the safety and efficacy of vigabatrin for treating cocaine dependence, JAMA 
Psychiatry 70, 630-637. 
59. Kampman, K. M., Pettinati, H. M., Lynch, K. G., Spratt, K., Wierzbicki, M. R., 
and O’Brien, C. P. (2013) A double-blind, placebo-controlled trial of topiramate 
for the treatment of comorbid cocaine and alcohol dependence, Drug and 
Alcohol Dependence 133, 94-99. 
60. Nuijten, M., Blanken, P., van den Brink, W., and Hendriks, V. (2014) Treatment 
of crack-cocaine dependence with topiramate: A randomized controlled 
feasibility trial in The Netherlands, Drug and Alcohol Dependence 138, 
177-184. 
61. Johnson, B. A., Ait-Daoud, N., Wang, X.-Q., Penberthy, J. K., Javors, M. A., 
Seneviratne, C., and Liu, L. (2013) Topiramate for the treatment of cocaine 
addiction: a randomized clinical trial, JAMA Psychiatry 70, 1338-1346. 
62. Richards, J. R., Garber, D., Laurin, E. G., Albertson, T. E., Derlet, R. W., 
Amsterdam, E. A., Olson, K. R., Ramoska, E. A., and Lange, R. A. (2016) 
Treatment of cocaine cardiovascular toxicity: a systematic review, Clinical 
 108 
 
Toxicology 54, 345-364. 
63. Brown, E. S., Todd, J. P., Hu, L. T., Schmitz, J. M., Carmody, T. J., Nakamura, 
A., Sunderajan, P., Rush, A. J., Adinoff, B., and Bret, M. E. (2015) A 
randomized, double-blind, placebo-controlled trial of citicoline for cocaine 
dependence in bipolar I disorder, American Journal of Psychiatry 172, 
1014-1021. 
64. Moran-Santa Maria, M. M., Baker, N. L., Ramakrishnan, V., Brady, K. T., and 
McRae-Clark, A. (2015) Impact of acute guanfacine administration on stress 
and cue reactivity in cocaine-dependent individuals, The American Journal of 
Drug and Alcohol Abuse 41, 146-152. 
65. Shorter, D., Lindsay, J., and Kosten, T. (2013) The alpha-1 adrenergic 
antagonist doxazosin for treatment of cocaine dependence: a pilot study, Drug 
and Alcohol Dependence 131, 66-70. 
66. Newton, T. F., De La Garza II, R., Brown, G., Kosten, T. R., Mahoney III, J. J., 
and Haile, C. N. (2012) Noradrenergic α 1 receptor antagonist treatment 
attenuates positive subjective effects of cocaine in humans: a randomized trial, 
PLoS One 7, e30854. 
67. De La Garza, R., Galloway, G., Newton, T., Mendelson, J., Haile, C., Dib, E., 
Hawkins, R., Chen, C.-Y., Mahoney, J., and Mojsiak, J. (2014) Assessment of 
safety, cardiovascular and subjective effects after intravenous cocaine and 
lofexidine, Progress in Neuro-Psychopharmacology and Biological Psychiatry 
50, 44-52. 
68. Mooney, M. E., Herin, D. V., Specker, S., Babb, D., Levin, F. R., and Grabowski, 
J. (2015) Pilot study of the effects of lisdexamfetamine on cocaine use: A 
randomized, double-blind, placebo-controlled trial, Drug and Alcohol 
Dependence 153, 94-103. 
69. Indave, B. I., Minozzi, S., Pani, P. P., and Amato, L. (2016) Antipsychotic 
medications for cocaine dependence, The Cochrane Library 3, CD006306. 
 109 
 
70. Comer, S. D., Mogali, S., Saccone, P. A., Askalsky, P., Martinez, D., Walker, E. 
A., Jones, J. D., Vosburg, S. K., Cooper, Z. D., and Roux, P. (2013) Effects of 
acute oral naltrexone on the subjective and physiological effects of oral 
D-amphetamine and smoked cocaine in cocaine abusers, 
Neuropsychopharmacology 38, 2427-2438. 
71. Gorelick, D. A. (2012) Pharmacokinetic strategies for treatment of drug 
overdose and addiction, Future Medicinal Chemistry 4, 227-243. 
72. Volkow, N., Wang, G.-J., Fischman, M., Foltin, R., Fowler, J., Abumrad, N., 
Vitkun, S., Logan, J., Gatley, S., and Pappas, N. (1997) Relationship between 
subjective effects of cocaine and dopamine transporter occupancy, Nature 386, 
827-830. 
73. Kosten, T., and Owens, S. M. (2005) Immunotherapy for the treatment of drug 
abuse, Pharmacology & Therapeutics 108, 76-85. 
74. Orson, F. M., Kinsey, B. M., Singh, R. A., Wu, Y., Gardner, T., and Kosten, T. R. 
(2008) Substance abuse vaccines, Annals of the New York Academy of Sciences 
1141, 257-269. 
75. Haney, M., and Kosten, T. R. (2004) Therapeutic vaccines for substance 
dependence, Expert Review of Vaccines 3, 11-18. 
76. Shen, X., and Kosten, T. R. (2011) Immunotherapy for drug abuse, CNS & 
Neurological Disorders Drug Targets 10, 876-879. 
77. Skolnick, P. (2015) Biologic Approaches to Treat Substance-Use Disorders, 
Trends in Pharmacological Sciences 36, 628-635. 
78. Martell, B. A., Orson, F. M., Poling, J., Mitchell, E., Rossen, R. D., Gardner, T., 
and Kosten, T. R. (2009) Cocaine vaccine for the treatment of cocaine 
dependence in methadone-maintained patients: a randomized, double-blind, 
placebo-controlled efficacy trial, Archives of General Psychiatry 66, 
1116-1123. 
79. Kosten, T. R., Domingo, C. B., Shorter, D., Orson, F., Green, C., Somoza, E., 
 110 
 
Sekerka, R., Levin, F. R., Mariani, J. J., and Stitzer, M. (2014) Vaccine for 
cocaine dependence: a randomized double-blind placebo-controlled efficacy 
trial, Drug and Alcohol Dependence 140, 42-47. 
80. Maoz, A., Hicks, M. J., Vallabhjosula, S., Synan, M., Kothari, P. J., Dyke, J. P., 
Ballon, D. J., Kaminsky, S. M., De Bishnu, P., and Rosenberg, J. B. (2013) 
Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to 
the nonhuman primate CNS dopamine transporter, Neuropsychopharmacology 
38, 2170-2178. 
81. Norman, A. B., Tabet, M. R., Norman, M. K., Buesing, W. R., Pesce, A. J., and 
Ball, W. J. (2007) A chimeric human/murine anticocaine monoclonal antibody 
inhibits the distribution of cocaine to the brain in mice, Journal of 
Pharmacology and Experimental Therapeutics 320, 145-153. 
82. Norman, A. B., Norman, M. K., Buesing, W. R., Tabet, M. R., Tsibulsky, V. L., 
and Ball, W. J. (2009) The effect of a chimeric human/murine anti-cocaine 
monoclonal antibody on cocaine self-administration in rats, Journal of 
Pharmacology and Experimental Therapeutics 328, 873-881. 
83. Xue, L., Hou, S., Tong, M., Fang, L., Chen, X., Jin, Z., Tai, H.-H., Zheng, F., 
and Zhan, C.-G. (2013) Preparation and in vivo characterization of a cocaine 
hydrolase engineered from human butyrylcholinesterase for metabolizing 
cocaine, Biochemical Journal 453, 447-454. 
84. Howell, L., Nye, J., Stehouwer, J., Voll, R., Mun, J., Narasimhan, D., Nichols, J., 
Sunahara, R., Goodman, M., and Carroll, F. I. (2014) A thermostable bacterial 
cocaine esterase rapidly eliminates cocaine from brain in nonhuman primates, 
Translational Psychiatry 4, e407. 
85. Collins, G. T., Narasimhan, D., Cunningham, A. R., Zaks, M. E., Nichols, J., Ko, 
M.-C., Sunahara, R. K., and Woods, J. H. (2012) Long-lasting effects of a 
PEGylated mutant cocaine esterase (CocE) on the reinforcing and 
discriminative stimulus effects of cocaine in rats, Neuropsychopharmacology 
 111 
 
37, 1092-1103. 
86. Brimijoin, S., Gao, Y., Anker, J. J., Gliddon, L. A., LaFleur, D., Shah, R., Zhao, 
Q., Singh, M., and Carroll, M. E. (2008) A Cocaine Hydrolase Engineered from 
Human Butyrylcholinesterase Selectively Blocks Cocaine Toxicity and 
Reinstatement of Drug Seeking in Rats, Neuropsychopharmacology 33, 
2715-2725. 
87. Schindler, C. W., Justinova, Z., Lafleur, D., Woods, D., Roschke, V., Hallak, H., 
Sklair‐ Tavron, L., Redhi, G. H., Yasar, S., and Bergman, J. (2013) 
Modification of pharmacokinetic and abuse‐related effects of cocaine by 
human‐derived cocaine hydrolase in monkeys, Addiction Biology 18, 30-39. 
88. Gao, D., Narasimhan, D. L., Macdonald, J., Brim, R., Ko, M.-C., Landry, D. W., 
Woods, J. H., Sunahara, R. K., and Zhan, C.-G. (2009) Thermostable variants of 
cocaine esterase for long-time protection against cocaine toxicity, Molecular 
Pharmacology 75, 318-323. 
89. Pan, Y., Gao, D., Yang, W., Cho, H., Yang, G., Tai, H.-H., and Zhan, C.-G. 
(2005) Computational redesign of human butyrylcholinesterase for anticocaine 
medication, Proceedings of the National Academy of Sciences of the United 
States of America 102, 16656-16661. 
90. Nasser, A. F., Fudala, P. J., Zheng, B., Liu, Y., and Heidbreder, C. (2014) A 
randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine 
abusers: pharmacokinetic profile of rbp-8000 and cocaine and effects of 
RBP-8000 on cocaine-induced physiological effects, Journal of Addictive 
Diseases 33, 289-302. 
91. Cohen-Barak, O., Wildeman, J., van de Wetering, J., Hettinga, J., 
Schuilenga-Hut, P., Gross, A., Clark, S., Bassan, M., Gilgun-Sherki, Y., 
Mendzelevski, B., and Spiegelstein, O. (2015) Safety, Pharmacokinetics, and 
Pharmacodynamics of TV-1380, a Novel Mutated Butyrylcholinesterase 
Treatment for Cocaine Addiction, After Single and Multiple Intramuscular 
 112 
 
Injections in Healthy Subjects, Journal of Clinical Pharmacology 55, 573-583. 
92. Shram, M. J., Cohen-Barak, O., Chakraborty, B., Bassan, M., Schoedel, K. A., 
Hallak, H., Eyal, E., Weiss, S., Gilgun, Y., Sellers, E. M., Faulknor, J., and 
Spiegelstein, O. (2015 ) Assessment of Pharmacokinetic and Pharmacodynamic 
Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and 
Intravenously Administered Cocaine in Recreational Cocaine Users, Journal of 
Clinical Psychopharmacology 35, 396-405. 
93. Bresler, M. M., Rosser, S. J., Basran, A., and Bruce, N. C. (2000) Gene cloning 
and nucleotide sequencing and properties of a cocaine esterase from 
Rhodococcus sp. strain MB1, Applied and Environmental Microbiology 66, 
904-908. 
94. Larsen, N. A., Heine, A., Redwan, E.-R., Yeates, T., Landry, D., and Wilson, I. 
(2002) Structure determination of a cocaine hydrolytic antibody from a 
pseudomerohedrally twinned crystal, Acta Crystallographica Section D: 
Biological Crystallography 58, 2055-2059. 
95. Fang, L., Chow, K. M., Hou, S., Xue, L., Chen, X., Rodgers, D. W., Zheng, F., 
and Zhan, C.-G. (2014) Rational design, preparation, and characterization of a 
therapeutic enzyme mutant with improved stability and function for cocaine 
detoxification, ACS Chemical Biology 9, 1764-1772. 
96. Cooper, Z. D., Narasimhan, D., Sunahara, R. K., Mierzejewski, P., Jutkiewicz, 
E. M., Larsen, N. A., Wilson, I. A., Landry, D. W., and Woods, J. H. (2006) 
Rapid and robust protection against cocaine-induced lethality in rats by the 
bacterial cocaine esterase, Molecular Pharmacology 70, 1885-1891. 
97. Brim, R. L., Nance, M. R., Youngstrom, D. W., Narasimhan, D., Zhan, C.-G., 
Tesmer, J. J., Sunahara, R. K., and Woods, J. H. (2010) A thermally stable form 
of bacterial cocaine esterase: a potential therapeutic agent for treatment of 
cocaine abuse, Molecular Pharmacology 77, 593-600. 
98. Brim, R. L., Noon, K. R., Collins, G. T., Stein, A., Nichols, J., Narasimhan, D., 
 113 
 
Ko, M.-C., Woods, J. H., and Sunahara, R. K. (2012) The fate of bacterial 
cocaine esterase (CocE): an in vivo study of CocE-mediated cocaine hydrolysis, 
CocE pharmacokinetics, and CocE elimination, Journal of Pharmacology and 
Experimental Therapeutics 340, 83-95. 
99. Jbilo, O., Bartels, C. F., Chatonnet, A., Toutant, J.-P., and Lockridge, O. (1994) 
Tissue distribution of human acetylcholinesterase and butyrylcholinesterase 
messenger RNA, Toxicon 32, 1445-1457. 
100. Lockridge, O. (2015) Review of human butyrylcholinesterase structure, 
function, genetic variants, history of use in the clinic, and potential therapeutic 
uses, Pharmacology & Therapeutics 148, 34-46. 
101. Sun, H., Pang, Y.-P., Lockridge, O., and Brimijoin, S. (2002) Re-engineering 
butyrylcholinesterase as a cocaine hydrolase, Molecular pharmacology 62, 
220-224. 
102. Zheng, F., Yang, W. C., Ko, M. C., Liu, J. J., Cho, H., Gao, D. Q., Tong, M., Tai, 
H. H., Woods, J. H., and Zhan, C.-G. (2008) Most Efficient Cocaine Hydrolase 
Designed by Virtual Screening of Transition States, Journal of the American 
Chemical Society 130, 12148-12155. 
103. Xue, L., Ko, M.-C., Tong, M., Yang, W., Hou, S., Fang, L., Liu, J., Zheng, F., 
Woods, J. H., Tai, H.-H., and Zhan, C.-G. (2011) Design, preparation, and 
characterization of high-activity mutants of human butyrylcholinesterase 
specific for detoxification of cocaine, Molecular Pharmacology 79, 290-297. 
104. Zheng, F., Xue, L., Hou, S., Liu, J., Zhan, M., Yang, W., and Zhan, C.-G. (2014) 
A highly efficient cocaine-detoxifying enzyme obtained by computational 
design, Nature Communications 5, 3457. 
105. Narasimhan, D., Collins, G. T., Nance, M. R., Nichols, J., Edwald, E., Chan, J., 
Ko, M.-C., Woods, J. H., Tesmer, J. J., and Sunahara, R. K. (2011) Subunit 
stabilization and polyethylene glycolation of cocaine esterase improves in vivo 
residence time, Molecular pharmacology 80, 1056-1065. 
 114 
 
106. Ashani, Y., and Pistinner, S. (2004) Estimation of the upper limit of human 
butyrylcholinesterase dose required for protection against organophosphates 
toxicity: a mathematically based toxicokinetic model, Toxicological Sciences 
77, 358-367. 
107. Huang, Y.-J., Huang, Y., Baldassarre, H., Wang, B., Lazaris, A., Leduc, M., 
Bilodeau, A. S., Bellemare, A., Côté, M., and Herskovits, P. (2007) 
Recombinant human butyrylcholinesterase from milk of transgenic animals to 
protect against organophosphate poisoning, Proceedings of the National 
Academy of Sciences of the United States of America 104, 13603-13608. 
108. Lockridge, O., Blong, R. M., Masson, P., Froment, M.-T., Millard, C. B., and 
Broomfield, C. A. (1997) A single amino acid substitution, Gly117His, confers 
phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on 
human butyrylcholinesterase, Biochemistry 36, 786-795. 
109. Schneider, J. D., Marillonnet, S., Castilho, A., Gruber, C., Werner, S., Mach, L., 
Klimyuk, V., Mor, T. S., and Steinkellner, H. (2014) Oligomerization status 
influences subcellular deposition and glycosylation of recombinant 
butyrylcholinesterase in Nicotiana benthamiana, Plant Biotechnology Journal 
12, 832-839. 
110. Zhong, X., and Wright, J. F. (2013) Biological insights into therapeutic protein 
modifications throughout trafficking and their biopharmaceutical applications, 
International journal of cell biology 2013. 
111. Chilukuri, N., Parikh, K., Sun, W., Naik, R., Tipparaju, P., Doctor, B., and 
Saxena, A. (2005) Polyethylene glycosylation prolongs the circulatory stability 
of recombinant human butyrylcholinesterase, Chemico-biological interactions 
157, 115-121. 
112. Yang, W., Xue, L., Fang, L., Chen, X., and Zhan, C.-G. (2010) Characterization 
of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine, 
Chemico-Biological Interactions 187, 148-152. 
 115 
 
113. Willyard, C. (2015) Quest for the quitting pill, Nature 522, S53-55. 
114. Chen, X., Huang, X., Geng, L., Xue, L., Hou, S., Zheng, X., Brimijoin, S., 
Zheng, F., and Zhan, C.-G. (2015) Kinetic characterization of a cocaine 
hydrolase engineered from mouse butyrylcholinesterase, Biochemical Journal 
466, 243-251. 
115. Hamza, A., Cho, H., Tai, H.-H., and Zhan, C.-G. (2005) Molecular dynamics 
simulation of cocaine binding with human butyrylcholinesterase and its mutants, 
The Journal of Physical Chemistry B 109, 4776-4782. 
116. Pan, Y., Gao, D., Yang, W., Cho, H., and Zhan, C.-G. (2007) Free energy 
perturbation (FEP) simulation on the transition states of cocaine hydrolysis 
catalyzed by human butyrylcholinesterase and its mutants, Journal of the 
American Chemical Society 129, 13537-13543. 
117. Gao, Y., Atanasova, E., Sui, N., Pancook, J. D., Watkins, J. D., and Brimijoin, S. 
(2005) Gene transfer of cocaine hydrolase suppresses cardiovascular responses 
to cocaine in rats, Molecular Pharmacology 67, 204-211. 
118. Gao, Y., LaFleur, D., Shah, R., Zhao, Q., Singh, M., and Brimijoin, S. (2008) An 
albumin-butyrylcholinesterase for cocaine toxicity and addiction: Catalytic and 
pharmacokinetic properties, Chemico-Biological Interactions 175, 83-87. 
119. Anker, J. J., Brimijoin, S., Gao, Y., Geng, L., Zlebnik, N. E., Parks, R. J., and 
Carroll, M. E. (2012) Cocaine hydrolase encoded in viral vector blocks the 
reinstatement of cocaine seeking in rats for 6 months, Biological Psychiatry 71, 
700-705. 
120. Brimijoin, S., Orson, F., Kosten, T. R., Kinsey, B., Shen, X. Y., White, S. J., and 
Gao, Y. (2013) Anti-cocaine antibody and butyrylcholinesterase-derived 
cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and 
cocaine-induced locomotor activity in mice, Chemico-Biological Interactions 
203, 212-216. 
121. Gao, Y., Geng, L., Orson, F., Kinsey, B., Kosten, T. R., Shen, X., and Brimijoin, 
 116 
 
S. (2013 ) Effects of anti-cocaine vaccine and viral gene transfer of cocaine 
hydrolase in mice on cocaine toxicity including motor strength and liver 
damage, Chemico-Biological Interactions 203, 208-211. 
122. Geng, L., Gao, Y., Chen, X., Hou, S., Zhan, C.-G., Radic, Z., Parks, R., Russell, 
S. J., Pham, L., and Brimijoin, S. (2013) Gene transfer of mutant mouse 
cholinesterase provides high lifetime expression and reduced cocaine responses 
with no evident toxicity, PLoS One 8, e67446. 
123. Zlebnik, N. E., Brimijoin, S., Gao, Y., Saykao, A. T., Parks, R. J., and Carroll, M. 
E. (2014) Long-term reduction of cocaine self-administration in rats treated 
with adenoviral vector-delivered cocaine hydrolase: evidence for enzymatic 
activity, Neuropsychopharmacology 39, 1538-1546. 
124. Hou, S., Zhan, M., Zheng, X., Zhan, C.-G., and Zheng, F. (2014) Kinetic 
characterization of human butyrylcholinesterase mutants for the hydrolysis of 
cocaethylene, Biochemical Journal 460, 447-457. 
125. Zhan, M., Hou, S., Zhan, C.-G., and Zheng, F. (2014) Kinetic characterization 
of high-activity mutants of human butyrylcholinesterase for the cocaine 
metabolite norcocaine, Biochemical Journal 457, 197-206. 
126. Saxena, A., Sun, W., Luo, C., and Doctor, B. P. (2005) Human serum 
butyrylcholinesterase: in vitro and in vivo stability, pharmacokinetics, and 
safety in mice, Chemico-Biological Interactions 157-158, 199-203. 
127. Saxena, A., Sun, W., Fedorko, J. M., Koplovitz, I., and Doctor, B. P. (2011) 
Prophylaxis with human serum butyrylcholinesterase protects guinea pigs 
exposed to multiple lethal doses of soman or VX, Biochem Pharmacol 81, 
164-169. 
128. Weber, A., Butterweck, H., Mais-Paul, U., Teschner, W., Lei, L., Muchitsch, E. 
M., Kolarich, D., Altmann, F., Ehrlich, H. J., and Schwarz, H. P. (2011) 
Biochemical, molecular and preclinical characterization of a 
double-virus-reduced human butyrylcholinesterase preparation designed for 
 117 
 
clinical use, Vox Sang 100, 285-297. 
129. Sun, W., Luo, C., Naik, R. S., Doctor, B. P., and Saxena, A. (2009) 
Pharmacokinetics and immunologic consequences of repeated administrations 
of purified heterologous and homologous butyrylcholinesterase in mice, Life 
Sciences 85, 657-661. 
130. Arpagaus, M., Chatonnet, A., Masson, P., Newton, M., Vaughan, T. A., Bartels, 
C. F., Nogueira, C. P., La Du, B. N., and Lockridge, O. (1991) Use of the 
polymerase chain reaction for homology probing of butyrylcholinesterase from 
several vertebrates, Journal of Biological Chemistry 266, 6966-6974. 
131. Braman, J., Papworth, C., and Greener, A. (2000) Site-Directed Mutagenesis 
Using Double-Stranded Plasmid DNA Templates, In The Nucleic Acid 
Protocols Handbook, pp 835-844. 
132. Masson, P., Xie, W., Froment, M. T., Levitsky, V., Fortier, P. L., Albaret, C., and 
Lockridge, O. (1999) Interaction between the peripheral site residues of human 
butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates, 
Biochimica et biophysica acta 1433, 281-293. 
133. Boeck, A. T., Schopfer, L. M., and Lockridge, O. (2002) DNA sequence of 
butyrylcholinesterase from the rat: expression of the protein and 
characterization of the properties of rat butyrylcholinesterase, Biochem 
Pharmacol 63, 2101-2110. 
134. Liu, J., and Zhan, C.-G. (2012) Reaction pathway and free energy profile for 
cocaine hydrolase-catalyzed hydrolysis of (−)-cocaine, Journal of Chemical 
Theory and Computation 8, 1426-1435. 
135. Nicolet, Y., Lockridge, O., Masson, P., Fontecilla-Camps, J. C., and Nachon, F. 
J. (2003) Crystal Structure of Human Butyrylcholinesterase and of  Its 
Complexes with Substrate and Products, Journal of Biological Chemistry 278, 
41141-41147. 
136. Henikoff, S., and Henikoff, J. G. (1992) Amino-acid substitution matrices from 
 118 
 
protein blocks, Proceedings of the National Academy of Sciences of the United 
States of America 89, 10915–10919. 
137. Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) CLUSTAL W: 
improving the sensitivity of progressive multiple sequence alignment through 
sequence weighting, position-specific gap penalties, and weight matrix choice, 
Nucleic Acids Research 22, 4673–4680. 
138. Case, D. A., Darden, T. A., Cheatham, T. E., Simmerling, C. L., Wang, J., Duke, 
R. E., Luo, R., Merz, K. M., Wang, B., Pearlman, D. A., Crowley, M., Brozell, 
S., Tsui, V., Gohlke, H., Mongan, J., Hornak, V., Cui, G., Beroza, P., 
Schafmeister, C., Caldwell, J. W., Ross, W. S., and Kollman, P. A. (2010) 
AMBER11, University of California: San Francisco. 
139. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., and Impey, R. W. (1983) 
Comparison of Simple Potential Functions for Simulating Liquid Water, 
Journal of Chemical Physics 79, 926-935. 
140. Morishita, T. (2000) Fluctuation formulas in molecular dynamics simulations 
with the weak coupling heat bath, Journal of Chemical Physics 113, 2976–
2982. 
141. Toukmaji, A., Sagui, C., Board, J., and Darden, T. A. (2000) Efficient 
particle-mesh Ewald based approach to fixed and induced dipolar interactions, 
Journal of Chemical Physics 113, 10913–10927. 
142. Ryckaert, J., Ciccotti, P. G., and Berendsen, H. J. C. (1977) Numerical 
integration of the Cartesian equations of motion of a system with constraints: 
molecular dynamics of n-alkanes, Journal of Computational Physics 23, 327–
341. 
143. Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A., and 
Haak, J. R. (1984) Molecular dynamics with coupling to an external bath, 
Journal of Chemical Physics 81, 3684–3690. 
144. Hou, S., Xue, L., Yang, W., Fang, L., Zheng, F., and Zhan, C.-G. (2013) 
 119 
 
Substrate selectivity of high-activity mutants of human butyrylcholinesterase, 
Organic and Biomolecular Chemistry 11, 7477-7485. 
145. Connors, N. J., and Hoffman, R. S. (2013) Experimental Treatments for 
Cocaine Toxicity: A Difficult Transition to the Bedside, Journal of 
Pharmacology and Experimental Therapeutics 347, 251-257. 
146. Schreiber, M. D., Madden, J. A., Covert, R. F., and Torgerson, L. J. (1994) 
Effects of cocaine, benzoylecgonine, and cocaine metabolites in cannulated 
pressurized fetal sheep cerebral arteries, Journal of Applied Physiology 77, 
834-839. 
147. Chen, X., Zheng, X., Zhan, M., Zhou, Z., Zhan, C.-G., and Zheng, F. (2016) 
Metabolic Enzymes of Cocaine Metabolite Benzoylecgonine, ACS Chemical 
Biology, Epub ahead of print: Jun 9, 2016. 
148. Fang, L., Hou, S., Xue, L., Zheng, F., and Zhan, C.-G. (2014) Amino-acid 
mutations to extend the biological half-life of a therapeutically valuable mutant 
of human butyrylcholinesterase, Chemico-Biological Interactions 214, 18-25. 
149. Pal, R., Megharaj, M., Kirkbride, K. P., and Naidu, R. (2013) Illicit drugs and 
the environment - A review, Science of The Total Environment 463-464, 
1079-1092. 
150. Pan, Y., Gao, D., and Zhan, C.-G. (2008) Modeling the Catalysis of 
Anti-Cocaine Catalytic Antibody: Competing Reaction Pathways and Free 
Energy Barriers, Journal of the American Chemical Society 130, 5140-5149. 
151. Yang, W., Pan, Y., Zheng, F., Cho, H., Tai, H.-H., and Zhan, C.-G. (2009) 
Free-Energy Perturbation Simulation on Transition States and Redesign of 
Butyrylcholinesterase, Biophysical Journal 96, 1931-1938. 
152. Zheng, F., Yang, W., Xue, L., Hou, S., Liu, J., and Zhan, C.-G. (2010) Design of 
high-activity mutants of human butyrylcholinesterase against (-)-cocaine: 
structural and energetic factors affecting the catalytic efficiency, Biochemistry 
49, 9113-9119. 
 120 
 
153. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. 
K., and Olson, A. J. (1998) Automated docking using a Lamarckian genetic 
algorithm and empirical binding free energy function, Journal of 
Computational Chemistry 19, 1639-1662. 
154. Solis, F. J., and Wets, R. J. B. (1981) Minimization by random search techniques, 
Mathematics of Operations Research 6, 19-30. 
155. Zhan, M., Hou, S., Zhan, C.-G., and Zheng, F. (2014) Kinetic characterization 
of high-activity mutants of human butyrylcholinesterase for the cocaine 
metabolite norcocaine, Biochem. J. 457, 197-206. 
156. Miller, J. H., Zheng, F., Jin, S., Opresko, L. K., Wiley, H. S., and Resat, H. (2005) 
A Model of Cytokine Shedding Induced by Low Doses of Gamma Radiation, 
Radiation Research 163, 337-342. 
157. Miller, J. H., and Zheng, F. (2004) Large-scale simulations of cellular signaling 
processes, Parallel Comput 30, 1137-1149. 
158. Zheng, F., and Zhan, C.-G. (2012) Modeling of pharmacokinetics of cocaine in 
human reveals the feasibility for development of enzyme therapies for drugs of 
abuse, PLoS Computational Biology 8, e1002610. 
159. Larsen, N. A., de Prada, P., Deng, S. X., Mittal, A., Braskett, M., Zhu, X., 
Wilson, I. A., and Landry, D. W. (2004) Crystallographic and biochemical 
analysis of cocaine-degrading antibody 15A10, Biochemistry 43, 8067-8076. 
160. Yang, G., Chun, J., Arakawa-Uramoto, H., Wang, X., Gawinowicz, M. A., Zhao, 
Z., and Landry, D. W. (1996) Anti-cocaine catalytic antibodies: a synthetic 
approach to improved antibody diversity, Journal of the American Chemical 
Society 118, 5881-5890. 
161. Polhuijs, M., Langenberg, J. P., and Benschop, H. P. (1997) New Method for 
Retrospective Detection of Exposure to Organophosphorus Anticholinesterases: 
Application to Alleged Sarin Victims of Japanese Terrorists, Toxicology and 
Applied Pharmacology 146, 156-161. 
 121 
 
162. Bartels, C. F., Xie, W., Miller-Lindholm, A. K., Schopfer, L. M., and Lockridge, 
O. (2000) Determination of the DNA Sequences of Acetylcholinesterase and 
Butyrylcholinesterase from Cat and Demonstration of the Existence of Both in 
Cat Plasma, Biochemical Pharmacology 60, 479-487. 
163. Ge, X., Zhang, W., Lin, Y., and Du, D. (2013) Magnetic Fe3O4@TiO2 
nanoparticles-based teststripimmunosensing device 
forrapiddetectionofphosphorylatedbutyrylcholinesterase, Biosensors and 
Bioelectronics 50, 486-491. 
164. Lockridge, O., and La Du, B. N. (1878) Comparison of Atypical and Usual 
Human Serum Cholinesterase, Journal of Biological Chemistry 253, 361-366. 
165. Ralston, J. S., Main, A. R., Kilpatrick, B. F., and Chasson, A. L. (1983) Use of 
procainamide gels in the purification of human and horse serum cholinesterases, 
Biochemical Journal 211, 243-250. 
166. Brzezinski, M. R., Spink, B. J., Dean, R. A., Berkman, C. E., Cashman, J. R., 
and Bosron, W. F. (1997) Human Liver Carboxylesterase hCE-1: Binding 
Specificity for Cocaine, Heroin, and Their Metabolites and Analogs, Drug 
Metabolism and Disposition 25, 1089-1096. 
167. Song, N., Parker, R. B., and Leizure, S. C. (1999) Cocaethylene formation in rat, 
dog, and human hepatic microsomes, Life Sciences 64, 2101-2108. 
168. Yang, J., Tucker, G. T., and Rostami-Hodjegan, A. (2004) Cytochrome P450 3A 
expression and activity in the human small intestine, Clinical Pharmacology & 
Therapeutics 76, 391. 
169. Chen, X., Zheng, X., Zhou, Z., Zhan, C.-G., and Zheng, F. (2016) Effects of a 
cocaine hydrolase engineered from human butyrylcholinesterase on metabolic 
profile of cocaine in rats, Chemico-Biological Interactions, Epub ahead of print: 
May 3, 2016. 
170. UNODC (2010) World drug report 2010, New York, United Nations 
Publications. 
 122 
 
171. Gorelick, D. A. (1997) Enhancing cocaine metabolism with 
butyrylcholinesterase as a treatment strategy, Drug and Alcohol Dependence 48, 
159-165. 
172. Zheng, F., and Zhan, C.-G. (2016) Cocaine Hydrolases Designed from 
Butyrylcholinesterase, In Biologics to Treat Substance Use Disorders, pp 
187-225, Springer. 
173. Herbst, E. D., Harris, D. S., Everhart, E. T., Mendelson, J., Jacob, P., and Jones, 
R. T. (2011) Cocaethylene formation following ethanol and cocaine 
administration by different routes, Experimental and Clinical 
Psychopharmacology 19, 95-104. 
174. McCance-Katz, E. F., Price, L. H., McDougle, C. J., Kosten, T. R., Black, J. E., 
and Jatlow, P. I. (1993) Concurrent cocaine-ethanol ingestion in humans: 
pharmacology, physiology, behavior, and the role of cocaethylene, 
Psychopharmacology 111, 39-46. 
175. Henning, R. J., Wilson, L. D., Glauser, J. M., Sebrosky, G., and Sutheimer, C. A. 
(1994) Cocaine plus ethanol is more cardiotoxic than cocaine or ethanol alone, 
Critical Care Medicine 22, 1896-1906. 
176. Thompson, M. L., Shuster, L., and Shaw, K. (1979) Cocaine-induced hepatic 
necrosis in mice—The role of cocaine metabolism, Biochemical Pharmacology 
28, 2389-2395. 
177. Crumb, W., and Clarkson, C. W. (1992) Characterization of the sodium channel 
blocking properties of the major metabolites of cocaine in single cardiac 
myocytes, Journal of Pharmacology and Experimental Therapeutics 261, 
910-917. 
178. Madden, J. A., Konkol, R. J., Keller, P. A., and Alvarez, T. A. (1995) Cocaine 
and benzoylecgonine constrict cerebral arteries by different mechanisms, Life 
Sciences 56, 679-686. 
179. Katz, J. L., Terry, P., and Witkin, J. M. (1992) Comparative behavioral 
 123 
 
pharmacology and toxicology of cocaine and its ethhanol-derived metabolite, 
cocaine ethyl-ester (cocaethylene), Life Sciences 50, 1351-1361. 
180. Xie, W., Altamirano, C. V., Bartels, C. F., Speirs, R. J., Cashman, J. R., and 
Lockridge, O. (1999) An improved cocaine hydrolase: the A328Y mutant of 
human butyrylcholinesterase is 4-fold more efficient, Molecular Pharmacology 
55, 83-91. 
181. Chen, X., Zheng, Xirong, Zhan, Max, Zhou, Ziyuan, Zhan, Chang-Guo, Zheng, 
Fang. Kinetic characterization of human butyrylcholinesterase mutants for the 
hydrolysis of norcocaethylene, To be submitted. 
182. Carrera, M. R. A., Ashley, J. A., Zhou, B., Wirsching, P., Koob, G. F., and Janda, 
K. D. (2000) Cocaine vaccines: antibody protection against relapse in a rat 
model, Proceedings of the National Academy of Sciences 97, 6202-6206. 
183. Carrera, M. R. A., Trigo, J. M., Wirsching, P., Roberts, A. J., and Janda, K. D. 
(2005) Evaluation of the anticocaine monoclonal antibody GNC92H2 as an 
immunotherapy for cocaine overdose, Pharmacology Biochemistry and 
Behavior 81, 709-714. 
184. Xi, Z.-X. (2012) Medication Development for the Treatment of Cocaine 
Addiction-Progress at Preclinical and Clinical Levels, INTECH Open Access 
Publisher. 
185. Gorelick, D. A., Gardner, E. L., and Xi, Z.-X. (2004) Agents in development for 
the management of cocaine abuse, Drugs 64, 1547-1573. 
186. O'Dell, L. E., George, F. R., and Ritz, M. C. (2000) Antidepressant drugs appear 
to enhance cocaine-induced toxicity, Experimental and Clinical 
Psychopharmacology 8, 133-141. 
187. Bordin, D. C. M., Alves, M. N., Cabrices, O. G., de Campos, E. G., and De 
Martinis, B. S. (2014) A rapid assay for the simultaneous determination of 
nicotine, cocaine and metabolites in meconium using disposable pipette 
extraction and gas chromatography–mass spectrometry (GC–MS), Journal of 
 124 
 
Analytical Toxicology 38, 31-38. 
188. Peres, M. D., Pelição, F. S., Caleffi, B., and De Martinis, B. S. (2014) 
Simultaneous quantification of cocaine, amphetamines, opiates and 
cannabinoids in vitreous humor, Journal of Analytical Toxicology 38, 39-45. 
189. Kohler, I., Schappler, J., and Rudaz, S. (2013) Highly sensitive capillary 
electrophoresis-mass spectrometry for rapid screening and accurate 
quantitation of drugs of abuse in urine, Analytica Chimica Acta 780, 101-109. 
190. Niessen, W. (2003) Progress in liquid chromatography–mass spectrometry 
instrumentation and its impact on high-throughput screening, Journal of 
Chromatography A 1000, 413-436. 
191. Liu, Y., Zheng, B., Strafford, S., Orugunty, R., Sullivan, M., Gus, J., Heidbreder, 
C., Fudala, P. J., and Nasser, A. (2014) Liquid chromatography/tandem mass 
spectrometry method for simultaneous determination of cocaine and its 
metabolite (−) ecgonine methyl ester in human acidified stabilized plasma 
samples, Journal of Chromatography B 961, 77-85. 
192. Xiong, L., Wang, R., Liang, C., Cao, F., Rao, Y., Wang, X., Zeng, L., Ni, C., Ye, 
H., and Zhang, Y. (2013) Determination of ecgonine and seven other cocaine 
metabolites in human urine and whole blood by ultra-high-pressure liquid 
chromatography–quadrupole time-of-flight mass spectrometry, Analytical and 
Bioanalytical Chemistry 405, 9805-9816. 
193. FDA. (2001) Guidance for Industry: Bioanalytical Methods Validation/US 
Department of Health and Human Services, Center for Drug Evaluation and 
Research, and Center for Veterinary Medicine. 
194. CHMP (2011) Guideline on bioanalytical method validation, European 
Medicines Agency. 
195. Imbert, L., Dulaurent, S., Mercerolle, M., Morichon, J., Lachâtre, G., and 
Gaulier, J.-M. (2014) Development and validation of a single LC–MS/MS assay 
following SPE for simultaneous hair analysis of amphetamines, opiates, 
 125 
 
cocaine and metabolites, Forensic Science International 234, 132-138. 
196. Hou, S., Zhan, M., Zheng, X., Zhan, C.-G., and Zheng, F. (2014) Kinetic 
characterization of human butyrylcholinesterase mutants for hydrolysis of 
cocaethylene, Biochemical Journal 460, 447-457. 
197. Roopenian, D. C., and Akilesh, S. (2007) FcRn: the neonatal Fc receptor comes 
of age, Nature Reviews Immunology 7, 715-725. 
198. Landry, D. W., Zhao, K., Yang, G. X., Glickman, M., and Georgiadis, T. M. 
(1993) Antibody-catalyzed degradation of cocaine, Science 259, 1899-1901. 
199. Braman, J., Papworth, C., and Greener, A. (1996) Site-directed mutagenesis 
using double-stranded plasmid DNA templates, Methods in molecular biology 
57, 31-44. 
200. Lockridge, O., Schopfer, L. M., Winger, G., and Woods, J. H. (2005) Large 
Scale Purification of Butyrylcholinesterase from Human Plasma Suitable for 
Injection into Monkeys; a Potential New Therapeutic for Protection against 
Cocaine and Nerve Agent Toxicity, Journal of Medical, Chemical, Biological 
and Radiological Defense 3, nihms5095. 
201. Mercolini, L., Mandrioli, R., Saladini, B., Conti, M., Baccini, C., and Raggi, M. 
A. (2008) Quantitative analysis of cocaine in human hair by HPLC with 
fluorescence detection, Journal of pharmaceutical and biomedical analysis 48, 
456-461. 
202. Ko, M. C., Bowen, L. D., Narasimhan, D., Berlin, A. A., Lukacs, N. W., 
Sunahara, R. K., Cooper, Z. D., and Woods, J. H. (2007) Cocaine esterase: 
interactions with cocaine and immune responses in mice, Journal of 
Pharmacology and Experimental Therapeutics 320, 926-933. 
203. Pan, Y., Muzyka, J., and Zhan, C.-G. (2009) Model of human 
butyrylcholinesterase (BChE) tetramer by homology modeling and dynamics 
simulation, Journal of Physical Chemistry B 113, 6543-6552. 
204. Maxwell, L. J., and Singh, J. A. (2010) Abatacept for rheumatoid arthritis: a 
 126 
 
Cochrane systematic review, Journal of Rheumatology 37, 234-245. 
205. Rigby, M. R., Harris, K. M., Pinckney, A., DiMeglio, L. A., Rendell, M. S., 
Felner, E. I., Dostou, J. M., Gitelman, S. E., Griffin, K. J., Tsalikian, E., Gottlieb, 
P. A., Greenbaum, C. J., Sherry, N. A., Moore, W. V., Monzavi, R., Willi, S. M., 
Raskin, P., Keyes-Elstein, L., Long, S. A., Kanaparthi, S., Lim, N., Phippard, D., 
Soppe, C. L., Fitzgibbon, M. L., McNamara, J., Nepom, G. T., and Ehlers, M. R. 
(2015 ) Alefacept provides sustained clinical and immunological effects in 
new-onset type 1 diabetes patients, Journal of Clinical Investigation 125, 
3285-3296. 
206. Sun, H., Shen, M. L., Pang, Y.-P., Lockridge, O., and Brimijoin, S. (2002) 
Cocaine Metabolism Accelerated by a Re-Engineered Human 
Butyrylcholinesterase, Journal of Pharmacology and Experimental 
Therapeutics 302, 710-716. 
207. Smith, M., Garner, D., and Niemann, J. T. (1991) Pharmacologic interventions 
after an LD50 cocaine insult in a chronically instrumented rat model: are 
beta-blockers contraindicated?, Annals of Emergency Medicine 20, 768-771. 
208. Bedford, J. A., Turner, C. E., and Elsohly, H. N. (1982) Comparative lethality of 
coca and cocaine, Pharmacology Biochemistry and Behavior 17, 1087-1088. 
209. Mets, B., Winger, G., Cabrera, C., Seo, S., Jamdar, S., Yang, G., Zhao, K., 
Briscoe, R. J., Almonte, R., Woods, J. H., and Landry, D. W. (1998) A catalytic 
antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats, 
Proceedings of the National Academy of Sciences of the United States of 
America 95, 10176-10181. 
 
 
 
 
 127 
 
VITA 
 
Education 
Graduate Certificate: Applied Statistics                                  2014 
Department of Statistics, University of Kentucky - Lexington, KY, USA 
Master of Medicine: Oncology and Molecular Cancer Epidemiology        2010 
Peking Union Medical College, Tsinghua University - Beijing, China 
Bachelor of Science: Biosciences                                            2007 
College of Life Sciences, Beijing Normal University - Beijing, China 
 
Awards & Honors 
1. AAPS Graduate Student Research Award in Biotechnology (2015) 
2. Professional scholarships of Peking Union Medical College (2008, 2009) 
3. Outstanding graduate student scholarships of Peking Union Medical College 
(2009) 
4. Professional scholarships of Beijing Normal University (2006) 
5. Academic scholarships of Beijing Normal University (2006) 
 
Publications 
1. Chen X, Zheng X, Ding K, Zhou Z, Zhan CG, Zheng F. A quantitative 
LC-MS/MS method for simultaneous determination of cocaine and its 
metabolites in whole blood. (In preparation for J Chromatogr B). 
2. Wang G, Zhang T, Huang H, Hou S, Chen X, Zheng F, Zhan CG. Plant 
expression of cocaine hydrolase-Fc fusion protein for treatment of cocaine 
abuse. BMC Biotechnol (In revision). 
3. Chen X, Zheng X, Zhan M, Zhou Z, Zhan CG, Zheng F. Metabolic Enzymes of 
Cocaine Biomarker Benzoylecgonine. ACS Chem Biol 2016 (Epub ahead of 
print: May 25, 2016). 
 128 
 
4. Chen X, Zheng X, Zhou Z, Hou S, Zhan CG, Zheng F. Effects of a cocaine 
hydrolase engineered from human butyrylcholinesterase on metabolic profile of 
cocaine in rats. Chem Biol Interact 2016 (Epub ahead of print: May 3, 2016).  
5. Chen X, Xue L, Hou S, Jin Z, Zhang T, Zheng F, Zhan CG. Long-acting cocaine 
hydrolase for addiction therapy. Proc Natl Acad Sci USA 2016, 113(2):422-7. 
6. Chen X, Huang X, Geng L, Xue L, Hou S, Zheng X, Brimijoin S, Zheng F, Zhan 
CG. Kinetic characterization of a cocaine hydrolase engineered from mouse 
butyrylcholinesterase. Biochem J 2015, 466(2):243-51. 
7. Du Z, Zhang W, Zhou Y, Yu D, Chen X, Chang J, Qiao Y, Zhang M, Huang Y, 
Wu C, Xiao Z, Tan W, Lin D. Associations of ATM polymorphisms with 
survival in advanced esophageal squamous cell carcinoma patients receiving 
radiation therapy. Int J Radiat Oncol Biol Phys 2015, 93(1):181-9. 
8. Xiang C, Wang J, Kou X, Chen X, Qin Z, Jiang Y, Sun C, Xu J, Tan W, Jin L, 
Lin D, He F, Wang H. Pulmonary expression of CYP2A13 and ABCB1 is 
regulated by FOXA2 and their genetic interaction is associated with lung cancer. 
FASEB J 2015, 29(5):1986-98. 
9. Fang L, Chow KM, Hou S, Xue L, Chen X, Rodgers DW, Zheng F, Zhan CG. 
Rational design, preparation, and characterization of a therapeutic enzyme 
mutant with improved stability and function for cocaine detoxification. ACS 
Chem Biol 2014, 9(8):1764-72.  
10. Xue L, Hou S, Tong M, Fang L, Chen X, Jin Z, Tai HH, Zheng F, Zhan CG. 
Preparation and in vivo characterization of a cocaine hydrolase engineered from 
human butyrylcholinesterase for metabolizing cocaine. Biochem J 2013, 
453(3):447-54. 
11. Geng L, Gao Y, Chen X, Hou S, Zhan CG, Radic Z, Parks RJ, Russell SJ, Pham 
L, Brimijoin S. Gene transfer of mutant mouse cholinesterase provides high 
lifetime expression and reduced cocaine responses with no evident toxicity. 
PLoS One 2013, 8(6):e67446.  
 129 
 
12. Zhou Y, Zhang W, Chen X, Xiao Z, Qiao Y, Yu D, Lin D, Tan W. The association 
between polymorphism of transforming growth factor-β1 and radiochemotherapy 
response and survival in esophageal squamous cell carcinoma patients. Chinese J of 
Prev Med 2011, 45(7):581-5. 
13. Chen X, Li H, Qiao Y, Yu D, Guo H, Tan W, Lin D. Association of CD28 gene 
polymorphism with cervical cancer risk in a Chinese population. Int J Immunogenet 
2011, 38 (1): 51-4.  
14. Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, Lin D, Wang L. Cyclooxygenase-2 
genetic variants are associated with survival in unresectable locally advanced non–
small Cell lung cancer. Clin Cancer Res 2010, 16(8):2383-90.  
15. Zhang W*, Chen X*(*Co-first authors), Luo A, Lin D, Tan W, Liu Z. Genetic 
variants of C1orf10 and risk of esophageal squamous cell carcinoma in a 
Chinese population. Cancer Sci 2009, 100(9): 1695-700.  
16. Chen X, Chen G, Liu J, Yang J, Yu D, Lin D, Tan W. Genetic polymorphisms in 
STKI5 and MMP-2 associated susceptibility to esophageal cancer in Mongolian 
population. Chinese J of Prev Med 2009, 43(7): 559-64.  
17. Lv H, Huang S, Guo Z, Chen X, Cong Y. Biomarkers and early diagnosis of 
prostate cancer. Bulletin of Biology 2006, 41(12):1-3. 
18. Chen X, He J, Zhang W. Ecological factors affecting choice of Pica pica 
sericea nest location in Universities in Beijing. Sichuan Journal of Zoology 
2006, 125(14): 855-61. 
 
 
 
 
 
                        Xiabin Chen 
Name of Student 
